FORM PTO-1390 (REV. 11-2000) U S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER	
0147-0223P	
U.S. APPLICATION NO. (If known, see 37 CFR 1.5)	
09/806767 NEW	

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/EP99/07633	October 12, 1999	October 12, 1998

TITLE OF INVENTION
MEANS AND METHODS FOR MODULATING STOMATA CHARACTERISTICA IN PLANTS

APPLICANT(S) FOR DO/EO/US
BERGER, Dieter; ALTMANN, Thomas

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39 (1).
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
   a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
   b. ☒ has been transmitted by the International Bureau. WO 00/22144
   c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
   a. ☒ is transmitted herewith.
   b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4)
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
   a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
   b. ☐ have been transmitted by the International Bureau.
   c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
   d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 20. below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98-International Search Report (PCT/ISA/210) w/ 6 documents
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information:
    1.) PCT Substitute Claims Letter w/ International Preliminary Examination Report (PCT/IPEA/409) and claims
    2.) PCT Request (PCT/RO/101)
    3.) 43 pages of Sequence Listing
    4.) Nine (9) sheets of Formal Drawings

U.S. APPLICATION NO (if known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO	ATTORNEY'S DOCKET NUMBER
NEW 09/806767	PCT/EP99/07633	0147-0223P

21. ☒ The following fees are submitted:	CALCULATIONS	PTO USE ONLY
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5):		
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO **$1,000.00**		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO **$860.00**		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **$710.00**		
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) **$690.00**		
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) **$100.00**		
ENTER APPROPRIATE BASIC FEE AMOUNT =	**$ 860.00**	
Surcharge of **$130.00** for furnishing the oath or declaration later than ☐ 20 ☒ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	**$ 130.00**	

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	29 - 20 =	9	X **$18.00**	**$ 162.00**	
Independent Claims	3 - 3 =	0	X **$80.00**	**$ 0**	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		Yes	+ **$270.00**	**$ 270.00**	
			TOTAL OF ABOVE CALCULATIONS =	**$ 1422.00**	
☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				**$ 0**	
			SUBTOTAL =	**$ 1422.00**	
Processing fee of **$130.00** for furnishing the English translation later than ☐20 ☐30 months from the earliest claimed priority date (37 CFR 1.492(f)).			+	**$ 0**	
			TOTAL NATIONAL FEE =	**$ 1422.00**	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **$40.00** per property			+	**$ 0**	
			TOTAL FEES ENCLOSED =	**$ 1422.00**	
			Amount to be: refunded	**$**	
			charged	**$**	

a. ☒ A check in the amount of $ **1422.00** to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account. No. _____ in the amount of $_____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-2448.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

Send all correspondence to:
Birch, Stewart, Kolasch & Birch, LLP or Customer No. 2292
P.O. Box 747
Falls Church, VA 22040-0747
(703)205-8000

Date: April 3, 2001

By _____
Leonard R. Svensson, #30,330

qc

#3

BOX SEQUENCE
PATENT
0147-0223P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:	BERGER, Dieter et al.	Conf.:	4759
Appl. No.:	09/806,767	Group:	Unassigned
Filed:	April 3, 2001	Examiner:	Unassigned

For: MEANS AND METHODS FOR MODULATING STOMATA CHARACTERISTICA IN PLANTS

AMENDMENT

Assistant Commissioner for Patents
Washington, DC 20231

August 10, 2001

Sir:

In response to the U.S. Patent Office Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Disclosures dated May 10, 2001, the period for response having been extended one (1) month to August 10, 2001, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

IN THE SPECIFICATION:

Please replace the description of figure 5, on page 33, with the following amended description:

--**Figure 5:** Sequence alignments in the four highly conserved domains, the D region(SEQ ID NOS: 62-70), the H region(SEQ ID NOS:71-79), the substrate binding site(SEQ ID NO:80-88), and the S region(SEQ ID NOS:89-97) of the subtilisins Subtilisin BPN´ (Wells et al. 1983, Nucleic Acids Res. 11, 7911-7925),

the KEX2 of yeast (Mizuno et al. 1988, *Biochem. Biophys. Res. Commun.* 156, 246-254), the human FURIN/PACE (Wise et al. 1990, *Proc. Natl. Acad. Sci USA* 87, 9378 - 9382), the human PC1/PC3 (Seidah et al., 1991, *Mol. Endocrinol.* 5, 111 - 122; Smeekens et al., 1991, *Proc. Natl. Acad. Sci. USA* 88, 340 - 344), the CUCUMISIN from *Cucumis melo* (Yamagata et al., 1994, *J. Biol. Chem.* 269, 32725 - 32731), LeP69 from *Lycopersicon esculentum* (Tornero et al., 1996, *Proc. Natl. Acad. Sci. USA* 93, 6332 - 6337), the AG12 from *Alnus glutinosa* (Ribeiro et al., 1995, *Plant Cell* 7, 785 - 794) and of SDD1. The positions of the invariant amino acids are marked with *. Identical amino acids present at corresponding positions in the different subtilisins are highlighted with black boxes.--

Please replace the Sequence Listing filed April 3, 2001, located immediately after the abstract, with substitute Sequence Listing enclosed herewith.

REMARKS

Sequence Listing

Enclosed herewith in full compliance to 37 C.F.R. §§1.821-1.825 is a substitute Sequence Listing to be inserted into the specification as indicated above. The substitute Sequence Listing in no way introduces new matter into the specification.

Also submitted herewith in full compliance to 37 C.F.R. §§1.821-1.825 is a disk copy of the substitute Sequence Listing. The disk copy of the substitute Sequence Listing, file "0147-0223P.ST25", is identical to the paper copy, except that it lacks formatting.

The substitute Sequence Listing contains sequences disclosed in figure 5 as filed that were not made part of the original Sequence Listing. The amendments to the Specification are being

made to reference these sequences by their SEQ ID NOS. These amendments are editorial in nature and do not constitute new matter.

Entry of the above amendments is earnestly solicited. An early and favorable first action on the merits is earnestly solicited.

Claims Fee

Claims 8, 11, and 15 as filed are improper, therefore these claims and their dependants are counted as one claim making the total claim count to 27. 29 claims were paid for on April 3, 2001, therefore the Applicants feel that the additional claims fee of $288.00 is not necessary. If the Commissioner disagrees then he is hereby authorized to charge Deposit Account No. 02-2448 for any additional claims fees.

Extension of Time

A one (1) month(s) extension of time for the filing of the present paper in accordance with the provisions of 37 C.F.R. §1.136 and 37 C.F.R. §1.17 has been petitioned for and the applicable fees have been paid in the accompanying response to the Notice to File Missing Parts filed on August 10, 2001 for the present application number.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By _____ #32,868
for Leonard R. Svensson, #30,330

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

LRS/SWG/KW
0147-0223P

Attachments: Paper and disk copy of Sequence Listing
Copy of Notice to Comply

PATENT
0147-0223P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:	BERGER, Dieter et al.	Conf.:	
Int'l. Appl. No.:	PCT/EP99/07633		
Appl. No.:	New	Group:	
Filed:	April 3, 2001	Examiner:	
For:	MEANS AND METHODS FOR MODULATING STOMATA CHARACTERISTICA IN PLANTS		

PRELIMINARY AMENDMENT

BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, DC 20231

April 3, 2001

Sir:

The following Preliminary Amendments and Remarks are respectfully submitted in connection with the above-identified application.

AMENDMENTS

IN THE SPECIFICATION:

Please amend the specification as follows:

Before line 1, insert --This application is the national phase under 35 U.S.C. § 371 of PCT International Application No. PCT/EP99/07633 which has an International filing date of October 12, 1999, which designated the United States of America.--

IN THE CLAIMS:

Please amend the claims as follows:

5. (Amended) A vector comprising a recombinant DNA molecule of claim 1.

6. (Amended) A host cell containing a vector of claim 5 or a recombinant DNA molecule of claim 1.

7. (Amended) A method for the production of transgenic plants with altered stomata characeristica compared to wild type plants comprising the introduction of a recombinant DNA molecule of claim 1 or the vector of claim 5.

8. (Amended) A transgenic plant cell comprising stably integrated into the genome a recombinant DNA molecule of claim 1 or a vector of claim 5 or obtainable according to the method of claim 7, wherein the expression of the nucleic acid molecule results in an increased expression or activity of subtilisin-like serine proteases in transgenic plants compared to wild type plants.

11. (Amended) A transgenic plant ell which contains stably integrated into the genome a recombinant DNA molecule of claim 1 or part thereof, a vector of claim 5 or obtainable according to the method of claim 7, wherein the presence, transcription and/or

expression of the nucleic acid molecule or part thereof leads to reduction of the synthesis or the activity of subtilisin-like serine proteases in transgenic plants compared to wild type plants.

13. (Amended) A transgenic plant or plant tissue comprising the plants cells of claim 11.

15. (Amended) The transgenic plant of claim 9, the plant cell of claim 8, or the plant tissue of claim 9, wherein said plant, plant cell or plant tissue is derived from a monocotyledonous or dicotyledonous plant.

17. (Amended) Harvestable parts or propagation material of plants of claim 9.

18. (Amended) A kit comprising recombinant DNA molecule of claim 1 or a vector of claim 5.

21. (Amended) Use of a nucleic acid molecule encoding or regulating the expression of a subtilisin-like serine protease or a nucleic acid molecule as defined in claim 1, a recombinant DNA molecule of claim 1, or a vector of claim 5 for the production of plants with improved fresh and dry weight, for enhancing the content of sugars and/or protein in plant leaves for the production of plants with reduced leaf temperatures or with reduced water loss and lower water consumption, for the

modification (enhancement) of CO_2 uptake into and H_2O release from leaves, for sustained photosynthesis under high intensity conditions or for the improvement of disease resistance plants.

REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application. The claims have also been amended to delete improper multiple dependencies and to place the application into better form for examination. Entry of the present amendment and favorable action on the above-identified application are earnestly solicited.

Attached hereto is a marked-up copy of the changes made to the application by this Amendment.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By mg/Nell #36,623
Leonard R. Svensson, #30,330

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

LRS/cqc
0147-0223P

Attachment: Version With Markings Showing Changes Made

(Rev. 01/22/01)

VERSION WITH MARKINGS SHOWING CHANGES MADE

The specification has been amended to provide cross-referencing to the International Application.

The claims have been amended as follows:

5. (Amended) A vector comprising a recombinant DNA molecule of [any one of claims 1 to 4]claim 1.

6. (Amended) A host cell containing a vector of claim 5 or a recombinant DNA molecule of [any one of claims 1 to 4]claim 1.

7. (Amended) A method for the production of transgenic plants with altered stomata characeristica compared to wild type plants comprising the introduction of a recombinant DNA molecule of [any one of claims 1 to 4]claim 1 or the vector of claim 5.

8. (Amended) A transgenic plant cell comprising stably integrated into the genome a recombinant DNA molecule of [any one of claims 1 to 4]claim 1 or a vector of claim 5 or obtainable according to the method of claim 7, wherein the expression of the nucleic acid molecule results in an increased expression or activity of subtilisin-like serine proteases in transgenic plants compared to wild type plants.

11. (Amended) A transgenic plant cell which contains stably integrated into the genome a recombinant DNA molecule of [any one of claims 1 to 4]claim 1 or part thereof, a vector of claim 5 or obtainable according to the method of claim 7, wherein the presence, transcription and/or expression of the nucleic acid molecule or part thereof leads to reduction of the synthesis or the activity of subtilisin-like serine proteases in transgenic plants compared to wild type plants.

13. (Amended) A transgenic plant or plant tissue comprising the plants cells of claim 11 [or 12].

15. (Amended) The transgenic plant of [any one of claims 9, 10, 13 or 14]claim 9, the plant cell of [any one of claims 8, 11 or 12]claim 8, or the plant tissue of claim 9 [or 13], wherein said plant, plant cell or plant tissue is derived from a monocotyledonous or dicotyledonous plant.

17. (Amended) Harvestable parts or propagation material of plants of [any one of claims 9, 10, 13 or 14 to 16]claim 9 [comprising plant cells of claim 8 11, 12, 15 or 16].

18. (Amended) A kit comprising recombinant DNA molecule of [any one of claims 1 to 4]claim 1 or a vector of claim 5.

21. (Amended) Use of a nucleic acid molecule encoding or regulating the expression of a subtilisin-like serine protease or a nucleic acid molecule as defined in [any one of claims 1 to 4]claim 1, a recombinant DNA molecule of [any one of claims 1 to 4]claim 1, or a vector of claim 5 for the production of plants with improved fresh and dry weight, for enhancing the content of sugars and/or protein in plant leaves for the production of plants with reduced leaf temperatures or with reduced water loss and lower water consumption, for the modification (enhancement) of CO_2 uptake into and H_2O release from leaves, for sustained photosynthesis under high intensity conditions or for the improvement of disease resistance plants.

New PCT Patent Application
Our Ref.. C 1748 PCT

Means and methods for modulating stomata characteristica in plants

The present invention relates to recombinant DNA molecules comprising nucleic acid molecules encoding subtilisin-like serine proteases that are involved in the regulation of stomatal density in plants; wherein said nucleic acid molecules could be operably linked to regulatory elements allowing the expression of the nucleic acid molecules in plants. The present invention also provides vectors comprising said recombinant DNA molecules as well as plant cells, plant tissues and plants transformed therewith. The present invention further relates to the use of the aforementioned recombinant DNA molecules and vectors in plant cell and tissue culture, plant breeding and/or agriculture, in particular for the production of plants with improved traits.

Several documents are cited throughout the text of this specification. Each of the documents cited herein (including any manufacturer's specifications, instructions, etc.) are hereby incorporated herein by reference; however, there is no admission that any document cited is indeed prior art as to the present invention.

Stomatal complexes (stomata) are specialised structures in the epidermices of all higher land plants that mediate and control the gas exchange between the internal tissues of the plants and the atmosphere. They consist of two guard cells that flank a central pore. In many plant species these central guard cells are surrounded by morphologically distinct epidermal cells (subsidiary cells). Usually, more than 90% of the gas exchange between a leaf and the atmosphere (uptake of CO_2 into the leaf and release of H_2O vapor) occurs through the stomatal pores. The major function of the stomata is to create an optimal balance between sufficient CO_2 uptake and limited water loss. To achieve this, short term control (in the range of minutes to hours) is exerted on the stomatal conductance by opening and closure of the stomatal pores through turgor driven movement of the guard cells (for review see Zeiger, Farquhar and Cowan (eds.) Stomatal Function,

Stanford University Press, Stanford 1987; Willmer and Fricker (eds.) Topics in Functional Biology, 2. Stomata, Second Edition, Chapman and Hall Ltd., London, New York, 1996). Besides these rapid and transient changes, long term modulation of stomatal characteristics occurs which predominantly involve morphological aspects such as presence or absence of stomata in the upper and/or lower leaf epidermis, density of stomata in the leaf epidermices, or the size of the stomata. These features are determined both, by endogenous (genetic) and by exogenous (environmental) factors. Hints towards genetic control were obtained through the observation of a broad variation of the stomatal density between different species of the same genus, between varieties or cultivars of the same species, or in F1 hybrids. Genetic analysis revealed multigenic, oligogenic, or monogenic control and a high heritability of characters such as stomatal density or size (for review see Jones, *In* Stomatal Function, Eds. E. Zeiger, G.D. Farquhar and I.R. Cowan, pp. 431-443, Stanford University Press, Stanford 1987). In addition to this endogenous control, stomatal characteristics are also modulated through environmental effects. Thus, air humidity (e.g. Schürmann, 1959, *Flora* 147, 417-520), light intensity (e.g. Gay and Hurd, 1975, *New Phytol.* 75, 37-46; Schoch et al., 1980, *J. Exp. Bot.* 31, 1211-1216; Rahim and Fordham, 1991, *Ann. Bot.* 67, 167-171), and CO_2-concentration (e.g. Woodward, 1987, *Nature* 327, 617-618; Woodward and Bazzaz, 1988, *J. Exp. Bot.* 39, 1771-1781; Goodfellow et al., 1997, *Tree Physiol.* 17, 291-299) were found to affect stomatal density. In several studies, stomatal density was found to be associated with plant yield (e.g. Walton, 1974, *Can J. Plant Sci.* 54, 749-754). Pima cotton varieties selected for high yield upon growth under conditions of high irradiance and artificial irrigation exhibit increased stomatal density associated with increased stomatal conductance and reduced leaf temperature (Cornish et al., 1991, *Plant Physiol.* 97, 484-489; Lu and Zeiger, 1994, *Physiol. Plant.* 92, 273-278; Lu et al., 1994, *Physiol. Plant.* 92, 266-272; Srivastava et al., 1995, *Plant Sci.* 19, 125-131). A similar relationship between stomatal conductance and yield was observed for a series of bread wheat varieties (Lu et al., 1998, *J. Exp. Bot.* 49, 453-460). According to these data, the modulation of stomatal characteristics are of high importance for the improvement of elite cultivars of crop plants. In the area of agriculture and forestry, a major aim is the continuous improvement of the crop plants with respect to higher yielding to provide sufficient food for the growing

global population and to ensure the supply of renewable resources. Traditionally, progress towards higher yielding varieties is attempted through breeding, a very labour und time consuming process to be conducted separately for every relevant plant species. Some progress has already been achieved through the application of genetic engineering to plants, i.e. the introduction and expression of recombinant nucleic acid molecules in plants. Such approaches are advantageous as they can usually be applied to many different plant species. In EP-A 0 511 979, for instance, the use of a procaryotic asparagine synthetase for expression in plant cells is described that, among other changes, leads to increased biomass production. WO 96/21737 describes yield increases in plants achieved through the expression of de- or non-regulated fructose-1,6-bisphosphatase through enhanced rate of photosynthesis. In WO 96/17069, the enhancement of biomass production in transgenic plants achieved through expression of a polyphosphate kinase from *E.coli* is described. In contrast to these cases, however, no means for a directed manipulation through genetic engineering of stomatal density or distribution in plants were hitherto available, due to the complete lack of knowlegde about genes that are involved in the control of these stomatal characteristics.

Recently, an *Arabidopsis thaliana* mutant, R-558, has been isolated after chemical mutagenesis which shows a two to four-fold increase in the stomatal density of all aerial plant organs, in the leaves in particular and the occurrence of ca. 10% clustered stomata, i.e. stomata placed in direct contact to at least one other stomata (D. Berger, 1997, PhD Thesis Freie Universität Berlin). Besides a minor change in the length of the pedicelli, no other morphological changes were visible in the mutant plants. The form and size of the leaves as well as the structure of the mesophyll (number of cell layers in palisade and spongy parenchyma, form and size of the mesophyll cells) and the intercellular system (including the substomatal cavities) are unchanged. The increased stomatal density resulted in elevated transpiration (loss of H_2O) and was associated with increased dry matter content in the leaves which in the wild type was ca. 3% and in the mutant ca. 7%. It was furthermore shown that the increased stomatal density in the R-558 mutant was associated with increased leaf fresh (+ 15%) and dry (+30%) weight, increasd glucose (+70%), fructose (+65%), and protein (+50%) contents in leaves, and enhanced transpiration and CO_2-assimilation (D. Berger, 1997, PhD Thesis, Freie

Universität Berlin) in comparison to the wild type. The mutation which caused the increased stomatal density has been mapped relative to a set of (molecular) genetic markers to a ca. 0.59 cM interval located on the top arm of chromosome 1 of *Arabidopsis thaliana* (D. Berger, 1997, PhD Thesis, Freie Universität Berlin). However, the regulation of stomatal density and distribution in plants is still not fully understood and means that can be used to manipulate stomatal characteristics such as density and distribution that may have applications in several aspects of agriculture were hitherto not available.

Thus, the technical problem underlying the present invention was to comply with the need for means and methods for modulating the stomatal density in plants. The solution to this technical problem is achieved by providing the embodiments characterized in the claims.

Accordingly, the invention relates to a recombinant DNA molecule comprising

(i) a nucleic acid molecule encoding a subtilisin-like serine protease or encoding a biologically active fragment of such a protein, selected from the group consisting of

  (a) nucleic acid molecules comprising a nucleotide sequence encoding a protein comprising the amino acid sequence as given in SEQ ID NO: 2, 8, 10 or 12;

  (b) nucleic acid molecules comprising a nucleotide sequence as given in SEQ ID NO: 1, 7, 9, or 11;

  (c) nucleic acid molecules encoding a protein comprising at least the D region, H region, substrate binding site and/or S region of the subtilisin-like serine protease encoded by a nucleic acid molecule of (a) or (b); or

  (d) nucleic acid molecules hybridizing with the complementary strand of a nucleic acid molecule as defined in any one of (a) to (c);

  (e) nucleic acid molecules encoding a protein the amino acid sequence of which is at least 65% identical to the amino acid sequence encoded by a nucleic acid molecule of any one of (a) to (c);

(f) nucleic acid molecules, the nucleotide sequence of which is degenerate as a result of the genetic code to a nucleotide sequence of a nucleic acid molecule as defined in any one of (a) to (e); or

(ii) a nucleic acid molecule encoding a mutant non-active or hyper-active form of or an antibody against the subtilisin-like serine protease encoded by a nucleic acid molecule of (i); or

(iii) a nucleic acid molecule which specifically hybridizes with a nucleic acid molecule of (i) or the complementary strand thereof.

The present invention is based on the identification of a new class of genes represented by *SDD1* from *Arabidopsis thaliana* which share common structural motifs, see infra. In one aspect, these genes are preferably involved in the control of stomatal density and/or distribution. The SDD1 gene is mutated in the *Arabidopsis thaliana* mutant R-558; see Examples 1 to 3. Computer-assisted amino acid sequence analysis of the protein encoded by this gene revealed that it belongs to a family of subtilisin-like serine proteases; see Example 4. Further representatives of this new class of genes have been cloned from potato; see Example 6.

The terms "subtilisin like-serine protease" and "subtilase" are used interchangeable herein and mean a specific class of serine proteases, called subtilisins or dibasic processing endoproteases. In subtilisins, four regions form the catalytic triad and the substrate binding site and are most highly conserved among subtilisins; see also Example 4 and Figure 7. In the context of the present invention, subtilisin-like serine proteases also mean such proteins which show a homology of at least 65% to the sequence shown in SEQ ID NOs: 2, 8, 10 or 12. In the context of the present invention, the term "subtilisin-like serin protease" preferably is understood to mean proteins comprising one or several of the characteristic motifs depicted in SEQ ID NOS: 13 to 37; see infra.

The substrate binding site preferably comprises the motif VICAA (SEQ ID NO: 38), more preferably the motif CAAGN (SEQ ID NO: 39), in particular the motif AAGNN (SEQ ID NO: 40) and most preferably the amino acid motif VICAAGNNG (SEQ ID NO: 41).

In another preferred embodiment, the nucleic acid molecule of the present invention encodes a protein described above with one or more of the following amino acid sequence motifs: SYHSA (SEQ ID NO: 49), GLSPT (SEQ ID NO: 50), WLKSG (SEQ ID NO: 51), FNSSS (SEQ ID NO: 52), ASTAG (SEQ ID NO: 53), AAMDV (SEQ ID NO: 54), WIATI (SEQ ID NO: 55), GPSGL (SEQ ID NO: 56), IAALLH (SEQ ID NO: 57), KPIMD (SEQ ID NO: 58), VSCHD (SEQ ID NO: 59), YPSIS (SEQ ID NO: 60), SLSYR (SEQ ID NO: 61).

In a further preferred embodiment the D, H and/or S region of the subtilase of the present invention comprise one or several of the following characteristic motifs:

D region:

IIGVL (SEQ ID NO: 42) or GVLDT (SEQ ID NO: 43)

H region:

THTAST (SEQ ID NO: 44) or S-RDS (SEQ ID NO: 45) or RDS-G (SEQ ID NO:46)

S region:

HVSGI (SEQ ID NO: 47) or FTV-SGT (SEQ ID NO: 48)

While a function of such proteins in the regulation of stomatal density in plants was hitherto unknown, the present invention for the first time provides evidence that the described nucleic acid molecules encode proteins that are involved in controlling the density and the distribution of stomata in plants; see Examples 3 and 7. Furthermore, it is shown that plants lacking or overexpressing such proteins show altered morphological and physiological features of high agronomic importance.

Thus, the present invention for the first time clearly establishes that stomatal characteristics such as density and distribution can be specifically modulated through the application of genetic engineering techniques and provides extremely useful tools for example to:

(i) generate plants with increased stomatal density and consequently with enhanced CO_2 assimilation, reduced leaf temperature, enhanced organ such as leaf fresh and dry weight, and enhanced sugar and protein contents in organs such as leaves;

(ii) generate plants with decreased stomatal density and consequently with reduced water loss and thus lower water consumption;

(iii) counteract environmental changes such as raises in atmospheric CO_2 levels, temperature and irradiation that would cause changes in stomatal density to sub- or supra-optimal levels;

In general a nucleic acid molecule encoding a subtilisin-like serine protease can be derived from any material source, for example, from any organism, preferably plants possessing such molecules, preferably form monocotyledonous or dicotyledonous plants, in particular from any plant of interest in agriculture, horticulture or wood culture, such as crop plants, namely those of the family Poaceae, any starch producing plants, such as potato, maniok, rice, wheat, corn, barley, oat, leguminous plants, oil producing plants, such as oilseed rape, soja, sunflower, linenseed, etc., plants using polypeptide as storage substances, such as soybean, plants using sucrose as storage substance, such as sugar beet or sugar cane, trees, ornamental plants etc. or plants belonging to the family Gramineae.

Furthermore, nucleic acid molecules can be used in accordance with the present invention hybridizing to the above-described nucleic acid molecules and encoding subtilisin-like serine protease. Such nucleic acid molecules can be isolated, e.g., from libraries, such as cDNA or genomic libraries by techniques well known in the art. For example, hybridizing nucleic acid molecules can be identified and isolated by using the above-described nucleic acid molecules or fragments thereof or complements thereof as probes to screen libraries by hybridizing with said molecules according to standard techniques. Possible is also the isolation of such nucleic acid molecules by applying the polymerase chain reaction (PCR) using as primers oligonucleotides derived form the above-described nucleic acid molecules. Nucleic acid molecules which hybridize with any of the aforementioned nucleic acid molecules also include fragments, derivatives and allelic variants of the above-described nucleic acid molecules that encode subtilisin-like serine proteases or biologically active fragments thereof. Fragments are understood to be parts of nucleic acid molecules long enough to encode the described protein or a fragment thereof having the biological activity as defined above. Preferably, said fragment comprises at least one region of subtilisin-like serine protease as defined in section (i) (c) supra.

The term "derivative" means in this context that the nucleotide sequence of these nucleic acid molecules differs from the sequences of the above-described nucleic acid molecules in one or more nucleotide positions and are highly homologous to said nucleic acid molecules. Homology is understood to refer to a sequence identity of at least 50 %, preferably 65% identity, particularly an identity of at least 70 % or 75%, preferably more than 80 % and still more preferably more than 90 % or 95% identity. The deviations from the sequences of the nucleic acid molecules described above can, for example, be the result of nucleotide substitution(s), deletion(s), addition(s), insertion(s) and/or recombination(s) either alone or in combination, that may naturally occur or be produced via recombinant DNA techniques well known in the art; see for example, the techniques described in Sambrook, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory (1989) N.Y. and Ausubel, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y. (1989), (1994). Homology further means that the respective nucleic acid molecules or encoded proteins are functionally and/or structurally equivalent. The nucleic acid molecules that are homologous to the nucleic acid molecules described above and that are derivatives of said nucleic acid molecules are, for example, variations of said nucleic acid molecules which represent modifications having the same biological function, in particular encoding proteins with the same or substantially the same biological activity as defined herein. They may be naturally occurring variations, such as subtilisin-like serine protease encoding sequences from other prokaryotes and eukaryotes, respectively, or mutations. These mutations may occur naturally or may be obtained by mutagenesis techniques; see supra. The allelic variations may be naturally occurring allelic variants as well as synthetically produced or genetically engineered variants; see supra. For example, the amino acid sequences of plant subtilisin-like serine proteases share significant similarities with bacterial, yeast and mammalian subtilisin-like serine protease; see Example 4. In addition, nucleic acid molecules can be employed in accordance with the present invention that encode homologs or analogs of the above described subtilisin-like serine protease but where otherwise unrelated to those proteins. Such proteins that do not display significant homologies to common subtilisin-like serine protease can be identified by a person skilled in the art using techniques

well known in the art, for example, via complementation of mutant genes, for example, in corresponding mutant plants; see Example 3.

In a further embodiment the term derivative encompasses a nucleotide sequence coding for a protein derived from any one of SEQ ID Nos. 2, 8, 10 or 12 which exhibits a degree of homology, i.e. identity to the protein depicted under SEQ ID Nos. 2, 8, 10 or 12 of at least 60%, in particular an homology of at least 70%, preferably more than 80% and still more preferably a homology of more than 90% and particularly preferred of more than 95% and which exhibits at least one, more preferably at least three, even more preferably of at least five, in particular at least ten and particularly preferred of at least twenty of the peptide motifs selected from the group consisting of

a) QTYIV, (SEQ ID NO: 13),
b) IVQLH, (SEQ ID NO: 14),
c) SSRLL, (SEQ ID NO: 15),
d) QTTYS, (SEQ ID NO: 16),
e) SSSCN, (SEQ ID NO: 17),
f) VLGNG, (SEQ ID NO: 18),
g) GAHIA, (SEQ ID NO: 19),
h) FRAME, (SEQ ID NO: 20),
i) VICAA, (SEQ ID NO: 21),
j) AAGNN, (SEQ ID NO: 22),
k) SSVAN, (SEQ ID NO: 23),
l) YGESL, (SEQ ID NO: 24),
m) GSEFC, (SEQ ID NO: 25),
n) CLRGS, (SEQ ID NO: 26),
o) RGVNG, (SEQ ID NO: 27),
p) PATLIG, (SEQ ID NO: 28),
q) IFGGT, (SEQ ID NO: 29),
r) PQNLG, (SEQ ID NO: 30),
s) VNFTV, (SEQ ID NO: 31),
t) HVSGI, (SEQ ID NO: 32),
u) GFSLN, (SEQ ID NO: 33),
v) RRVTN, (SEQ ID NO: 34),
w) PNSIY, (SEQ ID NO: 35),
x) LSYRV, (SEQ ID NO: 36), and
y) SPISV. (SEQ ID NO: 37)

The proteins encoded by the various derivatives, variants, homologs or analogs of the above-described nucleic acid molecules may share specific common characteristics, such as molecular weight, immunological reactivity, conformation, etc., as well as physical properties, such as electrophoretic mobility, chromatographic behavior, sedimentation coefficients, pH optimum, temperature

optimum, stability, solubility, spectroscopic properties, etc. All these nucleic acid molecules and derivatives can be employed in accordance with the present invention as long as the biological activity of the encoded protein remains substantially unaffected in kind, namely that the protein is capable of modulating stomata density in plants. Any one of the above described nucleic acid molecules, in particular those that represent hyper-active mutant forms of subtilisin-like serine proteases are particular suitable for overexpression in transgenic plants. These transgenic plants may either possess an endogenous functional subtilisin-like serine protease or they may lack the corresponding genes, e.g. due to mutation.

The nucleic acid molecules mentioned in section (ii) and (iii) are particular useful for the suppression of genes encoding subtilisin-like serine proteases in plants. Hence, in one embodiment said nucleic acid molecules are preferably of at least 50 nucleotides in length hybridizing specifically with a nucleic acid molecule as described above or with a complementary strand thereof. Specific hybridization occurs preferably under stringent conditions and implies no or very little cross-hybridization with nucleotide sequences encoding no or substantially different proteins. In particular stringent conditions mean, e.g., the use of an aqueous solution of 1% BSA, 1mM EDTA, 0.5 M $NaHPO_4$ pH7.2, 7% SDS and incubation at 65°C. Preferably, stringent hybridization is obtained under the following conditions:

Hybridization buffer:

2 x SSC; 10 x Denhardt's solution (Ficoll 400 + PEG + BSA; ratio 1:1:1); 0.1% SDS; 5mM EDTA; 50 mM Na_2HPO_4; 250 µg/ml herring sperm DNA; 50 µ/ml tRNA; or

0.25M sodium phosphate buffer pH 7.2; 1mM EDTA; 7% SDS

Hybridization temperature: T=65 to 68°C

Washing buffer: 0.2 x SSC; 0.1% SDS

Washing temperature: T=68°C

Such nucleic acid molecules may be used as probes and/or for the control of gene expression. Nucleic acid probe technology is well known to those skilled in the art who will readily appreciate that such probes may vary in length. Preferred are nucleic acid probes of 50 nucleotides or more in length. Of course, it may also be

appropriate to use nucleic acids of up to 100 and more nucleotides in length. The nucleic acid probes of the invention are useful for various applications. On the one hand, they may be used as PCR primers for amplification of nucleic acid sequences according to the invention. Another application is the use as a hybridization probe to identify nucleic acid molecules hybridizing with a nucleic acid molecule of the invention by homology screening of genomic DNA or cDNA libraries. Nucleic acid molecules according to this preferred embodiment of the invention which are complementary to a nucleic acid molecule as described above can be used for repression of expression of a subtilisin-like serine protease encoding gene, for example due to an antisense or triple helix effect or for the construction of appropriate ribozymes (see, e.g., EP-A1 0 291 533, EP-A1 0 321 201, EP-A2 0 360 257) which specifically cleave the (pre)-mRNA of a gene comprising a nucleic acid molecule of the invention or part thereof. Selection of appropriate target sites and corresponding ribozymes can be done as described, for example, in Steinecke, Ribozymes, Methods in Cell Biology 50, Galbraith et al. eds Academic Press, Inc. (1995), 449-460. Furthermore, the person skilled in the art is well aware that it is also possible to label such a nucleic acid probe with an appropriate marker for specific applications, such as for the detection of the presence of a nucleic acid molecule of the invention in a sample derived from an organism, in particular plants.

The above described nucleic acid molecules may either be DNA or RNA or a hybrid thereof. Furthermore, said nucleic acid molecule may contain, for example, thioester bonds and/or nucleotide analogues, commonly used in oligonucleotide anti-sense approaches. Said modifications may be useful for the stabilization of the nucleic acid molecule against endo- and/or exonucleases in the cell.

Furthermore, nucleic acid molecules encoding antibodies specifically recognizing a subtilisin-like serine protease or parts, i.e. specific fragments or epitopes, of such a protein can be used for inhibiting the activity of the protein in plants. These antibodies can be monoclonal antibodies, polyclonal antibodies or synthetic antibodies as well as fragments of antibodies, such as Fab, Fv or scFv fragments etc. Monoclonal antibodies can be prepared, for example, by the techniques as originally described in Köhler and Milstein, Nature 256 (1975), 495, and Galfré, Meth. Enzymol. 73 (1981), 3, which comprise the fusion of mouse myeloma cells to

spleen cells derived from immunized mammals. Furthermore, antibodies or fragments thereof to the aforementioned peptides can be obtained by using methods which are described, e.g., in Harlow and Lane "Antibodies, A Laboratory Manual", CSH Press, Cold Spring Harbor, 1988. These antibodies can be used, for example, for the immunoprecipitation and immunolocalization of proteins according to the invention as well as for the monitoring of the synthesis of such proteins, for example, in recombinant organisms, and for the identification of compounds interacting with the protein according to the invention. For example, surface plasmon resonance as employed in the BIAcore system can be used to increase the efficiency of phage antibodies selections, yielding a high increment of affinity from a single library of phage antibodies which bind to an epitope of the protein of the invention (Schier, Human Antibodies Hybridomas 7 (1996), 97-105; Malmborg, J. Immunol. Methods 183 (1995), 7-13). Expression of antibodies or antibody-like molecules in plants can be achieved by methods well known in the art, for example, full-size antibodies (Düring, Plant. Mol. Biol. 15 (1990), 281-293; Hiatt, Nature 342 (1989), 469-470; Voss, Mol. Breeding 1 (1995), 39-50), Fab-fragments (De Neve, Transgenic Res. 2 (1993), 227-237), scFvs (Owen, Bio/Technology 10 (1992), 790-794; Zimmermann, Mol. Breeding 4 (1998), 369-379; Tavladoraki, Nature 366 (1993), 469-472) and dAbs (Benvenuto, Plant Mol. Biol. 17 (1991), 865-874) have been successfully expressed in Tobacco, Potato (Schouten, FEBS Lett. 415 (1997), 235-241) or *Arabidopsis*, reaching expression levels as high as 6.8% of the total protein (Fiedler, Immunotechnology 3 (1997), 205-216).

In addition, nucleic acid molecules encoding mutant forms of a subtilisin-like serine protease can be used to interfere with the activity of the wild type protein. Such mutant forms preferably have lost their biological activity as defined above and may be derived from the corresponding subtilisin-like serine protease by way of amino acid deletion(s), substitution(s), and/or additions in the amino acid sequence of the protein. As mentioned above, mutant forms of subtilisin-like serine proteases also encompass hyper-active mutant forms of such proteins which display, e.g. an increased substrate affinity and/or higher substrate turnover of the same. Furthermore, such hyper-active forms may be more stable in the cell due to the incorporation of amino acids that stabilize proteins in the cellular environment.

These mutant forms may be naturally occurring or genetically engineered mutants; see also supra.

The recombinant DNA molecule of the invention preferably comprises regulatory sequences allowing for the expression the nucleic acid molecules in plants. Preferably, said regulatory elements comprise a promoter active in plant cells. Expression comprises transcription of the nucleic acid molecule preferably into a translatable mRNA. Regulatory elements ensuring expression in plant cells are well known to those skilled in the art.

These regulatory elements may be homologous or preferably heterologous with respect to the nucleic acid molecule to be expressed and/or with respect to the plant species to be transformed. For example, a preferred regulatory element that can be employed in accordance with the present invention is the SDD1 promoter region as depicted in SEQ ID NO: 5 or part thereof.

Preferably, the promoter region of the SDD1 gene comprising SEQ ID NO: 6 is employed, which corresponds to the nucleotide sequence of SEQ ID NO: 5 starting at position 839. GUS expression studies show that the promoter of SDD1 of Arabidopsis thaliana in tissues having mitotic activity shows a high activity. For example, a very strong GUS expression can be found in developing stomata and in primordials, but also a weaker expression in lateral roots. By way of computer-assisted studies different domains could be identified which possibly are responsible for the expression pattern of this promoter. On the one hand, a domain was identified which allows expression in roots, on the other hand several characteristic motifs were identified which are termed Dof-motifs (see, e.g., Yanagisawa and Schmidt, Plant J. 17 (1999), 209-214) and which in the present case possibly allow for an expression in guard cells. These motifs have, e.g., been described in German patent application DE 19904754.5. It is assumed that a deletion of the domain, which possibly mediates the expression in roots and which is located within the first 400bp of SEQ ID NO: 6, advantageously changes the specificity of the promoter. For this reason preferred embodiments of the invention use promoter fragments comprising at the 5'-region a deletion of at least 400-450bp or of 450-600bp or at the most 900bp.

It is possible for the person skilled in the art to isolate with the help of the coding and regulatory sequences of the invention corresponding genes from other species, for example, potato, tomato, barley, wheat, oat, rye, rice, corn, soja, etc. This can be done by conventional techniques known in the art, for example, by using the regulatory sequences depicted in SEQ ID NO: 6 as a hybridization probe or by designing appropriate PCR primers. It is then possible to isolate the corresponding promoter region by conventional techniques and test it for its expression pattern. For this purpose, it is, for instance, possible to fuse the promoter to a reporter gene, such as GUS, luciferase or green fluorescent protein (GFP) and assess the expression of the reporter gene in transgenic plants.

For example the promoters from the two SDD1 homologs from Solanum toberosum described in Example 6 can be isolated by conventional means. Genomic clones can be amplified, e.g., fragments via long template PCR (employing for example the EXPAND kit, Boehringer Mannheim), using an upstream oriented SDD1 specific primer and a primer to the Lambda left or right arm sequence. The amplified fragment is sequenced via primer walking until several kb upstream from the transcription start point have been reached, if present on the clone, preferably more than 3 kb. Within the cloned genomic sequence, the transcription start site is determined by standard procedures well known to the person skilled in the art, such as 5'-RACE, primer extension or S1 mapping. To define cis-regulatory elements upstream of the transcription start site (i.e. within the putative promoter region), the respective region is fused to marker genes such as genes encoding GUS or GFP, and 5' deletion derivatives of these construct are generated. They are transformed into suitable plant material, and the expression of the marker gene depending on the remaining upstream sequence (putative promoter) is determined. These techniques are well known to the person skilled in the art.

The regulatory sequences so identified may differ at one or more positions from the above-mentioned regulatory sequence but still have the same specificity, namely they comprise the same or similar sequence motifs, preferably 6 to 10 nucleotides in length, responsible for the above described expression pattern. Preferably such regulatory sequences hybridize to one of the above-mentioned regulatory sequences, most preferably under stringent conditions. Particularly

preferred are regulatory sequences which share at least 85%, more preferably 90-95%, and most preferably 96-99% sequence identity with one of the above-mentioned regulatory sequences and have the same or substantially the same specificity. Particularly preferred are the regulatory sequences that comprise the above mentioned motifs which allow for an expression in guard cells. Such regulatory sequences also comprise those which are altered, for example by nucleotide deletion(s), insertion(s), substitution(s), addition(s), and/or recombination(s) and/or any other modification(s) known in the art either alone or in combination in comparison to the above-described nucleotide sequence. Methods for introducing such modifications in the nucleotide sequence of the regulatory sequences of the invention are well known to the person skilled in the art. It is also immediately evident to the person skilled in the art that further regulatory elements may be added to the regulatory sequences of the invention. For example, transcriptional enhancers and/or sequences which allow for induced expression of the regulatory sequences of the invention may be employed.

The possibility exists to modify the regulatory sequences as described above or sequence motifs thereof by, e.g., nucleotide replacements which do not affect the overall structure or binding motif of the regulatory sequence so that it remains capable of conferring the gene expression pattern as described above. Such regulatory sequences may be derived from subtilase genes of potato although other plants may be suitable sources for such regulatory sequences as well. Furthermore, the nucleotide sequences can be compared using appropriate computer programs known in the art such as BLAST, which stands for Basic Local Alignment Search Tool (Altschul, 1997; Altschul, J. Mol. Evol. 36 (1993), 290-390; Altschul, J. Mol. Biol. 215 (1990); 403-410), to search for local sequence alignments. BLAST produces alignments of nucleotide sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST is especially useful in determining exact matches or in identifying homologues.

In general, regulatory elements employed in accordance with the present invention comprise a promoter active in plant cells. To obtain expression in all tissues of a transgenic plant, preferably constitutive promoters are used, such as the 35S promoter of CaMV (Odell, Nature 313 (1985), 810-812) or promoters of the

polyubiquitin genes of maize (Christensen, Plant Mol. Biol. 18 (1982), 675-689). In order to achieve expression in specific tissues of a transgenic plant it is possible to use tissue specific promoters (see, e.g., Stockhaus, EMBO J. 8 (1989), 2245-2251). Known are also promoters which are specifically active in tubers of potatoes or in seeds of different plants species, such as maize, Vicia, wheat, barley etc. Inducible promoters may be used in order to be able to exactly control expression. An example for inducible promoters are the promoters of genes encoding heat shock proteins. Further useful promoters are described in the prior art; see, e.g.:

a) inducible promoters:
described in WO 93/21334 (=alcA/alcR system), WO 90/08826, WO 96/37609.

b) promoters active in photosynthetically active tissue:
the ST-LS1 promoter (Stockhaus et al., Proc. Natl. Acad. Sci. USA 84 (1987), 7943-7947; Stockhaus et al., EMBO J. 8 (1989), 2445-2451), the Ca/b promoter (see e.g. US-A-5,656,496; US-A-5,639,952; Bansal et al., Proc. Natl. Acad. Sci. USA 89 (1992), 3654-3658) and the Rubisco SSU promoter (see e.g. US-A-5,034,322; US-A-4,962,028) as well as the STL1 promoter (Eckes et al., Mol. Gen Genet. 205 (1986), 14-22).

c) promoters and cis-active elements mediating expression in guard cells:
- DE 19904754.5
- DE 4207358
- truncated AGPase promoter (Müller-Röber et al., Plant Cell 6 (1994), 601-612)
- Rhal promoter (Terryn et al., Plant Cell 5 (1993), 1761-1769)

d) promoters mediating expression in meristematic tissue:
- wheat histone H4 promoter (Bilgin et al., Plant Science 143 (1999), 35-44
- rice PCNA promoter (Kosugi et al., Plant J. 7 (1995), 877-886
- wheat histone H2B promoter (Yang et al., Plant Mol. Biol. 28 (1994), 155-172
- cyc07-promoter (Ito et al., Plant Mol. Biol. 24 (1994), 863-878.

Also microspore-specific regulatory elements and their uses have been described (WO96/16182). Furthermore, the chemically inducible Tet-system may be employed (Gatz, Mol. Gen. Genet. 227 (1991); 229-237). Further suitable promoters are

known to the person skilled in the art and are described, e.g., in Ward (Plant Mol. Biol. 22 (1993), 361-366). The regulatory elements may further comprise transcriptional and/or translational enhancers functional in plants cells. A plant translational enhancer often used is, e.g., the CaMV omega sequences and/or the inclusion of an intron (Intron-1 from the Shrunken gene of maize, for example) that has been shown to increase expression levels by up to 100-fold. (Maiti, Transgenic Research 6 (1997), 143-156; Ni, Plant Journal 7 (1995), 661-676). Furthermore, the regulatory elements may include transcription termination signals, such as a poly-A signal, which lead to the addition of a poly A tail to the transcript which may improve its stability. The termination signals usually employed are from the Nopaline Synthase gene or from the CaMV 35S RNA gene.

In a preferred embodiment of the recombinant DNA molecule of the invention, the subtilisin-like serine protease is derived from plants. Preferably, said plants are monocotyledonous or dicotyledonous plants such as those mentioned hereinbefore. A particular preferred embodiment of said plant is Arabidopsis.

The present invention also relates to vectors, particularly plasmids, cosmids, viruses, bacteriophages and other vectors used conventionally in genetic engineering that contain at least one recombinant DNA molecule according to the invention. Methods which are well known to those skilled in the art can be used to construct various plasmids and vectors; see, for example, the techniques described in Sambrook, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory (1989) N.Y. and Ausubel, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y. (1989). Alternatively, the recombinant DNA molecules and vectors of the invention can be reconstituted into liposomes for delivery to target cells.

Advantageously the above-described vectors of the invention comprises a selectable and/or scorable marker. Selectable marker genes useful for the selection of transformed plant cells, callus, plant tissue and plants are well known to those skilled in the art and comprise, for example, antimetabolite resistance as the basis of selection for dhfr, which confers resistance to methotrexate (Reiss, Plant Physiol. (Life Sci. Adv.) 13 (1994), 143-149); npt, which confers resistance to the aminoglycosides neomycin, kanamycin and paromycin (Herrera-Estrella,

EMBO J. 2 (1983), 987-995) and hpt, which confers resistance to hygromycin (Marsh, Gene 32 (1984), 481-485). Additional selectable genes have been described, namely trpB, which allows cells to utilize indole in place of tryptophan; hisD, which allows cells to utilize histinol in place of histidine (Hartman, Proc. Natl. Acad. Sci. USA 85 (1988), 8047); mannose-6-phosphate isomerase which allows cells to utilize mannose (WO 94/20627) and ODC (ornithine decarboxylase) which confers resistance to the ornithine decarboxylase inhibitor, 2-(difluoromethyl)-DL-ornithine, DFMO (McConlogue, 1987, In: Current Communications in Molecular Biology, Cold Spring Harbor Laboratory ed.) or deaminase from Aspergillus terreus which confers resistance to Blasticidin S (Tamura, Biosci. Biotechnol. Biochem. 59 (1995), 2336-2338). Useful scorable marker are also known to those skilled in the art and are commercially available. Advantageously, said marker is a gene encoding luciferase (Giacomin, Pl. Sci. 116 (1996), 59-72; Scikantha, J. Bact. 178 (1996), 121), green fluorescent protein (Gerdes, FEBS Lett. 389 (1996), 44-47) or ß-glucuronidase (Jefferson, EMBO J. 6 (1987), 3901-3907). This embodiment is particularly useful for simple and rapid screening of cells, tissues and organisms containing a vector of the invention. As described above, various selectable markers can be employed in accordance with the present invention. Advantageously, selectable markers may be used that are suitable for direct selection of transformed plants, for example, the phophinothricin-N-acetyltransferase gene the gene product of which detoxifies the herbicide L-phosphinothricin (glufosinate or BASTA); see, e.g., De Block, EMBO J. 6 (1987), 2513-2518 and Dröge, Planta 187 (1992), 142-151.

The present invention, also relates to host cells comprising a recombinant DNA molecule or vector of the invention. Host cells include prokaryotic and eukaryotic cells such as E. coli and yeast, respectively.

The recombinant DNA molecules according to the invention are in particular useful for the genetic manipulation of plant cells, plant tissue and plants in order to obtain plants with modified, preferably with improved or useful phenotypes as described above. Thus, the present invention relates to a method for the production of transgenic plants with altered stomata characteristica compared to wild type

plants comprising the introduction of a recombinant DNA molecule of the invention into the genome of a plant, plant cell or plant tissue.

Methods for the introduction of foreign DNA into plants as well as the selection and regeneration of transgenic plants from plant cells and plant tissue are also well known in the art. These include, for example, the transformation of plant cells, plant tissue or plants with T-DNA using Agrobacterium tumefaciens or Agrobacterium rhizogenes, the fusion of protoplasts, direct gene transfer (see, e.g., EP-A 164 575), injection, electroporation, biolistic methods like particle bombardment and other methods known in the art. The vectors used in the method of the invention may contain further functional elements, for example "left border"- and "right border"-sequences of the T-DNA of Agrobacterium which allow for stable integration into the plant genome. Furthermore, methods and vectors are known to the person skilled in the art which permit the generation of marker free transgenic plants, i.e. the selectable or scorable marker gene is lost at a certain stage of plant development or plant breeding. This can be achieved by, for example cotransformation (Lyznik, Plant Mol. Biol. 13 (1989), 151-161; Peng, Plant Mol. Biol. 27 (1995), 91-104) and/or by using systems which utilize enzymes capable of promoting homologous recombination in plants (see, e.g., WO97/08331; Bayley, Plant Mol. Biol. 18 (1992), 353-361); Lloyd, Mol. Gen. Genet. 242 (1994), 653-657; Maeser, Mol. Gen. Genet. 230 (1991), 170-176; Onouchi, Nucl. Acids Res. 19 (1991), 6373-6378). Methods for the preparation of appropriate vectors are described by, e.g., Sambrook (Molecular Cloning; A Laboratory Manual, 2nd Edition (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). Suitable strains of Agrobacterium tumefaciens and vectors as well as transformation of Agrobacteria and appropriate growth and selection media are well known to those skilled in the art and are described in the prior art (GV3101 (pMK90RK), Koncz, Mol. Gen. Genet. 204 (1986), 383-396; C58C1 (pGV 3850kan), Deblaere, Nucl. Acid Res. 13 (1985), 4777; Bevan, Nucleic. Acid Res. 12(1984), 8711; Koncz, Proc. Natl. Acad. Sci. USA 86 (1989), 8467-8471; Koncz, Plant Mol. Biol. 20 (1992), 963-976; Koncz, Specialized vectors for gene tagging and expression studies. In: Plant Molecular Biology Manual Vol 2, Gelvin and Schilperoort (Eds.), Dordrecht, The Netherlands: Kluwer Academic Publ. (1994), 1-22; EP-A-120 516; Hoekema: The Binary Plant Vector System, Offsetdrukkerij

Kanters B.V., Alblasserdam (1985), Chapter V, Fraley, Crit. Rev. Plant. Sci., 4, 1-46; An, EMBO J. 4 (1985), 277-287). Although the use of Agrobacterium tumefaciens is preferred in the method of the invention, other Agrobacterium strains, such as Agrobacterium rhizogenes, may be used, for example if a phenotype conferred by said strain is desired.

Methods for the transformation using biolistic methods are well known to the person skilled in the art; see, e.g., Wan, Plant Physiol. 104 (1994), 37-48; Vasil, Bio/Technology 11 (1993), 1553-1558 and Christou (1996) Trends in Plant Science 1, 423-431. Microinjection can be performed as described in Potrykus and Spangenberg (eds.), Gene Transfer To Plants. Springer Verlag, Berlin, NY (1995).

The transformation of most dicotyledonous plants is possible with the methods described above. But also for the transformation of monocotyledonous plants several successful transformation techniques have been developed. These include the transformation using biolistic methods as, e.g., described above as well as protoplast transformation, electroporation of partially permeabilized cells, introduction of DNA using glass fibers, etc. Transgenic plant tissue and plants can be regenerated by methods well known in the art. There are various references in the relevant literature dealing specifically with the transformation of maize (cf. e.g. WO95/06128, EP 0 513 849; EP 0 465 875). In EP 292 435 a method is described by means of which fertile plants may be obtained starting from mucousless, friable granulous maize callus. In this context it was furthermore observed by Shillito et al., Bio/Technology 7 (1989), 581 that for regenerating fertile plants it is necessary to start from callus-suspension cultures from which a culture of dividing protoplasts can be produced which is capable to regenerate to plants. After an in vitro cultivation period of 7 to 8 months Shillito et al. obtain plants with viable descendants which, however, exhibited abnormalities in morphology and reproductivity.

Prioli and Söndahl, Bio/Technology 7 (1989), 589 have described how to regenerate and to obtain fertile plants from maize protoplasts of the Cateto maize inbreed Cat 100-1. The authors assume that the regeneration of protoplasts to fertile plants depends on a number of various factors such as the genotype, the physiological state of the donor-cell and the cultivation conditions. With regard to rice various transformation methods can be applied, e.g. the transformation by agrobacterium-medicated gene transfer (Hiei et al., Plant J. 6 (1994), 271-282; Hiei et al., Plant Mol.

Biol. 35 (1997), 205-218; Park et al., J. Plant Biol. 38 (1995), 365-371), protoplast transformation (Datta in "Gene transfer to plants", I. Potrykus, G. Spangenberg (Eds.), Springer-Verlag Berlin Heidelberg (1995), pages 66-75; Datta et al., Plant Mol. Biol. 20 (1992), 619-629; Sadasivam et al., Plant Cell Rep. 13 (1994), 394-396), the biolistic approach (Li et al., Plant Cell Rep. 12 (1993), 250-255; Cao et al., Plant Cell Rep. 11 (1992), 586-591; Christou, Plant Mol. Biol. (1997), 197-203) and electroporation (Xu et al., in "Gene transfer to plants", I. Potrykus, G. Spangenberg (Eds.), Springer-Verlag Berlin Heidelberg (1995), pages 201-208.

Once the introduced DNA has been integrated in the genome of the plant cell, it usually continues to be stable there and also remains with the descendants of the originally transformed cell. It usually contains a selectable marker which confers resistance against biozides or against an antibiotic such as kanamycin, G 418, bleomycin, hygromycin or phosphinotricine etc. to the transformed plant cells. The individually selected marker should therefore allow for a selection of transformed cells against cells lacking the introduced DNA.

The transformed cells grow in the usual way within the plant (see also McCormick et al., Plant Cell Rep. 5 (1986), 81-84). The resulting plants can be cultivated in the usual way and cross-bred with plants having the same transformed genetic heritage or another genetic heritage. The resulting hybrid individuals have the corresponding phenotypic properties.

Two or more generations should be grown in order to ensure whether the phenotypic feature is kept stably and whether it is transferred. Furthermore, seeds should be harvested in order to ensure that the corresponding phenotype or other properties will remain.

In general, the plants, plant cells and plant tissue which can be modified with a recombinant DNA molecule or vector according to the invention can be derived from any desired plant species. They can be monocotyledonous plants or dicotyledonous plants, preferably they belong to plant species of interest in agriculture, wood culture or horticulture, such as crop plants (e.g. maize, rice, barley, wheat, rye, oats etc.), vegetable plants such as tomato, melon, banana, chicoree, salad, cabbage or potato, tobacco, alfalfa, clover, oil producing plants (e.g. oilseed rape, sunflower, peanut, soybean, etc.), cotton, sugar beet, linseed, flax, millet, hemp, sugar cane,

leguminous plants (e.g. beans, peas etc.), wood producing plants, preferably trees, etc.

Thus, the present invention relates also to transgenic plant cells which contain a nucleic acid molecule as defined above or a recombinant DNA molecule or vector according to the invention wherein the nucleic acid molecule is foreign to the transgenic plant cell.

By "foreign" it is meant that the nucleic acid molecule is either heterologous with respect to the plant cell, this means derived from a cell or organism with a different genomic background, or is homologous with respect to the plant cell but located in a different genomic environment than the naturally occurring counterpart of said nucleic acid molecule. This means that, if the nucleic acid molecule is homologous with respect to the plant cell, it is not located in its natural location in the genome of said plant cell when stably integrated into the genome, in particular it is surrounded by different genes. In this case the nucleic acid molecule may be either under the control of its own promoter or under the control of a heterologous promoter. The nucleic acid molecule, vector or recombinant DNA molecule according to the invention which is present in the plant cell may either be integrated into the genome of the plant cell or it may be maintained in some form extrachromosomally.

In one aspect the present invention relates to a transgenic plant cell comprising stably integrated into the genome a recombinant DNA molecule of the invention or a vector of the present invention or obtainable according to the method of the invention wherein the expression of the nucleic acid molecule results in an increased expression or activity of subtilisin-like serine proteases in transgenic plants compared to wild-type plants.

The term "increase in activity" in the context of the present invention is understood to mean an increase in the expression of endogenous genes coding for a protein of the invention and/or an increase of the amount of the protein of the invention in the cells.

The increase in expression can for example be determined by measuring the amount of transcripts encoding the protein of the invention, e.g., by Northern-blot analysis, preferably by the more sensitive NASBA method (as e.g. described by

Leone et al., Journal of Virological Methods 66 (1997), 19-27; Leone et al., Nucleic Acid Res. 26 (1998), 2150-2155; Nakahara et al., Nucleic Acid Res. 26 (1998), 1854-1856) or by RT-PCR. Preferably, an increase in this context means an increase of the amount of transcripts encoding subtilases as compared to corresponding cells which are not genetically modified by at least 5%, more preferably by at least 20%, in particular by at least 50%, and most preferably by at least 400%.

Preferably, the increased expression or activity of subtilisin-like serine proteases in transgenic plants results in decreased stomata density, see, e.g., Example 7.

The increase of the amount of the protein of the invention can for example be determined by Western-blot analysis. Preferably, an increase in this context means an increase of the amount of the protein of the invention as compared to corresponding cells which are not genetically modified by at least 5%, more preferably by at least 20%, in particular by at least 50%, and most preferably by at least 400%.

Alternatively, a plant cell having a nucleic acid molecule encoding a subtilisin-like serine protease present in its genome can be used and modified such that said plant cell expresses the endogenous gene corresponding to this nucleic acid molecules under the control of heterologous promoter and/or enhancer elements. The introduction of the heterologous promoter and mentioned elements which do not naturally control the expression of a nucleic acid molecule encoding a subtilisin-like serine protease using, e.g., gene targeting vectors can be done according to standard methods, see supra and, e.g., Hayashi, Science 258 (1992), 1350-1353; Fritze and Walden, Gene activation by T-DNA tagging. In *Methods in Molecular* biology 44 (Gartland, K.M.A. and Davey, M.R., eds). Totowa: Human Press (1995), 281-294) or transposon tagging (Chandlee, Physiologia Plantarum 78 (1990), 105-115). Suitable promoters and other regulatory elements such as enhancers include those mentioned hereinbefore.

Furthermore, the present invention relates to transgenic plants or plant tissue comprising plant cells of the invention or obtainable by the above described method Preferably, the transgenic plant of the invention displays a decreased stomata density, lower conductance of stomata and/or the water consumption is lowered compared to wild type plants.

Methods for determining stomatal density, leaf conductance and water consumption comprise the following:

- Method for determining stomatal density by means of taking copies using clear nail varnish as described in Sachs et al., Annals of Botany 71 (1993), 237-243.
- Method for determining conductance as described in Muschak et al., Photosynthetica 33 (1997), 455-465.
- Methods for determining water consumption are known to the person skilled in the art.

Preferably, the transgenic plant of the invention displays one or more of the following phenotypes:

a) stomatal density: reduced by at least 2%, preferably by at least 5%, more preferably by at least 10%, most preferably by at least 30%;

b) conductance reduced by at least 2%, preferably by at least 5%, more preferably by at least 10%, most preferably by at least 25%;

c) water consumption reduced by at least 1%, preferably by at least 3%, more preferably by at least 5%, most preferably by at least 10%;

as compared to a corresponding wild type plant.

In another aspect, the present invention relates to a transgenic plant cell which contains stably integrated into the genome a recombinant DNA molecule of the invention or part thereof, a vector of the present invention or obtainable according to the method of the invention, wherein the presence, transcription and/or expression of the nucleic acid molecule or part thereof leads to reduction of the synthesis or the activity of subtilisin-like serine proteases in transgenic plants compared to wild type plants.

Usually the activity will be reduced by at least 10%, preferably by at least 30%, more preferably by at least 70%, most preferably by at least 100%. Methods of how to determine a decrease in activity as well as the definition of the term "activity" have been mentioned in the above. As it appears to be the case that, even minor changes in the amount of expression can have some effect on the phenotype of the plant methods such as NASBA analysis and RT-PCR which are considerably more sensitive in place of the Northern-blot analysis are employed for the analysis of the transgenic plant.

Preferably, said reduction is achieved by an antisense, sense, ribozyme, co-suppression in vivo mutagenesis and/or dominant mutant effect. Therefore, DNA molecules encoding an antisense RNA which is complementary to transcripts of a DNA molecule of the invention are also the subject matter of the present invention, as well as these antisense molecules. Thereby, complementarity does not signify that the encoded RNA has to be 100% complementary. A low degree of complementarity is sufficient, as long as it is high enough in order to inhibit the expression of a protein of the invention upon expression in plant cells. The transcribed RNA is preferably at least 90% and most preferably at least 95% complementary to the transcript of the nucleic acid molecule of the invention. In order to cause an antisense-effect during the transcription in plant cells such DNA molecules have a length of at least 15 bp, preferably a length of more than 100 bp and most preferably a length or more than 500 bp, however, usually less than 5000 bp, preferably shorter than 2500 bp.

The invention further relates to DNA molecules which, during expression in plant cells, lead to the synthesis of an RNA which in the plant cells due to a cosupression-effect reduces the expression of the nucleic acid molecules of the invention encoding the described protein. The invention also relates to RNA molecules encoded thereby. The principle of the cosupression as well as the production of corresponding DNA sequences is precisely described, for example, in WO90/12084, Jorgensen, Trends Biotechnol. 8 (1990), 340-344; Niebel et al. (Curr. Top. Microbiol. Immunol. 197 (1995), 91-103; Flavell et al. (Curr. Top. Microbiol. Immunol. 197 (1995), 43-36; Palaqui and Vaucheret, Plant. Mol. Biol. 29 (1995), 149-159; Vaucheret et al., Mol. Gen. Genet. 248 (1995), 311-317; de Borne et al., Mol. Gen. Genet. 243 (1994), 613-621 and in other sources.
Such DNA molecules preferably encode an RNA having a high degree of homology to transcripts of the nucleic acid molecules of the invention. It is, however, not absolutely necessary that the coding RNA is translatable into a protein.

In a further embodiment the present invention relates to DNA molecules encoding an RNA molecule with ribozyme activity which specifically cleaves transcripts of a DNA molecule of the invention as well as these encoded RNA molecules.

Ribozymes are catalytically active RNA molecules capable of cleaving RNA molecules and specific target sequences. By means of recombinant DNA techniques it is possible to alter the specificity of ribozymes. There are various classes of ribozymes. For practical applications aiming at the specific cleavage of the transcript of a certain gene, use is preferably made of representatives of two different groups of ribozymes. The first group is made up of ribozymes which belong to the group I intron ribozyme type. The second group consists of ribozymes which as a characteristic structural feature exhibit the so-called "hammerhead" motif. The specific recognition of the target RNA molecule may be modified by altering the sequences flanking this motif. By base pairing with sequences in the target molecule these sequences determine the position at which the catalytic reaction and therefore the cleavage of the target molecule takes place. Since the sequence requirements for an efficient cleavage are low, it is in principle possible to develop specific ribozymes for practically each desired RNA molecule.

In order to produce DNA molecules encoding a ribozyme which specifically cleaves transcripts of a DNA molecule of the invention, for example a DNA sequence encoding a catalytic domain of a ribozyme is bilaterally linked with DNA sequences which are homologous to sequences encoding the target protein. Sequences encoding the catalytic domain may for example be the catalytic domain of the satellite DNA of the SCMo virus (Davies et al., Virology 177 (1990), 216-224 and Steinecke et al., EMBO J. 11 (1992), 1525-1530) or that of the satellite DNA of the TobR virus (Haseloff and Gerlach, Nature 334 (1988), 585-591). The DNA sequences flanking the catalytic domain are preferably derived from the above-described DNA molecules of the invention. The expression of ribozymes in order to decrease the activity in certain proteins in cells is also known to the person skilled in the art and is, for example, described in EP-A1 0 321 201. The expression of ribozymes in plant cells was, for example, also described, in Feyter et al. (Mol. Gen. Genet. 250 (1996), 329-338).

In a preferred embodiment this reduction is effected by means of an antisense effect. For this purpose the DNA molecules of the invention or parts thereof are linked in antisense orientation with a promoter ensuring the transcription in plant cells and possibly with a termination signal ensuring the termination of the transcription as well as the polyadenylation of the transcript. In order to ensure an

efficient antisense effect in the plant cells the synthesized antisense RNA should exhibit a minimum length of 15 nucleotides, preferably of at least 100 nucleotides and most preferably of at least 500 nucleotides. Furthermore, the DNA sequence encoding the antisense RNA should be homologous with respect to the plant species to be transformed. However, DNA sequences exhibiting a high degree of homology to DNA sequences which are present in the cells in endogenic form may also be used, preferably with a homology of more than 95%. To inhibit gene expression of the nucleic acid molecule of the invention, preferably DNA molecules are used that show a homology, i.e. identity to the nucleotide sequences of SEQ ID NO: 1, 7, 9 or 11 of at least 90%, more preferably at least 93%, in particular at least 95% and most preferably at least 98%.

In a further embodiment the reduction of the amount of proteins encoded by the DNA molecules of the invention is effected by a ribozyme effect. The basic effect of ribozymes as well as the construction of DNA molecules encoding such RNA molecules have already been described above. In order to express an RNA with ribozyme activity in transgenic cells the above-described DNA molecules encoding a riboyzme are linked with DNA elements which ensure the transcription in plant cells, particularly with a promoter and a termination signal. The ribozymes synthesized in the plant cells lead to the cleavage of the mRNA encoding the subtilisin-like serine proteases described above.

Furthermore, the subtilisin-like serine protease activity in the plant cells of the invention can also be decreased by the so-called "in vivo mutagenesis" also called "chimeraplasty", for which a hybrid RNA-DNA oligonucleotide ("chimeroplast") is introduced into cells by transformation of cells (Zhu et al., Proc. Natl. Acad. Sci. 96 (1999), 8768-8773, Kipp et al., poster session at the 5th International Congress of Plant Molecular Biology, September 21-27, 1997, Singapore; Dixon and Arntzen, meeting report on "Metabolic Engineering in Transgenic Plants", Keystone Symposia, Copper Mountain, CO, USA, TIBTECH 15 (1997), 441-447; WO95/15972; Kren et al., Hepatology 25 (1997), 1462-1468; Cole-Strauss et al., Science 273 (1996), 1386-1389).
Part of the DNA component of the RNA-DNA oligonucleotide is homologous to a nucleic acid sequence of an endogenous subtilisin-like serine protease, in

comparison to the nucleic acid sequence of the endogenous subtilisin-like serine protease it displays, however, a mutation or contains a heterologous region which is surrounded by the homologous regions. By means of base pairing of the homologous regions of the RNA-DNA oligonucleotide and of the endogenous nucleic acid molecule followed by a homologous recombination the mutation contained in the DNA component of the RNA-DNA oligonucleotide or the heterologous region can be transferred to the genome of a plant cell. This results in a decrease of the activity.

In addition, the present invention relates to transgenic plants or plant tissue comprising the above described plant cells of the invention.

In a preferred embodiment the transgenic plant displays increased stomatal density, higher conductance of stomata and/or higher content of sugars and protein in plant leaves or other tissue or organs, compared to wild type plants. An increase in the stomatal density is understood to refer to an elevated content of stomata in all aerial plant organs, preferably in the leaves of plants of the present invention in the order of at least about 10% compared to the corresponding non-transformed wild type plant, which already provides for beneficial effects on the vitality of the plant such as, e.g., improved dry matter. Advantageously, the stomatal density is increased by at least about 50%, preferably by more than about 75%, particularly preferred at least about more than 100% and still more preferably more than about 200%. With respect to a decrease in the stomatal density due to the increased expression or activity of subtilisin-like serine proteases according to the invention in the transgenic plant of the invention, the stomatal density is decreased by at least 2%, preferably by more than 5%, particularly preferred at least about more than 10%, and still more preferably more than about 30%. Preferably, the transgenic plant of the invention shows a yield increase, preferably with respect to a harvestable part of the plant.

The term "yield increase" in the present context is understood to mean preferably an increase in production of ingredients, in particular soluble sugars and/or proteins and/or biomass, in particular if measured in fresh or dry weight per plant.

An increase in protein and/or sugar content in this context means that the protein content in the plant cells of the invention is increased by at least 5%, preferably by

at least 20%, in particular by at least 50% and most preferably by at least 75% as compared to plant cells of wild type plants that are not modified and/or the sugar content is increased by at least 5%, preferably by at least 25%, in particular by at least 50% and most preferably by at least 75% as compared to plant cells of wild type plants that are not modified.

Methods for determining sugar and protein content are known to the person skilled in the art.

The term "yield increase" means an increase of dry weight by least 3%, preferably by at least 10%, in particular by at least 20% and most preferably by at least 30% and/or an increase in fresh weight by least 2%, preferably by at least 5%, in particular by at least 10% and most preferably by at least 20%.

In yet another aspect, the invention also relates to harvestable parts and to propagation material of the transgenic plants according to the invention which contain transgenic plant cells described above, i.e. at least one recombinant DNA molecule or vector according to the invention and/or which are derived from the above described plants. Harvestable parts can be in principle any useful parts of a plant, for example, leaves, stems, flowers, fruit, seeds, roots etc. Propagation material includes, for example, seeds, fruits, cuttings, seedlings, tubers, rootstocks etc.

In addition, the present invention relates to a kit comprising the recombinant DNA molecule or the vector of the invention. The kit of the invention may contain further ingredients such as selection markers and components for selective media suitable for the generation of transgenic plant cells, plant tissue or plants. The kit of the invention may advantageously be used for carrying out the method of the invention and could be, inter alia, employed in a variety of applications, e.g., in the diagnostic field or as research tool. The parts of the kit of the invention can be packaged individually in vials or in combination in containers or multicontainer units. Manufacture of the kit follows preferably standard procedures which are known to the person skilled in the art. The kit or its ingredients according to the invention can be used in plant cell and plant tissue culture, for example in agriculture. The kit of the invention and its ingredients are expected to be very

useful in breeding new varieties of, for example, plants which display improved properties such as those described herein.

Thus, the present invention also relates to a method for the production of a transgenic plant comprising an increased yield and/or increased stomatal density compared to wild type plants, wherein

(a) a plant cell is genetically modified by the introduction of a foreign nucleic acid molecule the presence of which or the expression of which results in a decreased activity of a subtilase;

(b) a plant is regenerated from the cell prepared according to step (a); and

(c) further plants, if any, are generated from the plant prepared according to step (b).

Likewise, the present invention relates to a method for the production of a transgenic plant having a decreased water consumption and/or decreased stomatal density compared to wild type plants wherein

(a) a plant cell is genetically modified by the introduction of a foreign nucleic acid molecule the presence of which or the expression of which results in an increased activity of a subtilase;

(b) a plant is regenerated from the cell prepared according to step (a); and

(c) further plants, if any, are generated from the plant prepared according to step (b).

Furthermore, the present invention relates to use of at least one nucleic acid molecule encoding and/or regulating the expression of a subtilisin-like serine protease, a nucleic acid molecule hybridizing with such a nucleic acid molecule, a nucleic acid molecule encoding a product that interferes with the expression or activity of subtilisin-like serine proteases in plants, or a recombinant DNA molecule or vector of the invention in the production of transgenic plants for increasing yield, and/or increasing stomatal density, and/or increasing leaf fresh and/or dry weight, and/or increasing leaf dry matter content, and/or increasing sugar content in leaves, and/or increasing protein content in leaves, and/or increasing CO_2-assimilation, and/or sustaining photosynthesis (prevention of photoinhibition) under conditions of high irradiance (see Example 1), and/or changing the water consumption of plants, and or couteracting the consequences

of changing environmental contitions with respect to stomatal density by the inhibition or stimulation of a subtilisin-like serine protease encoding gene. Preferably such nucleic acid molecules are derived from plant genes encoding subtilases. Modulation of the activity of these genes leads to several morphological and physiological changes that are useful for the engineering of improved plants for agriculture, wood culture, or horticulture. Furthermore, the above described nucleic acid molecules and the recombinant DNA molecules and vectors according to the invention may be useful for the alteration or modification of plant/pathogene interaction. The term "pathogen" includes, for example, bacteria, viruses and fungi as well as protozoa. The plants, plant tissue and plant cells of the invention as well as harvestable parts and propagation of such plants can be used for the preparation of feed and food or additives therefor.

Deposit

One plasmid produced and used within the scope of the present invention was deposited at the Deutsche Sammlung von Mikroorganismen und Zellkulturen (German Collection of Microorganisms and Cell Cultures) (DSMZ) in Braunschweig, Federal Republic of Germany, which is recognized as an international depository, in accordance with the requirements of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. On October 4, 1999 the following plasmid pAH 14/58 was deposited at the German Collection of Microorganisms and Cell Cultures, (DSMZ) (Deposit number): DSM 13076

These and other embodiments are disclosed and encompassed by the description and examples of the present invention. Further literature concerning any one of the methods, uses and compounds to be employed in accordance with the present invention may be retrieved from public libraries, using for example electronic devices. For example the public database "Medline" may be utilized which is available on the Internet, for example under http://www.ncbi.nlm.nih.gov/PubMed/medline.html. Further databases and addresses, such as http://www.ncbi.nlm.nih.gov/, http://www.infobiogen.fr/, http://www.fmi.ch/biology/research_tools.html, http://www.tigr.org/, are known to

the person skilled in the art and can also be obtained using, e.g., http://www.lycos.com. An overview of patent information in biotechnology and a survey of relevant sources of patent information useful for retrospective searching and for current awareness is given in Berks, TIBTECH 12 (1994), 352-364.

The Figures show:

Figure 1: Top: Release of water vapour (transpiration) from leaves of the wildtype (wt) and the R-558 mutant (R-558) at irradiances of 300 µE (µmol m^{-2} s^{-1}) and 1200 µE (µmol m^{-2} s^{-1}) of white light measured by an infrared gas analyzer.

Bottom: Net uptake of CO_2 (assimilation) into leaves of the wildtype and the R-558 mutant (R-558) at irradiances of 300 µE (µmol m^{-2} s^{-1}) and 1200 µE (µmol m^{-2} s^{-1}) of white light measured by an infrared gas analyzer.

Figure 2: Schematic representation of the SDD1 protein marked with the amino acid positions bordering the putative pre- and the pro-sequence and the positions of the four invariant amino acids (D, H, N, S) found in all known subtilisins. Furthermore, the consequence of the mutation present in the R-558 mutant is indicated which converts the R codon at amino acid position 492 into a stop codon leading to the formation of a C-terminally truncated protein lacking the essential serine residue at position 552 (S552).

Figure 3: Schematic representation of the plasmid pG-*SDD1*

Fragment A: 7067 bp SalI – EcoRV subfragment of the BAC IGF20D22 that includes the 2328 bp coding region of *SDD1* in addition to 2 kb upstream DNA (promoter) and 2.8 kb downstream DNA was inserted into the SalI and SmaI sites of the vector pBIB-Hyg.

Vector: pBIB-Hyg (Becker, 1990, *Nucleic Acids Res.* 18, 203).

Figure 4: Schematic representation of the plasmid p35S-*SDD1*

Fragment A: 35S promoter of the Cauliflower Mosaic Virus; (Gardner et al., 1981, *Nucleic Acids Res.* 9, 2871-2888)

Fragment B: 2328 nucleotides coding region of the SDD1 gene (SEQ ID No. 1)

Fragment C: polyadenylation signal of the gene 3 from the T-DNA of the Ti-plasmid pTi ACH 5 (Gielen et al., 1984, *EMBO J.* 3, 835-846)

Vector: pBIB-Hyg (Becker, 1990, *Nucleic Acids Res.* 18, 203).

Figure 5: Sequence alignments in the four highly conserved domains, the D region, the H region, the substrate binding site, and the S region of the subtilisins Subtilisin BPN´ (Wells et al. 1983, Nucleic Acids Res. 11, 7911-7925), the KEX2 of yeast (Mizuno et al. 1988, *Biochem. Biophys. Res. Commun.* 156, 246-254), the human FURIN/PACE (Wise et al. 1990, *Proc. Natl. Acad. Sci USA* 87, 9378 - 9382), the human PC1/PC3 (Seidah et al., 1991, *Mol. Endocrinol.* 5, 111 - 122; Smeekens et al., 1991, *Proc. Natl. Acad. Sci. USA* 88, 340 - 344), the CUCUMISIN from *Cucumis melo* (Yamagata et al., 1994, *J. Biol. Chem.* 269, 32725 - 32731), LeP69 from *Lycopersicon esculentum* (Tornero et al., 1996, *Proc. Natl. Acad. Sci. USA* 93, 6332 - 6337), the AG12 from *Alnus glutinosa* (Ribeiro et al., 1995, *Plant Cell* 7, 785 - 794) and of SDD1. The positions of the invariant amino acids are marked with *. Identical amino acids present at corresponding positions in the different subtilisins are highlighted with black boxes.

Figure 6: Schematic representation of the plasmid p35S-α*SDD1*

Fragment A: 35S promoter of the Cauliflower Mosaic Virus; (Gardner et al., 1981, *Nucleic Acids Res.* 9, 2871-2888)

Fragment B: 2079 bp – fragment (position 74 – 2153 according to the sequence shown in SEQ ID No. 1) of the *SDD1* gene inserted in antisense orientation to the 35S promoter.

Fragment C: polyadenylation signal of the gene 3 from the T-DNA of the Ti-plasmid pTi ACH 5 (Gielen et al., 1984, *EMBO J.* 3, 835-846)

Vector: pBIB-Hyg (Becker, 1990, *Nucleic Acids Res.* 18, 203).

Figure 7: Amino acid comparison of three different subtilases; at_subp1=Subtilase from Arabidopsis thaliana, see SEQ ID No. 2, st_subp1=Subtilase from Solanum tuberosum, see SEQ ID No. 8; st_subp2=Subtilase from Solanum tuberosum, see SEQ ID No. 12.

The Examples illustrate the invention:

Example 1: H_2O transpiration and CO_2 assimilation are increased in the *Arabidopsis thaliana* R-558 mutant particularly under conditions of high irradiance

Arabidopsis thaliana R-558 mutant plants and corresponding wildtype plants (wt) were grown until bolting in soil (Einheitserde Typ P / Einheitserde Typ T / sand: 2 / 1 / 1) under standard culture conditions in a climatised growth chamber at 16 h photoperiod (180 µmol m^{-2} s^{-1} fluorescent light; lamp type: TLD36W/840 and TLD36W/830, Philips, Hamburg, Germany) with day and night temperature and relative humidity of 20°C, 60% relative humidity and 16°C, 75% relative humidity, respectively. Single leaves (n=10) were clamped into a gas exchange measurement chamber of an infrared gas analyzer (Walz, Effeltrich, Germany) with H_2O release from as well as CO_2 uptake into the leaves were measured according to the procedure described by Muschak et al. (*Photosynthetica* 33, 455-465, 1997). As shown in Figure 1, the leaves of the mutant plants showed increased transpiration of H_2O and increased assimilation (net uptake) of CO_2 under low light (300 µmol m^{-2} s^{-1}) and under high light (1200 µmol m^{-2} s^{-1})

conditions applied during the measurements. Enhancement of CO_2 assimilation, being almost double in the R-558 mutant in comparison to the wild type, was most prominent under the high light conditions which caused a depression of CO_2 assimilation in the wild type in comparison to the low light conditions (photoinhibition).

Example 2: Isolation of the *SDD1* gene through map-based gene cloning

The genetic locus affected by the mutation in the R-558 mutant has previously been mapped to the top arm of the *Arabidopsis thaliana* chromosome 1 to an interval of approximately 0.59 cM bordered by the molecular markers IGF-20G19LE and IGF-25I3RE (D. Berger, 1997, PhD Thesis Freie Universität Berlin). Two clones of the *Arabidopsis thaliana* genomic IGF-BAC library (Mozo et al., 1998, *Mol. Gen. Genet.* 258, 562-570), IGF20D22 and IGF21M11, which fully cover this region, were sequenced by the SPP consortium (see http://sequence-www.stanford.edu/ara/SPP.html) as part of the *Arabidopsis* genome initiative (Bevan et al., 1997; *Plant Cell* 9, 476-478; http://genome-www.stanford.edu/Arabidopsis/agi.html). The 0.59 cM region was thus identified to cover 113 kb of genomic DNA sequence. In order to identify the *SDD1* gene corresponding to the mutant locus, this region was scanned for mutations by application of the restriction SSCP- (single strand conformational polymorphism) technique (Dean and Gerrard, 1991, *BioTechniques* 10, 332 - 333; Iwahana et al., 1992, *BioTechniques* 12, 64 - 66) which for this purpose was adapted for the use in plants. This approach is novel and has not been applied for mutation scanning in plants before. Thus, 57 DNA fragments of 2-kb each, were separately PCR amplified from total DNA of wild type and R-558 plants and after digestion with Alu I and/or Hinf I they were analysed through polyacrylamid gel electrophoresis as described by Dean and Gerrard, 1991 (*BioTechniques* 10, 332 – 333) and Iwahana et al., 1992 (*BioTechniques* 12, 64 – 66). A single SSCP was detected that discriminated between the two genotypes and which upon sequencing of the corresponding DNA fragments was shown to be caused by a single C/G -> T/A mutation (Seq. ID No. 1; Seq. ID No. 3). This mutation introduced a premature stop codon into an ORF of a predicted gene spanning 2328 bp that encoded for a

deduced polypeptide of 775 amino acids (Fig. 2; Seq. ID No. 2; Seq. ID No. 4; Genbank Accession AC002411; http://pgec-genome.pw.usda.gov/F20D22.anno.html#anchor12).

Example 3: Genetic complementation of the R-558 mutant by *Agrobacterium tumefaciens* – mediated DNA-transfer

In order to confirm the identity of the 2328 bp DNA sequence (Seq. ID No. 1;) as the protein coding region of the *SDD1* gene defective in the R-558 mutant, genetic complementation experiments were performed with the introduction of a wild type DNA-copy into the R-558 mutant through *Agrobacterium tumefaciens* – mediated genetic transformation.

Two plasmids were generated for this purpose:

Plasmid pG-*SDD1'* (Fig. 3) carries the 7067 bp SalI - EcoRV subfragment of the BAC IGF20D22 that includes the 2328 bp coding region of *SDD1* in addition to 2 kb upstream DNA (promoter) and 2.8 kb downstream DNA was inserted into the SalI and SmaI sites of the T-DNA vector pBIB-Hyg (Becker, 1990, *Nucleic Acids Res.* 18, 203).

The second plasmid, p35S-*SDD1* (Fig. 4), harbours the three fragments, A, B, C, inserted into the pBIB-Hyg vector (Becker, 1990, *Nucleic Acids Res.* 18, 203). Fragment A, which was inserted between the EcoRI and SacI restricition sites in the polylinker of pBIB-Hyg, includes the 35S promoter of the Cauliflower Mosaic Virus (CaMV) comprising the nucleotides 7146 through 7464 as described by Gardner et al. (*Nucleic Acids Res.* 9, 2871-2888, 1981). Fragment C contains the polyadenylation signal of the gene 3 from the T-DNA of the Ti-plasmid pTi ACH 5 (Gielen et al., *EMBO J.* 3, 835 – 846, 1984), nucleotides 11749 through 11939 which was isolated as Pvu II - Hind III fragment from the plasmid pAGV 40 (Herrera-Estrella et al., *Nature* 303, 209 – 213, 1983) and which, after addition of a Sph I linker to the Pvu II restriction site, was inserted into the Sph I and Hind III restriction sites of pBIB-Hyg. The resulting intervening plasmid was called pBIN-AR-Hyg. Fragment B covers the 2328 nucleotides coding region of the *SDD1* gene (Seq. ID No. 1) that was amplified by PCR from the BAC IGF20D22 and

provided with Asp718 and XbaI linker sequences and which was inserted into the Asp718 and XbaI restriction sites of pBIN-AR-Hyg.

Both plasmids were separately introduced into *Agrobacterium tumefaciens* according to the procedure described by Höfgen and Willmitzer (*Nucleic Acids Res.* 16, 9877, 1988) and the corresponding T-DNAs were stably introduced into the R-558 mutant by *Agrobacterium tumefaciens* - *in planta* transformation following the method described by Bechtold et al. (*Compt. Rend. Acad. Sci.* 316, 1194 – 1199, 1993). Transformed seedlings selected for antibiotic (Hygromycin) resistance were grown to maturity and tested for the expression of mutant or wildtype phenotypes by microscopic examination of rosette leaves cleased with 80 % ethanol.

Table 1: Analysis of stomatal density and distribution in the abaxial epidermices of cotyledons and leaves of wild type (wt), mutant (R-558) and transgenic mutant (R-558 / G-SDD1; R-558 /35S-SDD1)

Plant	Cotyledon			Primary Leaf			
	Single Stomata[a]	Clustered Stomata[b]	n[c]	Single Stomata[a]	Clustered Stomata[b]	n[c]	Density [no./mm²]
wt #1	100 %	0 %	58	100 %	0 %	163	97.0
wt #2	100 %	0 %	40	100 %	0 %	174	124.3
wt #3	100 %	0 %	51	98.9 %	1.1 %	176	125.7
wt #4	100 %	0 %	49	100 %	0 %	160	114.3
wt #5	100 %	0 %	58	100 %	0 %	166	118.6
R-558 #1	61 %	39 %	136	86 %	14 %	492	351.4
R-558 #2	56 %	44 %	62	90.1 %	9.9 %	421	300.7
R-558 #3	54 %	46 %	137	89.6 %	10.4 %	395	282.1
R-558 #4	58 %	42 %	109	93.9 %	6.1 %	409	292.1
R-558 #5	60 %	40 %	85	91.6 %	8.4 %	403	287.9
R-558 / G-*SDD1* #1	100 %	0 %	47	100 %	0 %	279	199.3
R-558 / G-*SDD1* #2	100 %	0 %	53	83.4 %	16.6 %	181	161.6
R-558 / G-*SDD1* #3	100 %	0 %	52	100 %	0 %	139	99.3
R-558 / G-*SDD1* #4	96.4 %	3.6 %	55	100 %	0 %	195	139.3
R-558 / G-*SDD1* #5	100 %	0 %	53	100 %	0 %	180	128.6
R-558 / G-*SDD1* #6	100 %	0 %	55	100 %	0 %	169	120.7
R-558 / G-*SDD1* #7	100 %	0 %	53	100 %	0 %	163	116.4
R-558 / G-*SDD1* #8	96.8 %	3.2 %	62	100 %	0 %	285	203.6
R-558 / G-*SDD1* #9	100 %	0 %	37	100 %	0 %	98	70.0
R-558 / G-*SDD1* #10	96.7 %	3.3 %	60	100 %	0 %	199	142.1
R-558 / 35S-*SDD1* #1	82 %	18 %	66	100 %	0 %	167	119.3
R-558 / 35S-*SDD1* #2	100 %	0 %	34	100 %	0 %	123	87.9
R-558 / 35S-*SDD1* #3	93 %	7 %	55	100 %	0 %	168	120
R-558 / 35S-*SDD1* #4	74 %	26 %	80	100 %	0 %	136	97.1
R-558 / 35S-*SDD1* #5	100 %	0 %	45	100 %	0 %	122	87.1
R-558 / 35S-*SDD1* #6	80 %	20 %	70	100 %	0 %	195	139.3
R-558 / 35S-*SDD1* #7	53 %	47 %	131	98 %	2 %	200	142.9
R-558 / 35S-*SDD1* #8	91 %	9 %	68	100 %	0 %	123	87.9
R-558 / 35S-*SDD1* #9	80 %	20 %	90	95.1 %	4.9 %	123	87.9
R-558 / 35S-*SDD1* #10	94 %	6 %	65	100 %	0 %	108	77.1

[a] Stomata separated from other stomata by at least one epidermal cell. [b] Stomata placed in direct contact to at least one other stoma. [c] Number of stomata sampled.

As shown in Table 1, 7 out of 10 and 2 out of 10 transformants harbouring the T-DNAs of the pG-*SDD1* or the p35S-*SDD1* plasmids, respectively, showed a wildtype phenotype on cotyledons with respect to the appearance/absence of clustered stomata. 7 transformants carrying the T-DNA of p35S-*SDD1* showed an intermediate phenotype in cotyledons due to inappropriate expression of the transgene in this organ. In primary leaves, all 10 transformants harboring the T-DNA of pG-*SDD1* and all 10 transformants carrying the T-DNA of p35S-*SDD1* showed a strong reduction in stomatal density and/or the fraction of clustered stomata as compared to the R-558 mutant. These data unequivocally demonstrated the identity of the 2325 bp DNA fragment as the coding region of the *SDD1* gene.

Example 4: Analysis of the *SDD1* nucleotide sequence and SDD1 amino acid sequence

The analysis of the *SDD1* nucleotide and derived amino acid sequences was performed using the GCG 8.1 and BLAST 2.0 computer programs (see: Program Manual for the Wisconsin Package, Version 8, September 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711; Altschul et al. 1997, *Nucleic Acids Res.* 25, 3389-3402).

The derived amino acid sequence of *SDD1* shows significant identity / similarity to known members of a specific class of serine proteases, called subtilisins or dibasic processing endoproteases. In subtilisins, four regions form the catalytic triad and the substrate binding site and are most highly conserved among subtilisins, prominent representatives of which are the bacterial SUBTILISIN BPN' (Wells et al. 1983, Nucleic Acids Res. 11, 7911-7925), the KEX2 of yeast (Mizuno et al. 1988, *Biochem. Biophys. Res. Commun.* 156, 246-254), the human furin/PACE (GenBank, Acc. No. X17094) and PC1/PC3 (Seidah et al., 1991, *Mol. Endocrinol.* 5, 111 - 122; Smeekens et al., 1991, *Proc. Natl. Acad. Sci. USA* 88, 340 - 344). Several genes from plants encoding subtilases have been isolated such as CUCUMISIN from *Cucumis melo* (Yamagata et al., 1994, *J. Biol. Chem.* 269, 32725 - 32731), P69 from *Lycopersicon esculentum* (Tornero et al., 1996, *Proc. Natl. Acad. Sci. USA* 93, 6332 - 6337), or AG12 from *Alnus glutinosa*

(Ribeiro et al., 1995, *Plant Cell* 7, 785 - 794). The *in vivo* functions of these plant enzymes, however, are hitherto unknown. In the four conserved regions, SDD1 displays highest sequence similarity to the subtilisins listed above and contains the four characteristic invariant amino acids present in all subtilisins hitherto known (Fig. 5). This unequivocally proves the belonging of SDD1 to this class of endoproteases. The amino acid sequence motif VICAAGNNG within the substrate binding site, however, is unique and distinguishes *SDD1* from all other known subtilisins. The mutation present in the R-558 mutant creates a premature stop codon leading to the formation of a C-terminally truncated protein which lacks the essential S-domain containing the catalytically active serine residue (Fig. 2).

Example 5: Modulation of stomatal density in plants through modulation of *SDD1* expression by genetic engineering

The usefulness of the *SDD1* gene for the creation of plants with various different levels of increased or decreased stomatal densities through modulation of the degree of *SDD1* gene expression was shown by the analysis of further transgenic plants. 4 out of 10 of the transgenic plants carrying the aforementioned (Example 4) T-DNA of p35S-*SDD1* and 1 out of 10 of the transgenic plants carrying the aforementioned (Example 4) T-DNA of pG-*SDD1* showed lower stomatal density than the corresponding wildtype plants analyzed in parallel (Table 1).

Furthermore, *SDD1* antisense inhibition studies were performed: To this end, the plasmid p35S-α*SDD1* was generated which contains an antisense-gene construct called `35S-α*SDD1*´ (Fig. 6). A 2079 bp - fragment (position 74 - 2153 according to the sequence shown in seq. ID 1) of the *SDD1* gene was PCR-amplified and subcloned into the pCR 2.1 - vector (Invitrogen, Leek The Netherlands). Using the flanking Asp718 (3´) and XbaI (5´) restriction sites, the 2 kb *SDD1* - fragment was cut from the pCR 2.1 - vector and inserted into the Asp718 and XbaI sites of the pBIN-AR-Hyg. vector (see example 3), thus placing it in antisense orientation to the CaMV 35S – promoter.

The plasmid p35S-α*SDD1* was introduced into *Agrobacterium tumefaciens* according to Höfgen and Willmitzer (*Nucleic Acids Res.* 16, 9887, 1988) and was used to generate transgenic *Arabidopsis thaliana* plants through application of the

procedure described by Schmidt and Willmitzer (*Plant Cell Rep.* 7, 583-586, 1988). Among the transgenic plants carrying the T-DNA of p35S-α*SDD1* thus generated, individuals with increased stomatal density were obtained.

It was thus demonstrated that through the application of genetic engineering techniques, a gene encoding a subtilisin-like serine protease, can be used to generate plants with various different levels of decreased or increased stomatal densities brought about by the modulation of the expression of said gene.

Example 6: Cloning of two SDD1 homologs from *Solanum tuberosum*

A 2328 bp fragment representing the complete SDD1 coding region from *Arabidopsis* was amplified from the clone IGF20D22 of the *Arabidopsis thaliana* genomic IGF-BAC library (Mozo et al., 1998, Mol. Gen. Genet. 258, 562-570) via PCR and was used as a radiolabeled probe (Random Primed DNA Labeling Kit, Boehringer Mannheim) in the screening procedure.

Plaque lifting was performed on 1.6 x 10^6 pfus of a genomic library from *Solanum tuberosum* L. line AM80/5793 (Liu et al., 1991, Plant Mol. Biol. 17, 1139-1154), using Hybond N filters (Amersham).

After pre-hybridization for 4 h at 42^0 C in buffer A (5 x SSC, 0,5 % BSA, 5 x Denhardt, 1 % SDS, 40 mM phosphate buffer, pH 7.2, 100 mg/l herring sperm DNA, 25 % formamid) filters were hybridized to the radiolabeled probe (see above). After 8 h of hybridization the filters were washed 3 times for 20 min at 50^{0}C in a buffer containing 3 x SSC and 0.5 % SDS. X-ray film exposure was usually performed for 14h.

Ten strongly hybridizing phage plaques were rescreened and purified to homogenity. Phage DNA was prepared according to the method described by Patterson & Dean 1987 (NAR Vol.15 (15), 6298).

According to their restriction patterns and Southern analysis, using the radiolabeled *SDD1* PCR fragment as a probe, phages were divided into two different classes. In case of class I a 3864 bp hybridizing EcoRI/SalI fragment was subcloned into pMCS5 (EcoRI/SalI) (Mo Bi Tec, Göttingen), yielding plasmid pAH10/58. In case of class II a ~4.5 kb hybridizing ScaI- fragment was subcloned in pMCS5 (Mo Bi Tec, Göttingen), yielding plasmid pAH 14/58. Both of the plasmids were subjected to DNA-sequencing analysis and contained the

nucleotide sequences, coding for *SDD1* homologs from *Solanum tuberosum* P1gen (SEQ ID NO: 7), P1 - corresponding to P1gen without the intron - (SEQ ID NO: 9), and P2 (SEQ ID NO: 11) The class I a fragments are characterized by the presence of introns, class IIa fragments by the absence of introns. The amino acid sequences encoded by P1 and P2 are shown in SEQ ID NOS: 8, 10 and 12, respectively, and compared to that of SDD1 in Figure 7.

Example 7: Overexpression of subtilase in tobacco

A genomic fragment of 2.3 kb was amplified by PCR from the genome of A. thaliana var. C24, and Asp 718/ Xba I (the primers comprised these sequences) and cloned into the vector pBinAR Hyg (Höfgen and Willmitzer (1990), Plant Sci. 66: 221-230).

Agrobacteria GV2260 (Deblaere (1985), Nucl. Acid Res. 13: 4777-4788) were transformed by way of heat shock, and tobacco plants were infected cv. SNN and regenerated (Rosahl et al., (1987) EMBO J. 6: 1155-1159).

In total, 24 plants were examined as to their RNA expression. For this, RNA from leaf plants was prepared according to Logemann et al. (1987) Anal. Biochem. 163: 16-20) in tissue culture (22°C, 50% atmospheric humidity, 2000 Lux, 16h/8h light rhythm). About 10µg RNA were loaded onto a denaturating gel (Lehrach et al., (1977) Biochem. 16: 4743-4751) and thereupon transferred onto a positively charged membrane Hybond N+ (Amersham Buchler, Braunschweig) via capillary transfer. Thereafter, the RNA was fixed onto the membrane via heat fixation (2h/80°C), washed in 2XSSC for a short period of time (2-3 min), prehybridized for at least 1h at 65°C (0.25M Na-P buffer pH 7.2; 1% BSA, 7% SDS and 10mM EDTA) and hybridized overnight at 65°C with a radioactively labeled probe (Feinberg, and Vogelstein, (1983) Anal. Biochem. 132: 6-13). After two washes with 2XSSC at 65°C for 30 min each the filter was exposed on an X-ray filter overnight at –80°C.

In total, 24 plants were analyzed by way of "Northern technique", of which 12 could be classified as positive, 9 being classified as strong and 3 as weaker expressers. Copies using clear nail varnish were prepared from these plants as well as from the wild type, 5 leafs from different plants of the wild type were analyzed. For doing so, 5 areas each were counted and stomatal density was

determined as stomata/mm^2. When doing so, it was surprisingly found that stomatal density on the adaxial leaf surface was about twice as high as on the abaxial surface; see table 2.

Table 2

Microscopic analysis of stomatal density

WT/adaxial

Pl.-Nr						Stomata/mm2
1	71	65	73	68	69	56
2	58	69	62	51	52	47
3	78	74	68	73	76	60
4	83	87	71	82	73	64
5	77	75	79	76	73	62
6	69	69	64	68	63	54
7	61	67	61	64	63	51
					MV:	56 STD: 6,13

WT/abaxial

Pl.-Nr.						Stomata/mm2
1	101	108	105	98	109	84
2	128	144	140	139	147	113
3	163	154	160	157	165	129
4	111	115	116	121	107	92
5	183	176	180	168	171	142
6	131	138	135	141	139	111
					MV:	112 STD: 21,79

AR Subt./adaxial

Pl.Nr.						Stomata/mm2
13	27	21	20	23	21	18
14	17	23	24	22	20	17
15	21	20	23	19	22	17
16	17	13	19	18	23	15
19	24	28	29	26	28	22
22	25	23	27	22	26	20
30	22	26	24	21	25	19
37	27	26	30	33	28	23
38	30	26	33	30	28	24
40	27	23	26	25	31	21
41	21	23	25	22	20	18
42	27	25	22	23	22	19
					MV:	19 STD: 2,72

AR Subt./abaxial

Pl.Nr.						Stomata/mm2
13	74	71	72	71	76	59
14	73	61	72	70	76	57
15	80	78	71	83	75	63
16	86	99	72	83	97	71
19	84	95	87	93	94	73

22	58	47	62	62	56	46	
30	93	93	96	87	91	75	
37	92	97	95	100	93	77	
38	76	80	78	77	83	64	
40	81	77	88	73	76	64	
41	62	56	61	68	59	50	
42	82	75	78	81	75	63	
mean value					MV:	63	STD. 9,58

	WT	AR Subt.
adaxial	56	19
abaxial	112	63

STD = standard deviation
MV = mean value
WT = wild type
AR = transgenic plant

After microscopic analysis of the copies of the transgenic plants which were taken by using clear nail varnish, a decrease in stomatal density by about 50% on both leaf sides could be detected. The hypostomatic phenotype, however, is also found in the transgenic plants; see table 2.

No differences could be found between strong and weak "expressers"; thus even a minor increase of SDD1 activity seems to be sufficient to result in a phenotype.

Claims

1. A recombinant DNA molecule comprising:

   (i) a nucleic acid molecule encoding a subtilisin-like serine protease or encoding a biologically active fragment of such a protein, selected from the group consisting of

   (a) nucleic acid molecules comprising a nucleotide sequence encoding a protein comprising the amino acid sequence as given in SEQ ID NO: 2, 8, 10 or 12;

   (b) nucleic acid molecules comprising a nucleotide sequence as given in SEQ ID NO: 1, 7, 9 or 11;

   (c) nucleic acid molecules encoding a protein comprising at least the D region, H region, substrate binding site and/or S region of the subtilisin-like serine protease encoded by a nucleic acid molecule of (a) or (b); or

   (d) nucleic acid molecules hybridizing with the complementary strand of a nucleic acid molecule as defined in any one of (a) to (c);

   (e) nucleic acid molecules encoding a protein the amino acid sequence of which is at least 65% identical to the amino acid sequence encoded by a nucleic acid molecule of any one of (a) to (c);

   (f) nucleic acid molecules, the nucleotide sequence of which is degenerate as a result of the genetic code to a nucleotide sequence of a nucleic acid molecule as defined in any one of (a) to (e); or

   (ii) a nucleic acid molecule encoding a mutant non-active or a hyper-active form of or an antibody against the subtilisin-like serine protease encoded by a nucleic acid molecule of (i); or

(iii) a nucleic acid molecule which specifically hybridizes with a nucleic acid molecule of (i) or the complementary strand thereof.

2. The recombinant DNA molecule of claim 1 wherein the nucleic acid molecule is DNA, cDNA, genomic DNA or synthetically synthesized DNA.

3. The recombinant DNA molecule of claim 1 wherein the nucleic acid molecule is derived from a plant, preferably Arabidopsis or potato.

4. The recombinant DNA molecule of any one of claims 1 to 3 wherein said nucleic acid molecule is operably linked to regulatory elements allowing the expression of the nucleic acid molecule in plants.

5. A vector comprising a recombinant DNA molecule of any one of claims 1 to 4.

6. A host cell containing a vector of claim 5 or a recombinant DNA molecule of any one of claims 1 to 4.

7. A method for the production of transgenic plants with altered stomata characteristica compared to wild type plants comprising the introduction of a recombinant DNA molecule of any one of claims 1 to 4 or the vector of claim 5 into the genome of a plant, plant cell or plant tissue.

8. A transgenic plant cell comprising stably integrated into the genome a recombinant DNA molecule of any one of claims 1 to 4 or a vector of claim 5 or obtainable according to the method of claim 7, wherein the expression of the nucleic acid molecule results in an increased expression or activity of subtilisin-like serine proteases in transgenic plants compared to wild type plants.

9. A transgenic plant or a plant tissue comprising plant cells of claim 8.

10. The transgenic plant of claim 9 which displays a decreased stomata density, lower conductance of stomata and/or wherein the water consumption is lowered compared to wild type plants.

11. A transgenic plant cell which contains stably integrated into the genome a recombinant DNA molecule of any one of claims 1 to 4 or part thereof, a vector of claim 5 or obtainable according to the method of claim 7, wherein the presence, transcription and/or expression of the nucleic acid molecule or part thereof leads to reduction of the synthesis or the activity of subtilisin-like serine proteases in transgenic plants compared to wild type plants.

12. The plant cell of claim 11, wherein the reduction is achieved by an antisense, sense, ribozyme, co-suppression and/or dominant mutant effect.

13. A transgenic plant or plant tissue comprising the plant cells of claim 11 or 12.

14. The transgenic plant of claim 13 which displays increased stomatal density and/or higher conductance of stomata and/or increased content of sugars and/or protein in plant leaves compared to wild type plants.

15. The transgenic plant of any one of claims 9, 10, 13 or 14, the plant cell of any one of claims 8, 11 or 12, or the plant tissue of claim 9 or 13, wherein said plant, plant cell or plant tissue is derived from a monocotyledonous or dicotyledonous plant.

16. The transgenic plant, plant cell or plant tissue of claim 15, wherein said plant is derived from maize, rice, barley, wheat, rye, oats, tomato, melon, banana, chicoree, salad, cabbage, potato, tobacco, alfalfa, clover, oilseed rape, sunflower, peanut, soybean, cotton, sugar beet, linseed, flax, millet, hemp, sugar cane, bean, pea or tree.

17. Harvestable parts or propagation material of plants of any one of claims 9, 10, 13 or 14 to 16 comprising plant cells of claim 8, 11, 12, 15 or 16.

18. A kit comprising a recombinant DNA molecule of any one of claims 1 to 4 or a vector of claim 5.

19. A method for the production of a transgenic plant comprising an increased yield and/or increased stomatal density compared to wild type plants, wherein
    (a) a plant cell is genetically modified by the introduction of a foreign nucleic acid molecule the presence of which or the expression of which results in a decreased activity of a subtilase;
    (b) a plant is regenerated from the cell prepared according to step (a); and
    (c) further plants, if any, are generated from the plant prepared according to step (b).

20. A method for the production of a transgenic plant having a decreased water consumption and/or decreased stomatal density compared to wild type plants wherein
    (a) a plant cell is genetically modified by the introduction of a foreign nucleic acid molecule the presence of which or the expression of which results in an increased activity of a subtilase;
    (b) a plant is regenerated from the cell prepared according to step (a); and
    (c) further plants, if any, are generated from the plant prepared according to step (b).

21. Use of a nucleic acid molecule encoding or regulating the expression of a subtilisin-like serine protease or a nucleic acid molecule hybridizing with such a nucleic acid molecule, a nucleic acid molecule as defined in any one of claims 1 to 4, a recombinant DNA molecule of any one of claims 1 to 4, or a vector of claim 5 for the production of plants with improved fresh and dry weight, for enhancing the content of sugars and/or protein in plant leaves for the production of plants with reduced leaf temperatures or with reduced water loss and lower water consumption, for the modulation (enhancement) of CO_2 uptake into and H_2O release from leaves, for sustained photosynthesis under high intensity conditions or for the improvement of disease resistance of plants.


Transpiration E (mmol/m²xs)
1,4
1,2
1
0,8
0,6
0,4
0,2
0
300µE
1200µE
wt
R-558
Assimilation A (µmol/m²xs)
4,5
4
3,5
3
2,5
2
1,5
1
0,5
0
300µE
1200µE
wt
R-558

Figure 1



Figure 2



Figure 3



Figure 4

D region

		*
Ag12	136	GEDVIIGVI DSGVWPESDS FKDDGM
SDD1	137	GQGTIIGVL DTGVWPESPS FDDTGM
LeP69	137	GKGVIIGVI DTGILPDHPS FSDVGM
Cucumisin	131	ESNIVVGVL DTGIWPESPS FDDEGF
Furin/PACE	144	GHGIVVSIL DDGIEKNHPD LAGNYD
PC1/PC3	158	GKGVVITVL DDGLEWNHTD IYANYD
KEX2	166	GAGVVAAIV DDGLDYENED LKDNFC
Subtilisin BPN´	130	GSNVKVAVI DSGIDSSHPD LKVAGG
Consensus		G-GV---V- D-G-----P- --D-G-

H region

		*
Furin/PACE	186	YTQMNDNRHG TRCAGEVAAV ANNGVC
PC1/PC3	200	YDPTNENKHG TRCAGEIAMQ ANNHKC
KEX2	205	KPRLSDDYHG TRCAGEIAAK KGNNFC
Cucumisin	196	NGPRDTNGHG THTASTAAGG LVSQAN
LeP69	195	GSPIDDDGHG THTASTAAGA FVNGAN
Ag12	208	NSARDTLGHG THTASTAAGN YVNGAS
SDD1	214	ISARDSTGHG THTASTVGGS SVSMAN
Subtilisin BPN´	163	NPFQDNNSHG THVAGTVAAL NNSIGV
Consensus		----D---HG TH-A-T-A-- --N---

substrate binding site

		*
Furin/PACE	284	GLGSIFVWAS GNGGR
PC1/PC3	298	GKGSIFVWAS GNGGR
KEX2	303	SKGAIYVFAS GNGGT
Cucumisin	296	ERGILTSNSA GNGGP
LeP69	295	ERGILVSCSA GNNGP
Ag12	307	EKGVVVSTSA GNAGP
SDD1	313	ERGISVICAA GNNGP
Subtilisin BPN´	251	ASGVVVVAAA GNEGT
Consensus		--G-----AA GN-G-

S region

		*
Furin/PACE	363	SHTGTSAS APLAAGIIAL TLE
PC1/PC3	377	THTGTSAS APLAAGIFAL ALE
KEX2	380	SHGGTSAA APLAAGVYTL LLE
LeP69	527	IISGTSMS CPHLSGVRAL LKS
SDD1	547	VMSGTSMS CPHVSGITAL IRS
Ag12	532	MVSGTSMA CPHASGVAAL LKA
Cucumisin	520	IISGTSMS CPHITGIATY VKT
Subtilisin BPN´	323	AYNGTSMA SPHVAGAAAL ILS
Consensus		---GTSMS -PH--G--AL

Figure 5



Figure 6


At_subtila
P1gesp
St_P2Sca
20
40
60
80
100
120
140
160
180
200
220
240
260
280
300

Figure 7


At_subtila
P1gesp
St_P2Sca
GMAPGAHIAVYKVCWDNGCYSSDILAAIDVAIQDKVDV : 287
GMAPGAHIATYKVCWSSGCYSSDILAAMDVAIRDGVDI : 341
GMAPGAHIATYKVCWFSGCYSSDILAAMDVAIRDGVDI : 278
GMAPGAHIAiYKVCWfsGCYSSDILAAmDVAIrDgVDi
LSLSIGGFPIPLYDDTIAIGTFRAMERGISVICAAGNN : 325
LSLSIGGFPVPLYEDTIAIGSFRAMERGISVICAAGNN : 379
LSLSLGGFPIPLYDDTIAIGSFRAMEHGISVICAAGNN : 316
LSLSlGGFPiPLYdDTIAIGsFRAMErGISVICAAGNN
GPIESSVANTAPWVSTIGAGTLDRRFPAVVRLANGKLL : 363
GPILSSVANEAPWIATIGASTLDRKFPAIIQLGNGKYV : 417
GPIQSSVANGAPWIATIGASTLDRRFPASVQLGNGKFL : 354
GPI SSVAN APWiaTIGAsTLDRrFPA vqLgNGK l
YGESLYPGKGIKNAGREVEVIYVTGCDKGSEFCLRGSL : 401
YGESLYPGKQVHNSQKVLEIVYLNPGDNGSEFCLRGSL : 455
YGESLYPGKKWPSSQKNLEIVYVKDKDKGSEFCLRGSL : 392
YGESLYPGK v nsqk lEivYv dgDkGSEFCLRGSL
EEEIRGKMVICDRGVNGRSEKGEAVKEAGGVAMILAN : 439
RAKVHGKIVVCDRGVNGRAEKGQVVKESGGVAMILAN : 493
SKAQVRGKMVVCDRGVNGRAEKGQVVKEAGGAAMILAN : 430
pra vrGKmVvCDRGVNGRaEKGqvVKEaGGvAMILAN
TELNQEEDSIDVHLLPATLIGYTESVLLKAYVNATVKP : 477
TAVNMEEDSVDVHVLPATLIGFDESIQLQSYMNSTRKP : 531
TAINMEEDSIDVHVLPATLIGFDESIQLQNYLNSTKRP : 468
TaiNmEEDSiDVHvLPATLIGfdESiqLq Y NsT kP
KARIIFGGTVIGRSRAPEVAQFSARGPSLANPSILKPD : 515
TARIIFGGTVIGKSSAPAVAQFSSRGPSFTDPSILKPD : 569
TARFIFGGTVIGKSRAPAVAQFSSRGPSYTDPSILKPD : 506
tARiIFGGTVIGkSrAPaVAQFSsRGPS tdPSILKPD
MIAPGVNIIAAWPQNLGPTGLPYDSRRVNFTVMSGTSM : 553
VIAPGVNIIAAWPQNLGPSGLAEDSRRVNFTVLSGTSM : 607
LIAPGVNIIAAWPQNLGPSGLPEDSRRVNFTVMSGTSM : 544
IAPGVNIIAAWPQNLGPsGLpeDSRRVNFTVmSGTSM

Figure 7


* 620 * 640
At_subtila : SCPHVSGITALIRSAYPNWSPAAIKSALMTTADLYDRG : 591
P1gesp : ACPHVSGIAALLHSIFPKWSPAAIKSALMTTADITNFQ : 645
St_P2Sca : ACPHVSGIAALLHSAFPKWTPAAIRSALMTTADIADFM : 582
aCPHVSGIaALlhSahPkWsPAAIkSALMTTADt dhq
* 660 * 680
At_subtila : GKAIKDGNKPAGVFAIGAGHVNPQKAINPGLVYNIQPV : 629
P1gesp : GKFIMDGDTRAGLFAIGAGHVNPGRSDDPGLIYDINAN : 683
St_P2Sca : GKFIMDGDAPAKIFAAGAGHVNPGRAIDPGLIYDIGVD : 620
GKpImDGd pAglFAiGAGHVNPgraidPGLiYdIq
* 700 * 720
At_subtila : DYITYLCTLGFTRSDIIAITHKNVSCNGILRKNPGFSL : 667
P1gesp : DYITHLCTIGYKNSEILSITHKNVSCHDVLQKNRGFSL : 721
St_P2Sca : EYITHLCTIGYRNSEVFSITHRNVSCHDILQNNRGFSL : 658
dYIThLCTiGy nSeilsITHkNVSChdiLqkNrGFSL
* 740 * 760
At_subtila : NYPSIAVIEKRGKTTEMITRRVTNVGSPNSIYSVNVKA : 705
P1gesp : NYPSISVIFKAGKTRKMITRRVTNVGSPNSIYSVEIVA : 759
St_P2Sca : NYPSISITFRAGMTRKIIKRRVTNVGNPNSIYSVDIEA : 696
NYPSIsviFkaGkTrkmItRRVTNVGsPNSIYSV i A
* 780 * 8
At_subtila : PEGIKVIVNPKRLVFKHVDQTLSYRVWFVLKKKNRFGV : 743
P1gesp : PEGVKVRVKPRRLVFKHVNQSLSYRVWFISRKR-FCTQ : 796
St_P2Sca : PEGVKVRVKPRRLIFKHVNQSLSYRVWFISRKX-FESV : 733
PEGvKVrVkPrRLvFKHVnQsLSYRVWFisrK ig k
00 * 820 *
At_subtila : VASFAQGQLTWVNSHNLMQRVRSPISVTLKTN- : 775
P1gesp : FRSFAIGQLMWINSRDLYQKVRSPISVAWASKK : 829
St_P2Sca : FMSFAIGQLTWFNVGNKATKVKSPISVTWASMK : 766
r SFAeGQLtW Ns nk qkVrSPISVtwas k

Figure 7

Attorney Docket No. 147-223P

ADDED PAGE TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR SIGNING BY ADMINISTRATOR(TRIX), EXECUTOR(TRIX) OR LEGAL REPRESENTATIVE ON BEHALF OF DECEASED OR INCAPACITATED INVENTOR (37 CFR 1.42 AND 1.43)

I,

Ms. Janina Lisso

(type or print name(s) of administrator(trix), executor(trix) legal representative or all heirs)

hereby declare that I am a citizen of

Germany

residing at Mittelweg 28

06862 Roßlau

Germany

and that I am executing and signing the declaration to which this is attached as *(check one)*:

- ☐ the administrator(trix) of
- ☐ executor(trix) of the last will and testament of
- ☒ legal representative (or heirs) of

Dieter Berger

Full name of (first, second, etc.) deceased or incapacitated inventor

Germany

Country of citizenship of deceased or incapacitated inventor

Berlin, Germany

Residence (City, State, and Country) of deceased or incapacitated inventor

Detmolderstr. 63, 10715 Berlin, Germany

Mailing Address of deceased or incapacitated inventor

NOTE: The name of the first, second etc. deceased or incapacitated inventor should preferably also be filled in at the appropriate prior space of the declaration adding the words "deceased-completed on added page" or "incapacitated-completed on added page."

That, upon information and belief, I aver those facts which the inventor is required to state.

Date: 9.07.01

X

(Signature of administrator(trix), executor(trix) legal representative (or all heirs))

DI/US

Attorney Docket No. 147-223P

BIRCH, STEWART, KOLASCH & BIRCH, LLP
P.O. Box 747 • Falls Church, Virginia 22040-0747
Telephone: (703) 205-8000 • Facsimile: (703) 205-8050

PLEASE NOTE: YOU MUST COMPLETE THE FOLLOWING

COMBINED DECLARATION AND POWER OF ATTORNEY FOR PATENT AND DESIGN APPLICATIONS

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated next to my name; that I verily believe that I am the original, first and sole inventor (if only one inventor is named below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Insert Title: MEANS AND METHODS FOR MODULATING STOMATA CHARACTERISTICA IN PLANTS

Fill in Appropriate Information - For Use Without Specification Attached:

the specification of which is attached hereto. If not attached hereto,
the specification was filed on April 3, 2000 as
United States Application Number 09/806,767;
and amended on _____ (if applicable) and/or
the specification was filed on October 2, 1999 as PCT
International Application Number PCT/EP99/07631; and was
amended under PCT Article 19 on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendments referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I do not know and do not believe the same was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to this application, that the same was not in public use or on sale in the United States of America more than one year prior to this application, that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representative or assigns more than twelve months (six months for designs) prior to this application, and that no application for patent or inventor's certificate on this invention has been filed in any country foreign to the United States of America prior to this application by me or my legal representative or assigns, except as follows.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Insert Priority Information: (if appropriate)

Prior Foreign Application(s)			Priority Claimed	
EP 98 119244.6 (Number)	EPO (Country)	October 12, 1998 (Month/Day/Year Filed)	☐ Yes	☒ No
(Number)	(Country)	(Month/Day/Year Filed)	☐ Yes	☐ No
(Number)	(Country)	(Month/Day/Year Filed)	☐ Yes	☐ No
(Number)	(Country)	(Month/Day/Year Filed)	☐ Yes	☐ No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional applications(s) listed below.

Insert Provisional Application(s): (if any)

(Application Number)	(Filing Date)
(Application Number)	(Filing Date)

All Foreign Applications, if any, for any Patent or Inventor's Certificate Filed More than 12 Months (6 Months for Designs) Prior to the Filing Date of This Application:

Insert Requested Information: (if appropriate)

Country	Application Number	Date of Filing (Month/Day/Year)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States and/or PCT application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States and/or PCT application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Insert Prior U.S. Application(s): (if any)

(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)
(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)

Attorney Docket No. 147-223P

I hereby appoint the following attorneys to prosecute this application and/or an international application based on this application and to transact all business in the Patent and Trademark Office connected therewith and in connection with the resulting patent based on instructions received from the entity who first sent the application papers to the attorneys identified below, unless the inventor(s) or assignee provides said attorneys with a written notice to the contrary:

Raymond C. Stewart	(Reg. No. 21,066)	Terrell C. Birch	(Reg. No. 29,382)
Joseph A. Kolasch	(Reg. No. 22,463)	James M. Slattery	(Reg. No. 28,380)
Bernard L. Sweeney	(Reg. No. 24,448)	Michael K. Mutter	(Reg. No. 29,680)
Charles Gorenstein	(Reg. No. 29,271)	Gerald M. Murphy, Jr.	(Reg. No. 28,977)
Leonard R. Svensson	(Reg. No. 30,330)	Terry L. Clark	(Reg. No. 32,644)
Andrew D. Meikle	(Reg. No. 32,868)	Marc S. Weiner	(Reg. No. 32,181)
Joe McKinney Muncy	(Reg. No. 32,334)	Donald J. Daley	(Reg. No. 34,313)
John W. Bailey	(Reg. No. 32,881)	John A. Castellano	(Reg. No. 35,094)
Gary D. Yacura	(Reg. No. 35,416)	Thomas S. Auchterlonie	(Reg. No. 37,275)
Mark J. Nuell	(Reg. No. 36,623)		

Send Correspondence to:

BIRCH, STEWART, KOLASCH & BIRCH, LLP or Customer No. 2292
P.O. Box 747 • Falls Church, Virginia 22040-0747
Telephone: (703) 205-8000 • Facsimile: (703) 205-8050

PLEASE NOTE: YOU MUST COMPLETE THE FOLLOWING:

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

GIVEN NAME/FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
BERGER, Dieter	Legal Representative: Ms. Janina Lisso	
Residence (City, State & Country)		CITIZENSHIP
Berlin, Germany		German
MAILING ADDRESS (Complete Street Address including City, State & Country)		
Detmolderstr. 61, 10715 Berlin, Germany		

GIVEN NAME/FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
ALTMANN, Thomas		
Residence (City, State & Country)		CITIZENSHIP
Potsdam, Germany		German
MAILING ADDRESS (Complete Street Address including City, State & Country)		
Roßkastanienstr. 61, 14469 Potsdam, Germany		

GIVEN NAME/FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Residence (City, State & Country)		CITIZENSHIP
MAILING ADDRESS (Complete Street Address including City, State & Country)		

GIVEN NAME/FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Residence (City, State & Country)		CITIZENSHIP
MAILING ADDRESS (Complete Street Address including City, State & Country)		

*DATE OF SIGNATURE

SEQUENCE LISTING

<110> Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

<120> Means and methods for modulating stomata characteristica in plants

<130> C1748PCT

<140>
<141>

<160> 61

<170> PatentIn Ver. 2.1

<210> 1
<211> 2328
<212> DNA
<213> Arabidopsis thaliana

<220>
<221> CDS
<222> (1)..(2325)

<400> 1

```
atg gaa ccc aaa cct ttc ttt ctc tgc att atc ttt ctt cta ttt tgt   48
Met Glu Pro Lys Pro Phe Phe Leu Cys Ile Ile Phe Leu Leu Phe Cys
  1               5                  10                  15

tct tct tcg tca gag atc ctg cag aag cag act tac att gtt cag ctt   96
Ser Ser Ser Ser Glu Ile Leu Gln Lys Gln Thr Tyr Ile Val Gln Leu
            20                  25                  30

cat cct aat agc gaa acc gct aaa acc ttt gcc tca aag ttt gat tgg   144
His Pro Asn Ser Glu Thr Ala Lys Thr Phe Ala Ser Lys Phe Asp Trp
        35                  40                  45

cat ctt tct ttt ctc caa gaa gcg gtt tta ggt gtt gaa gaa gaa gag   192
His Leu Ser Phe Leu Gln Glu Ala Val Leu Gly Val Glu Glu Glu Glu
    50                  55                  60

gaa gag cct tct tct cga ctt ctc tac tcc tat ggc tct gcg att gaa   240
Glu Glu Pro Ser Ser Arg Leu Leu Tyr Ser Tyr Gly Ser Ala Ile Glu
65                  70                  75                  80

gga ttt gct gct cag ttg act gaa tca gaa gcc gag ata ctg aga tat   288
Gly Phe Ala Ala Gln Leu Thr Glu Ser Glu Ala Glu Ile Leu Arg Tyr
                85                  90                  95

tca cct gaa gtt gtt gca gtg aga cct gac cat gtt ctt cag gtt caa   336
Ser Pro Glu Val Val Ala Val Arg Pro Asp His Val Leu Gln Val Gln
            100                 105                 110

acc act tac tct tac aag ttc ttg gga ctc gac ggt ttt gga aac tcc   384
Thr Thr Tyr Ser Tyr Lys Phe Leu Gly Leu Asp Gly Phe Gly Asn Ser
        115                 120                 125

ggt gta tgg tct aaa tct cgg ttt ggt caa ggc aca att atc ggc gtg   432
Gly Val Trp Ser Lys Ser Arg Phe Gly Gln Gly Thr Ile Ile Gly Val
    130                 135                 140

ctt gat act gga gtt tgg cct gaa agt cct agc ttt gac gat acc gga   480
```

```
Leu Asp Thr Gly Val Trp Pro Glu Ser Pro Ser Phe Asp Asp Thr Gly
145                 150                 155                 160

atg cct tcg att cca cgg aaa tgg aaa ggg att tgc caa gaa gga gaa   528
Met Pro Ser Ile Pro Arg Lys Trp Lys Gly Ile Cys Gln Glu Gly Glu
                165                 170                 175

agt ttc agt tct tcg agc tgt aac cgg aag cta atc ggt gct aga ttc   576
Ser Phe Ser Ser Ser Ser Cys Asn Arg Lys Leu Ile Gly Ala Arg Phe
            180                 185                 190

ttc atc aga gga cac cgt gtc gct aat tca cca gag gaa tca cca aac   624
Phe Ile Arg Gly His Arg Val Ala Asn Ser Pro Glu Glu Ser Pro Asn
        195                 200                 205

atg cct cgt gaa tac att tcc gca aga gat tca acg gga cac ggg act   672
Met Pro Arg Glu Tyr Ile Ser Ala Arg Asp Ser Thr Gly His Gly Thr
    210                 215                 220

cac acc gcc tca aca gtt ggt gga tcc tct gtt tcg atg gcg aat gtt   720
His Thr Ala Ser Thr Val Gly Gly Ser Ser Val Ser Met Ala Asn Val
225                 230                 235                 240

ctt ggc aat gga gct ggt gtg gct cgt ggg atg gct cct gga gct cac   768
Leu Gly Asn Gly Ala Gly Val Ala Arg Gly Met Ala Pro Gly Ala His
                245                 250                 255

att gca gtc tat aaa gtc tgt tgg ttc aat ggt tgt tac agc tct gac   816
Ile Ala Val Tyr Lys Val Cys Trp Phe Asn Gly Cys Tyr Ser Ser Asp
            260                 265                 270

att cta gca gct ata gat gta gcg att caa gat aaa gtc gat gtt ctt   864
Ile Leu Ala Ala Ile Asp Val Ala Ile Gln Asp Lys Val Asp Val Leu
        275                 280                 285

tcg ctt tcc ctt ggc ggt ttc cct att cct ttg tat gat gac aca atc   912
Ser Leu Ser Leu Gly Gly Phe Pro Ile Pro Leu Tyr Asp Asp Thr Ile
    290                 295                 300

gcc att gga aca ttc cga gcc atg gaa cgc ggt ata tct gta atc tgt   960
Ala Ile Gly Thr Phe Arg Ala Met Glu Arg Gly Ile Ser Val Ile Cys
305                 310                 315                 320

gca gct ggt aac aac ggt cca atc gaa agc tct gtt gca aac aca gct  1008
Ala Ala Gly Asn Asn Gly Pro Ile Glu Ser Ser Val Ala Asn Thr Ala
                325                 330                 335

cct tgg gtc tca acc att ggc gca ggc acg ctt gat cga aga ttt ccc  1056
Pro Trp Val Ser Thr Ile Gly Ala Gly Thr Leu Asp Arg Arg Phe Pro
            340                 345                 350

gct gtg gtc aga tta gcc aac gga aag ctt ctc tat gga gag tca ttg  1104
Ala Val Val Arg Leu Ala Asn Gly Lys Leu Leu Tyr Gly Glu Ser Leu
        355                 360                 365

tat ccg gga aaa ggt ata aag aat gcc ggg aga gag gtt gag gtg act  1152
Tyr Pro Gly Lys Gly Ile Lys Asn Ala Gly Arg Glu Val Glu Val Ile
    370                 375                 380

tac gtc aca gga gga gat aaa gga agt gag ttc tgt ttg aga ggg tca  1200
Tyr Val Thr Gly Gly Asp Lys Gly Ser Glu Phe Cys Leu Arg Gly Ser
385                 390                 395                 400
```

```
ctt cca aga gaa gaa atc cga ggc aaa atg gtg att tgt gat cgc gga   1248
Leu Pro Arg Glu Glu Ile Arg Gly Lys Met Val Ile Cys Asp Arg Gly
                405                 410                 415

gtc aat gga aga tcg gag aaa gga gaa gcg gtt aaa gaa gct gga gga   1296
Val Asn Gly Arg Ser Glu Lys Gly Glu Ala Val Lys Glu Ala Gly Gly
            420                 425                 430

gtt gca atg atc tta gcc aat aca gag atc aac caa gaa gaa gat tct   1344
Val Ala Met Ile Leu Ala Asn Thr Glu Ile Asn Gln Glu Glu Asp Ser
        435                 440                 445

att gac gtt cat ctc tta cca gct aca ttg att ggt tac act gag tca   1392
Ile Asp Val His Leu Leu Pro Ala Thr Leu Ile Gly Tyr Thr Glu Ser
    450                 455                 460

gtc ctt ctg aag gct tat gtt aat gcc acg gtg aaa cca aag gcg cgg   1440
Val Leu Leu Lys Ala Tyr Val Asn Ala Thr Val Lys Pro Lys Ala Arg
465                 470                 475                 480

ata att ttt ggt ggt acg gtg att ggg agg tca cga gca ccg gag gtg   1488
Ile Ile Phe Gly Gly Thr Val Ile Gly Arg Ser Arg Ala Pro Glu Val
                485                 490                 495

gct cag ttt tca gct cga gga ccg agt tta gcc aat cct tcg ata cta   1536
Ala Gln Phe Ser Ala Arg Gly Pro Ser Leu Ala Asn Pro Ser Ile Leu
            500                 505                 510

aaa ccg gat atg att gct ccg gga gtc aat atc att gcg gct tgg cct   1584
Lys Pro Asp Met Ile Ala Pro Gly Val Asn Ile Ile Ala Ala Trp Pro
        515                 520                 525

caa aat cta gga cca acc gga ctt cct tat gat tca aga aga gtt aac   1632
Gln Asn Leu Gly Pro Thr Gly Leu Pro Tyr Asp Ser Arg Arg Val Asn
    530                 535                 540

ttc act gta atg tca gga act tca atg tct tgt cca cat gtt agc gga   1680
Phe Thr Val Met Ser Gly Thr Ser Met Ser Cys Pro His Val Ser Gly
545                 550                 555                 560

atc act gct ctt atc cgg tct gca tac ccg aac tgg tct cca gct gca   1728
Ile Thr Ala Leu Ile Arg Ser Ala Tyr Pro Asn Trp Ser Pro Ala Ala
                565                 570                 575

atc aaa tcc gca ttg atg aca aca gcg gat ttg tac gat cgt caa ggg   1776
Ile Lys Ser Ala Leu Met Thr Thr Ala Asp Leu Tyr Asp Arg Gln Gly
            580                 585                 590

aaa gcg ata aag gat ggt aac aaa cca gcc ggt gtg ttt gcg att gga   1824
Lys Ala Ile Lys Asp Gly Asn Lys Pro Ala Gly Val Phe Ala Ile Gly
        595                 600                 605

gca ggg cat gtg aat ccg caa aag gcg ata aac ccg gga ttg gtt tac   1872
Ala Gly His Val Asn Pro Gln Lys Ala Ile Asn Pro Gly Leu Val Tyr
    610                 615                 620

aac att caa cca gtg gat tac ata act tac ctc tgc act ctt gga ttc   1920
Asn Ile Gln Pro Val Asp Tyr Ile Thr Tyr Leu Cys Thr Leu Gly Phe
625                 630                 635                 640

aca aga tca gat att tta gca atc act cat aag aac gtg agc tgc aat   1968
Thr Arg Ser Asp Ile Leu Ala Ile Thr His Lys Asn Val Ser Cys Asn
                645                 650                 655
```

```
gga ata ttg cgg aaa aac ccg ggt ttt agt ctc aat tac ccg tcg ata   2016
Gly Ile Leu Arg Lys Asn Pro Gly Phe Ser Leu Asn Tyr Pro Ser Ile
            660                 665                 670

gcc gtg att ttc aaa cgt ggc aag act acg gag atg atc aca agg cgt   2064
Ala Val Ile Phe Lys Arg Gly Lys Thr Thr Glu Met Ile Thr Arg Arg
        675                 680                 685

gtc act aac gtt ggg agt cct aac tcg ata tac tca gtg aat gtc aag   2112
Val Thr Asn Val Gly Ser Pro Asn Ser Ile Tyr Ser Val Asn Val Lys
    690                 695                 700

gct cca gag ggg atc aaa gtt att gtc aat cct aag aga ctt gtg ttc   2160
Ala Pro Glu Gly Ile Lys Val Ile Val Asn Pro Lys Arg Leu Val Phe
705                 710                 715                 720

aaa cac gtg gat cag acg ctg agc tat aga gta tgg ttt gta ttg aag   2208
Lys His Val Asp Gln Thr Leu Ser Tyr Arg Val Trp Phe Val Leu Lys
                725                 730                 735

aag aaa aac aga gga ggg aag gtg gct agc ttt gca caa ggg cag ttg   2256
Lys Lys Asn Arg Gly Gly Lys Val Ala Ser Phe Ala Gln Gly Gln Leu
            740                 745                 750

act tgg gtc aac tct cat aat ctg atg cag cga gtt aga agt cca atc   2304
Thr Trp Val Asn Ser His Asn Leu Met Gln Arg Val Arg Ser Pro Ile
        755                 760                 765

tct gta acc ttg aag act aac tga                                  2328
Ser Val Thr Leu Lys Thr Asn
    770                 775
```

<210> 2
<211> 775
<212> PRT
<213> Arabidopsis thaliana

<400> 2

```
Met Glu Pro Lys Pro Phe Phe Leu Cys Ile Ile Phe Leu Leu Phe Cys
  1               5                  10                  15

Ser Ser Ser Ser Glu Ile Leu Gln Lys Gln Thr Tyr Ile Val Gln Leu
             20                  25                  30

His Pro Asn Ser Glu Thr Ala Lys Thr Phe Ala Ser Lys Phe Asp Trp
         35                  40                  45

His Leu Ser Phe Leu Gln Glu Ala Val Leu Gly Val Glu Glu Glu Glu
     50                  55                  60

Glu Glu Pro Ser Ser Arg Leu Leu Tyr Ser Tyr Gly Ser Ala Ile Glu
 65                  70                  75                  80

Gly Phe Ala Ala Gln Leu Thr Glu Ser Glu Ala Glu Ile Leu Arg Tyr
                 85                  90                  95

Ser Pro Glu Val Val Ala Val Arg Pro Asp His Val Leu Gln Val Gln
            100                 105                 110

Thr Thr Tyr Ser Tyr Lys Phe Leu Gly Leu Asp Gly Phe Gly Asn Ser
        115                 120                 125
```

```
Gly Val Trp Ser Lys Ser Arg Phe Gly Gln Gly Thr Ile Ile Gly Val
    130                 135                 140

Leu Asp Thr Gly Val Trp Pro Glu Ser Pro Ser Phe Asp Asp Thr Gly
145                 150                 155                 160

Met Pro Ser Ile Pro Arg Lys Trp Lys Gly Ile Cys Gln Glu Gly Glu
                165                 170                 175

Ser Phe Ser Ser Ser Ser Cys Asn Arg Lys Leu Ile Gly Ala Arg Phe
            180                 185                 190

Phe Ile Arg Gly His Arg Val Ala Asn Ser Pro Glu Glu Ser Pro Asn
        195                 200                 205

Met Pro Arg Glu Tyr Ile Ser Ala Arg Asp Ser Thr Gly His Gly Thr
    210                 215                 220

His Thr Ala Ser Thr Val Gly Gly Ser Ser Val Ser Met Ala Asn Val
225                 230                 235                 240

Leu Gly Asn Gly Ala Gly Val Ala Arg Gly Met Ala Pro Gly Ala His
                245                 250                 255

Ile Ala Val Tyr Lys Val Cys Trp Phe Asn Gly Cys Tyr Ser Ser Asp
            260                 265                 270

Ile Leu Ala Ala Ile Asp Val Ala Ile Gln Asp Lys Val Asp Val Leu
        275                 280                 285

Ser Leu Ser Leu Gly Gly Phe Pro Ile Pro Leu Tyr Asp Asp Thr Ile
    290                 295                 300

Ala Ile Gly Thr Phe Arg Ala Met Glu Arg Gly Ile Ser Val Ile Cys
305                 310                 315                 320

Ala Ala Gly Asn Asn Gly Pro Ile Glu Ser Ser Val Ala Asn Thr Ala
                325                 330                 335

Pro Trp Val Ser Thr Ile Gly Ala Gly Thr Leu Asp Arg Arg Phe Pro
            340                 345                 350

Ala Val Val Arg Leu Ala Asn Gly Lys Leu Leu Tyr Gly Glu Ser Leu
        355                 360                 365

Tyr Pro Gly Lys Gly Ile Lys Asn Ala Gly Arg Glu Val Glu Val Ile
    370                 375                 380

Tyr Val Thr Gly Gly Asp Lys Gly Ser Glu Phe Cys Leu Arg Gly Ser
385                 390                 395                 400

Leu Pro Arg Glu Glu Ile Arg Gly Lys Met Val Ile Cys Asp Arg Gly
                405                 410                 415

Val Asn Gly Arg Ser Glu Lys Gly Glu Ala Val Lys Glu Ala Gly Gly
            420                 425                 430

Val Ala Met Ile Leu Ala Asn Thr Glu Ile Asn Gln Glu Glu Asp Ser
        435                 440                 445

Ile Asp Val His Leu Leu Pro Ala Thr Leu Ile Gly Tyr Thr Glu Ser
    450                 455                 460
```

Val Leu Leu Lys Ala Tyr Val Asn Ala Thr Val Lys Pro Lys Ala Arg
465 470 475 480

Ile Ile Phe Gly Gly Thr Val Ile Gly Arg Ser Arg Ala Pro Glu Val
485 490 495

Ala Gln Phe Ser Ala Arg Gly Pro Ser Leu Ala Asn Pro Ser Ile Leu
500 505 510

Lys Pro Asp Met Ile Ala Pro Gly Val Asn Ile Ile Ala Ala Trp Pro
515 520 525

Gln Asn Leu Gly Pro Thr Gly Leu Pro Tyr Asp Ser Arg Arg Val Asn
530 535 540

Phe Thr Val Met Ser Gly Thr Ser Met Ser Cys Pro His Val Ser Gly
545 550 555 560

Ile Thr Ala Leu Ile Arg Ser Ala Tyr Pro Asn Trp Ser Pro Ala Ala
565 570 575

Ile Lys Ser Ala Leu Met Thr Thr Ala Asp Leu Tyr Asp Arg Gln Gly
580 585 590

Lys Ala Ile Lys Asp Gly Asn Lys Pro Ala Gly Val Phe Ala Ile Gly
595 600 605

Ala Gly His Val Asn Pro Gln Lys Ala Ile Asn Pro Gly Leu Val Tyr
610 615 620

Asn Ile Gln Pro Val Asp Tyr Ile Thr Tyr Leu Cys Thr Leu Gly Phe
625 630 635 640

Thr Arg Ser Asp Ile Leu Ala Ile Thr His Lys Asn Val Ser Cys Asn
645 650 655

Gly Ile Leu Arg Lys Asn Pro Gly Phe Ser Leu Asn Tyr Pro Ser Ile
660 665 670

Ala Val Ile Phe Lys Arg Gly Lys Thr Thr Glu Met Ile Thr Arg Arg
675 680 685

Val Thr Asn Val Gly Ser Pro Asn Ser Ile Tyr Ser Val Asn Val Lys
690 695 700

Ala Pro Glu Gly Ile Lys Val Ile Val Asn Pro Lys Arg Leu Val Phe
705 710 715 720

Lys His Val Asp Gln Thr Leu Ser Tyr Arg Val Trp Phe Val Leu Lys
725 730 735

Lys Lys Asn Arg Gly Gly Lys Val Ala Ser Phe Ala Gln Gly Gln Leu
740 745 750

Thr Trp Val Asn Ser His Asn Leu Met Gln Arg Val Arg Ser Pro Ile
755 760 765

Ser Val Thr Leu Lys Thr Asn
770 775

<210> 3
<211> 2328
<212> DNA
<213> Arabidopsis thaliana

<220>
<221> CDS
<222> (1)..(1473)

<400> 3

```
atg gaa ccc aaa cct ttc ttt ctc tgc att atc ttt ctt cta ttt tgt   48
Met Glu Pro Lys Pro Phe Phe Leu Cys Ile Ile Phe Leu Leu Phe Cys
  1               5                  10                  15

tct tct tcg tca gag atc ctg cag aag cag act tac att gtt cag ctt   96
Ser Ser Ser Ser Glu Ile Leu Gln Lys Gln Thr Tyr Ile Val Gln Leu
             20                  25                  30

cat cct aat agc gaa acc gct aaa acc ttt gcc tca aag ttt gat tgg   144
His Pro Asn Ser Glu Thr Ala Lys Thr Phe Ala Ser Lys Phe Asp Trp
         35                  40                  45

cat ctt tct ttt ctc caa gaa gcg gtt tta ggt gtt gaa gaa gaa gag   192
His Leu Ser Phe Leu Gln Glu Ala Val Leu Gly Val Glu Glu Glu Glu
     50                  55                  60

gaa gag cct tct tct cga ctt ctc tac tcc tat ggc tct gcg att gaa   240
Glu Glu Pro Ser Ser Arg Leu Leu Tyr Ser Tyr Gly Ser Ala Ile Glu
 65                  70                  75                  80

gga ttt gct gct cag ttg act gaa tca gaa gcc gag ata ctg aga tat   288
Gly Phe Ala Ala Gln Leu Thr Glu Ser Glu Ala Glu Ile Leu Arg Tyr
                 85                  90                  95

tca cct gaa gtt gtt gca gtg aga cct gac cat gtt ctt cag gtt caa   336
Ser Pro Glu Val Val Ala Val Arg Pro Asp His Val Leu Gln Val Gln
            100                 105                 110

acc act tac tct tac aag ttc ttg gga ctc gac ggt ttt gga aac tcc   384
Thr Thr Tyr Ser Tyr Lys Phe Leu Gly Leu Asp Gly Phe Gly Asn Ser
        115                 120                 125

ggt gta tgg tct aaa tct cgg ttt ggt caa ggc aca att atc ggc gtg   432
Gly Val Trp Ser Lys Ser Arg Phe Gly Gln Gly Thr Ile Ile Gly Val
    130                 135                 140

ctt gat act gga gtt tgg cct gaa agt cct agc ttt gac gat acc gga   480
Leu Asp Thr Gly Val Trp Pro Glu Ser Pro Ser Phe Asp Asp Thr Gly
145                 150                 155                 160

atg cct tcg att cca cgg aaa tgg aaa ggg att tgc caa gaa gga gaa   528
Met Pro Ser Ile Pro Arg Lys Trp Lys Gly Ile Cys Gln Glu Gly Glu
                165                 170                 175

agt ttc agt tct tcg agc tgt aac cgg aag cta atc ggt gct aga ttc   576
Ser Phe Ser Ser Ser Ser Cys Asn Arg Lys Leu Ile Gly Ala Arg Phe
            180                 185                 190

ttc atc aga gga cac cgt gtc gct aat tca cca gag gaa tca cca aac   624
Phe Ile Arg Gly His Arg Val Ala Asn Ser Pro Glu Glu Ser Pro Asn
        195                 200                 205

atg cct cgt gaa tac att tcc gca aga gat tca acg gga cac ggg act   672
```

```
Met Pro Arg Glu Tyr Ile Ser Ala Arg Asp Ser Thr Gly His Gly Thr
210                 215                 220

cac acc gcc tca aca gtt ggt gga tcc tct gtt tcg atg gcg aat gtt   720
His Thr Ala Ser Thr Val Gly Gly Ser Ser Val Ser Met Ala Asn Val
225                 230                 235                 240

ctt ggc aat gga gct ggt gtg gct cgt ggg atg gct cct gga gct cac   768
Leu Gly Asn Gly Ala Gly Val Ala Arg Gly Met Ala Pro Gly Ala His
                245                 250                 255

att gca gtc tat aaa gtc tgt tgg ttc aat ggt tgt tac agc tct gac   816
Ile Ala Val Tyr Lys Val Cys Trp Phe Asn Gly Cys Tyr Ser Ser Asp
            260                 265                 270

att cta gca gct ata gat gta gcg att caa gat aaa gtc gat gtt ctt   864
Ile Leu Ala Ala Ile Asp Val Ala Ile Gln Asp Lys Val Asp Val Leu
        275                 280                 285

tcg ctt tcc ctt ggc ggt ttc cct att cct ttg tat gat gac aca atc   912
Ser Leu Ser Leu Gly Gly Phe Pro Ile Pro Leu Tyr Asp Asp Thr Ile
    290                 295                 300

gcc att gga aca ttc cga gcc atg gaa cgc ggt ata tct gta atc tgt   960
Ala Ile Gly Thr Phe Arg Ala Met Glu Arg Gly Ile Ser Val Ile Cys
305                 310                 315                 320

gca gct ggt aac aac ggt cca atc gaa agc tct gtt gca aac aca gct  1008
Ala Ala Gly Asn Asn Gly Pro Ile Glu Ser Ser Val Ala Asn Thr Ala
                325                 330                 335

cct tgg gtc tca acc att ggc gca ggc acg ctt gat cga aga ttt ccc  1056
Pro Trp Val Ser Thr Ile Gly Ala Gly Thr Leu Asp Arg Arg Phe Pro
            340                 345                 350

gct gtg gtc aga tta gcc aac gga aag ctt ctc tat gga gag tca ttg  1104
Ala Val Val Arg Leu Ala Asn Gly Lys Leu Leu Tyr Gly Glu Ser Leu
        355                 360                 365

tat ccg gga aaa ggt ata aag aat gcc ggg aga gag gtt gag gtg att  1152
Tyr Pro Gly Lys Gly Ile Lys Asn Ala Gly Arg Glu Val Glu Val Ile
    370                 375                 380

tac gtc aca gga gga gat aaa gga agt gag ttc tgt ttg aga ggg tca  1200
Tyr Val Thr Gly Gly Asp Lys Gly Ser Glu Phe Cys Leu Arg Gly Ser
385                 390                 395                 400

ctt cca aga gaa gaa atc cga ggc aaa atg gtg att tgt gat cgc gga  1248
Leu Pro Arg Glu Glu Ile Arg Gly Lys Met Val Ile Cys Asp Arg Gly
                405                 410                 415

gtc aat gga aga tcg gag aaa gga gaa gcg gtt aaa gaa gct gga gga  1296
Val Asn Gly Arg Ser Glu Lys Gly Glu Ala Val Lys Glu Ala Gly Gly
            420                 425                 430

gtt gca atg atc tta gcc aat aca gag atc aac caa gaa gaa gat tct  1344
Val Ala Met Ile Leu Ala Asn Thr Glu Ile Asn Gln Glu Glu Asp Ser
        435                 440                 445

att gac gtt cat ctc tta cca gct aca ttg att ggt tac act gag tca  1392
Ile Asp Val His Leu Leu Pro Ala Thr Leu Ile Gly Tyr Thr Glu Ser
    450                 455                 460
```

```
gtc ctt ctg aag gct tat gtt aat gcc acg gtg aaa cca aag gcg cgg   1440
Val Leu Leu Lys Ala Tyr Val Asn Ala Thr Val Lys Pro Lys Ala Arg
465                 470                 475                 480

ata att ttt ggt ggt acg gtg att ggg agg tca tgagcaccgg aggtggctca 1493
Ile Ile Phe Gly Gly Thr Val Ile Gly Arg Ser
                485                 490

gttttcagct cgaggaccga gtttagccaa tccttcgata ctaaaaccgg atatgattgc 1553

tccgggagtc aatatcattg cggcttggcc tcaaaatcta ggaccaaccg gacttcctta 1613

tgattcaaga agagttaact tcactgtaat gtcaggaact tcaatgtctt gtccacatgt 1673

tagcggaatc actgctctta tccggtctgc atacccgaac tggtctccag ctgcaatcaa 1733

atccgcattg atgacaacag cggatttgta cgatcgtcaa gggaaagcga taaaggatgg 1793

ttaacaaacca gccggtgtgt ttgcgattgg agcagggcat gtgaatccgc aaaaggcgat 1853

aaacccggga ttggtttaca acattcaacc agtggattac ataacttacc tctgcactct 1913

tggattcaca agatcagata ttttagcaat cactcataag aacgtgagct gcaatggaat 1973

attgcggaaa aacccgggtt ttagtctcaa ttacccgtcg atagccgtga ttttcaaacg 2033

tggcaagact acggagatga tcacaaggcg tgtcactaac gttgggagtc ctaactcgat 2093

atactcagtg aatgtcaagg ctccagaggg gatcaaagtt attgtcaatc ctaagagact 2153

tgtgttcaaa cacgtggatc agacgctgag ctatagagta tggtttgtat tgaagaagaa 2213

aaacagagga gggaaggtgg ctagctttgc acaagggcag ttgacttggg tcaactctca 2273

taatctgatg cagcgagtta gaagtccaat ctctgtaacc ttgaagacta actga      2328
```

<210> 4
<211> 491
<212> PRT
<213> Arabidopsis thaliana

<400> 4

```
Met Glu Pro Lys Pro Phe Phe Leu Cys Ile Ile Phe Leu Leu Phe Cys
  1               5                  10                  15

Ser Ser Ser Ser Glu Ile Leu Gln Lys Gln Thr Tyr Ile Val Gln Leu
             20                  25                  30

His Pro Asn Ser Glu Thr Ala Lys Thr Phe Ala Ser Lys Phe Asp Trp
         35                  40                  45

His Leu Ser Phe Leu Gln Glu Ala Val Leu Gly Val Glu Glu Glu Glu
     50                  55                  60

Glu Glu Pro Ser Ser Arg Leu Leu Tyr Ser Tyr Gly Ser Ala Ile Glu
 65                  70                  75                  80

Gly Phe Ala Ala Gln Leu Thr Glu Ser Glu Ala Glu Ile Leu Arg Tyr
                 85                  90                  95

Ser Pro Glu Val Val Ala Val Arg Pro Asp His Val Leu Gln Val Gln
            100                 105                 110
```

```
Thr Thr Tyr Ser Tyr Lys Phe Leu Gly Leu Asp Gly Phe Gly Asn Ser
        115                 120                 125

Gly Val Trp Ser Lys Ser Arg Phe Gly Gln Gly Thr Ile Ile Gly Val
    130                 135                 140

Leu Asp Thr Gly Val Trp Pro Glu Ser Pro Ser Phe Asp Asp Thr Gly
145                 150                 155                 160

Met Pro Ser Ile Pro Arg Lys Trp Lys Gly Ile Cys Gln Glu Gly Glu
                165                 170                 175

Ser Phe Ser Ser Ser Ser Cys Asn Arg Lys Leu Ile Gly Ala Arg Phe
            180                 185                 190

Phe Ile Arg Gly His Arg Val Ala Asn Ser Pro Glu Glu Ser Pro Asn
        195                 200                 205

Met Pro Arg Glu Tyr Ile Ser Ala Arg Asp Ser Thr Gly His Gly Thr
    210                 215                 220

His Thr Ala Ser Thr Val Gly Gly Ser Ser Val Ser Met Ala Asn Val
225                 230                 235                 240

Leu Gly Asn Gly Ala Gly Val Ala Arg Gly Met Ala Pro Gly Ala His
                245                 250                 255

Ile Ala Val Tyr Lys Val Cys Trp Phe Asn Gly Cys Tyr Ser Ser Asp
            260                 265                 270

Ile Leu Ala Ala Ile Asp Val Ala Ile Gln Asp Lys Val Asp Val Leu
        275                 280                 285

Ser Leu Ser Leu Gly Gly Phe Pro Ile Pro Leu Tyr Asp Asp Thr Ile
    290                 295                 300

Ala Ile Gly Thr Phe Arg Ala Met Glu Arg Gly Ile Ser Val Ile Cys
305                 310                 315                 320

Ala Ala Gly Asn Asn Gly Pro Ile Glu Ser Ser Val Ala Asn Thr Ala
                325                 330                 335

Pro Trp Val Ser Thr Ile Gly Ala Gly Thr Leu Asp Arg Arg Phe Pro
            340                 345                 350

Ala Val Val Arg Leu Ala Asn Gly Lys Leu Leu Tyr Gly Glu Ser Leu
        355                 360                 365

Tyr Pro Gly Lys Gly Ile Lys Asn Ala Gly Arg Glu Val Glu Val Ile
    370                 375                 380

Tyr Val Thr Gly Gly Asp Lys Gly Ser Glu Phe Cys Leu Arg Gly Ser
385                 390                 395                 400

Leu Pro Arg Glu Glu Ile Arg Gly Lys Met Val Ile Cys Asp Arg Gly
                405                 410                 415

Val Asn Gly Arg Ser Glu Lys Gly Glu Ala Val Lys Glu Ala Gly Gly
            420                 425                 430

Val Ala Met Ile Leu Ala Asn Thr Glu Ile Asn Gln Glu Glu Asp Ser
        435                 440                 445
```

Ile Asp Val His Leu Leu Pro Ala Thr Leu Ile Gly Tyr Thr Glu Ser
450 455 460

Val Leu Leu Lys Ala Tyr Val Asn Ala Thr Val Lys Pro Lys Ala Arg
465 470 475 480

Ile Ile Phe Gly Gly Thr Val Ile Gly Arg Ser
485 490

<210> 5
<211> 1970
<212> DNA
<213> Arabidopsis thaliana

<400> 5
gtcgactttg attcaagctt tgtttcgatt gattgagcca actgctggaa aaattactat 60
tgacaacatt gacatttctc aaattggtct tcatgatctt cgtagtcgcc ttgggattat 120
acctcaagat cctacattat ttgaaggaac aatccgagca aatcttgacc cacttgaaga 180
acattcagat gataaaatct gggaggtatc tataaatatg ttgtttgata ctcttatctt 240
gtttatgttt tagacactaa actctgagat ttggagtttg attctagaga tttacccaac 300
tttgctgaca ggcgcttgat aaatcccagc ttggagacgt tgttagagga aaagacctaa 360
aacttgactc tccaggtaac tatttacatc aaaagtcctc tctttttccc gggtcttttt 420
cgcttctttc tactgatttt tttggctcaa aaccgagtag tactggaaaa tggagataac 480
tggagtgtag ggcagagaca gcttgtgtca cttggacgag cattactgaa acaagccaaa 540
atacttgttc ttgatgaagc aacagcatcg gttgacacag caacagacaa tctgatccag 600
aagataatca gaacagagtt tgaagactgc acggtctgca ccattgctca ccggatacca 660
actgttatag acagtgacct agttttggtt ctcagcgacg gttagtctca tacaaattaa 720
aaacatggat ctttcttcat attactcgtc gtcttttggg agaattcaat gtttatgttt 780
atggtttgtt gcaggtagag tagcagagtt tgatactcct gcacggctat tagaagacaa 840
atcatcgatg ttcttgaaat tggtaacaga atactcctca agatctactg gaatccctga 900
attatgatcc tccatgttaa aaattcagtt taggggttt ctttttccaa gaggatataa 960
aagaactgat atgtgacaaa agcttaaggt ctaaagtaag agagagtttt ccacagggtt 1020
taagaaaaga aaaagcatga aaggatgcca aaatctccgc gcttaaaaaa ctttgggttt 1080
aaatctcttc tgtcgaacat tgggagaaac tttttttgta tggaacagtt agtttctttg 1140
gttttcatgt ttatcaataa actgcaaaaa caaacaaaga ttagagtaga aactactaat 1200
cattcgtcat catccctcaa gtgtgatctg tattgggctt attataagtg taatcagtac 1260
tgggcttata agttgtacag agcccaatat aacaatatct gtacgacgtc gttttgttgt 1320
gacgtagtac ccgatgacaa aacgaggcgt gttgagcgtg cgtgtataaa tgcacgtagt 1380
gaacgaacac taaccacgct gctgcattta attcctttct caacggtcgt attttcctat 1440
tcaaggcttt aactaagttt aatagtatgt ttttaaaaaa atacatatat ttggccaatg 1500
gttgattatt aagttattgt taaatgaatt ttctttggct tggtaaaact tcaatggaaa 1560
ccaaataaat ttcaaaatct tttgttgctg aaaaaggcta cacaaactac tatacgcaat 1620
aaaacctaac cataacatct cgtgaacaag gaaaaaaaaa ggaaaaacag agacacagag 1680
acaaggcaga caaaaaagcc ttacaagtga aaaaccttaa acagcttcag ttaatatagt 1740
tcatgtctta gaaaaaaata aaagagaaga agctcctacc tctgcaacat acaaaggata 1800
ctcgtgaggc agagctctta ctcttcacga gcttcatcat cttcttcctt agactccaaa 1860
tcccaggttt tgaattctct tcattcttct ttaaataccc tattcttctt cttctctaaa 1920
accatgcact tcaactacac taaaccaact ccttttttta actctctcca 1970

<210> 6
<211> 1140
<212> DNA
<213> Arabidopsis thaliana

<400> 6
aaatcatcga tgttcttgaa attggtaaca gaatactcct caagatctac tggaatccct 60
gaattatgat cctccatgtt aaaaattcag tttaggggtt ttcttttctc aagaggatat 120
aaaagaactg atatgtgaca aaagcttaag gtctaaagta agagagagtt ttccacaggg 180
tttaagaaaa gaaaaagcat gaaaggatgc caaaatctcc gcgcttaaaa aactttgggt 240

```
ttaaatctct tctgtcgaac attgggagaa actttttttg tatggaacag ttagtttctt 300
tggttttcat gtttatcaat aaactgcaaa aacaaacaaa gattagagta gaaactacta 360
atcattcgtc atcatccctc aagtgtgatc tgtattgggc ttattataag tgtaatcagt 420
actgggctta taagttgtac agagcccaat ataacaatat ctgtacgacg tcgttttgtt 480
gtgacgtagt acccgatgac aaaacgaggc gtgttgagcg tgcgtgtata aatgcacgta 540
gtgaacgaac actaaccacg ctgctgcatt taattccttt ctcaacggtc gtattttcct 600
attcaaggct ttaactaagt ttaatagtat gtttttaaaa aaatacatat atttggccaa 660
tggttgatta ttaagttatt gttaaatgaa ttttctttgg cttggtaaaa cttcaatgga 720
aaccaaataa atttcaaaat cttttgttgc tgaaaaaggc tacacaaact actatacgca 780
ataaaaccta accataacat ctcgtgaaca aggaaaaaaa aaggaaaaac agagacacag 840
agacaaggca gacaaaaaag ccttacaagt gaaaaacctt aaacagcttc agttaatata 900
gttcatgtct tagaaaaaaa taaaagagaa gaagctccta cctctgcaac atacaaagga 960
tactcgtgag gcagagctct tactcttcac gagcttcatc atcttcttcc ttagactcca 1020
aatcccaggt tttgaattct cttcattctt ctttaaatac cctattcttc ttcttctcta 1080
aaaccatgca cttcaactac actaaaccaa ctccttttt taactctctc caatggaacc 1140
```

<210> 7
<211> 3865
<212> DNA
<213> Solanum tuberosum

<220>
<221> exon
<222> (3)..(551)

<220>
<221> intron
<222> (552)..(966)

<220>
<221> exon
<222> (967)..(1654)

<220>
<221> intron
<222> (1655)..(1737)

<220>
<221> exon
<222> (1738)..(2222)

<220>
<221> intron
<222> (2223)..(2485)

<220>
<221> exon
<222> (2486)..(3252)

<220>
<221> CDS
<222> (3)..(551)

<220>
<221> CDS
<222> (967)..(1653)

<220>
<221> CDS
<222> (1737)..(2222)

<220>

<221> CDS
<222> (2486)..(3253)

<400> 7

```
ga att ctg ttc aac ccc ttt aaa tac ccc cat caa att ata tca aca    47
   Ile Leu Phe Asn Pro Phe Lys Tyr Pro His Gln Ile Ile Ser Thr
     1               5                  10                  15

aac att cca tta ttc aac ttc aaa tat aat tca atg gaa ctc aat ttc   95
Asn Ile Pro Leu Phe Asn Phe Lys Tyr Asn Ser Met Glu Leu Asn Phe
                20                  25                  30

caa ttc tat ttt ctc tgt ttt cta ctc tgt ttt att ccc ctg cta caa   143
Gln Phe Tyr Phe Leu Cys Phe Leu Leu Cys Phe Ile Pro Leu Leu Gln
            35                  40                  45

gct caa aat ttg caa act tat ata gta caa tta cat cca caa cat gca   191
Ala Gln Asn Leu Gln Thr Tyr Ile Val Gln Leu His Pro Gln His Ala
        50                  55                  60

tca aca aga acc cct ttt agt tct aaa ttt cag tgg cac ctt tca ttt   239
Ser Thr Arg Thr Pro Phe Ser Ser Lys Phe Gln Trp His Leu Ser Phe
    65                  70                  75

ctt gaa aat ttc aca aac att cca tta ttc aac ttc aaa tat att caa   287
Leu Glu Asn Phe Thr Asn Ile Pro Leu Phe Asn Phe Lys Tyr Ile Gln
80                  85                  90                  95

tgg aac tca att cca att cta ttt ctc tgt ttc tac tct gtt tat tcc   335
Trp Asn Ser Ile Pro Ile Leu Phe Leu Cys Phe Tyr Ser Val Tyr Ser
                100                 105                 110

cct gct aca agc att tcc tca ggt gaa aac tcg agt tct cgc ctt ttg   383
Pro Ala Thr Ser Ile Ser Ser Gly Glu Asn Ser Ser Ser Arg Leu Leu
            115                 120                 125

tac tct tac cat tct gca ttt gaa ggt ttt gca gca ctt cta tct gaa   431
Tyr Ser Tyr His Ser Ala Phe Glu Gly Phe Ala Ala Leu Leu Ser Glu
        130                 135                 140

aat gag cta aag gca ctg aag aaa tcg aat aat gtg tta tca ata tat   479
Asn Glu Leu Lys Ala Leu Lys Lys Ser Asn Asn Val Leu Ser Ile Tyr
    145                 150                 155

ccg gag agg aag ctt gag gtt caa aca act tat tct tac aag ttc tta   527
Pro Glu Arg Lys Leu Glu Val Gln Thr Thr Tyr Ser Tyr Lys Phe Leu
160                 165                 170                 175

gga ctt agt cct aca aag gaa ggt atgttacata gtttgtaata tatataaagt  581
Gly Leu Ser Pro Thr Lys Glu Gly
                180

tgaggaaaca atgagtcata aggctttatt tattaaatga ctagtctgga ctagagtgtc 641

acacgtagga tttaaacttg tgaattaagg aaaattctta aacccccttt acaactgctc 701

tggagtcatt tcttatgtca atgtgattca acagttcata tataacaaaa aggatttgtc 761

tttaccttgt tttcgaagta aaaatatttc aacgaagggg attcaaccga accccattgg 821

ttcccttcaa ctctgctaat agatattttc tatgtatttc atttaagact tgaatttttа 881

agctttaaat tttctatgtt ccctcggagc ctttcntctn acttactttt atactgtctt 941
```

```
tgtatctttt ttttctaat aaggt act tgg tta aag tct gga ttt ggt cga   993
                          Thr Trp Leu Lys Ser Gly Phe Gly Arg
                              185                 190

ggc gcg atc att gga gtt ctt gat act gga att tgg cca gaa agt cca  1041
Gly Ala Ile Ile Gly Val Leu Asp Thr Gly Ile Trp Pro Glu Ser Pro
      195                 200                 205

agt ttt gtt gat cat gga atg tct cct att cca aag aaa tgg aaa ggt  1089
Ser Phe Val Asp His Gly Met Ser Pro Ile Pro Lys Lys Trp Lys Gly
  210                 215                 220

ntc tgc caa gaa gga aaa aac ttc aat tct tca agt tgc aat cgc aag  1137
Xaa Cys Gln Glu Gly Lys Asn Phe Asn Ser Ser Ser Cys Asn Arg Lys
225                 230                 235                 240

ctt att ggt gca agg ttt ttc cag ata gga cac atg atg gca tca aag  1185
Leu Ile Gly Ala Arg Phe Phe Gln Ile Gly His Met Met Ala Ser Lys
                245                 250                 255

aca tca aaa tca ata gat ttt atg gag gat tat gta tca cct cga gat  1233
Thr Ser Lys Ser Ile Asp Phe Met Glu Asp Tyr Val Ser Pro Arg Asp
            260                 265                 270

tct caa ggc cat ggt aca cat aca gca tct act gca ggg gga gct ccc  1281
Ser Gln Gly His Gly Thr His Thr Ala Ser Thr Ala Gly Gly Ala Pro
        275                 280                 285

gtt cca atg gcg agt gtg ctt gga aat gga gca gga gag gct cga ggg  1329
Val Pro Met Ala Ser Val Leu Gly Asn Gly Ala Gly Glu Ala Arg Gly
    290                 295                 300

atg gcc cct ggt gct cat atc gcg ata tac aaa gtt tgt tgg tct agt  1377
Met Ala Pro Gly Ala His Ile Ala Ile Tyr Lys Val Cys Trp Ser Ser
305                 310                 315                 320

ggt tgt tat agt tct gat ata ctt gca gca atg gat gta gct att aga  1425
Gly Cys Tyr Ser Ser Asp Ile Leu Ala Ala Met Asp Val Ala Ile Arg
                325                 330                 335

gat gga gta gac ata ttg tct ctt tca att ggt ggt ttc cct gtt cca  1473
Asp Gly Val Asp Ile Leu Ser Leu Ser Ile Gly Gly Phe Pro Val Pro
            340                 345                 350

ctt tat gag gat act att gct att ggc agt ttt cga gct atg gaa cgt  1521
Leu Tyr Glu Asp Thr Ile Ala Ile Gly Ser Phe Arg Ala Met Glu Arg
        355                 360                 365

gga att tca gtt ata tgt gct gca gga aat aat ggt cca att cta agt  1569
Gly Ile Ser Val Ile Cys Ala Ala Gly Asn Asn Gly Pro Ile Leu Ser
    370                 375                 380

tca gta gca aat gag gct cct tgg att gcc act att ggt gct agc aca  1617
Ser Val Ala Asn Glu Ala Pro Trp Ile Ala Thr Ile Gly Ala Ser Thr
385                 390                 395                 400

ctt gac agg aaa ttt cca gca ata att cag cta ggt atgtcacatt       1663
Leu Asp Arg Lys Phe Pro Ala Ile Ile Gln Leu Gly
                405                 410

ttgtttctta aaatgatatt tcgcgtgttt ccagcctaaa ttatgtgtcc ctcattcata 1723
```

```
ttttccaaca ggt aat ggc aag tat gtg tat gga gaa tcc ttg tac ccg    1772
               Asn Gly Lys Tyr Val Tyr Gly Glu Ser Leu Tyr Pro
                       415                 420

ggc aaa caa gtt cat aat tct cag aaa gtt ctt gag att gtt tat ctc   1820
Gly Lys Gln Val His Asn Ser Gln Lys Val Leu Glu Ile Val Tyr Leu
425                 430                 435                 440

aat gac ggt gat aat gga agt gaa ttt tgc tta aga ggg tct ctg cca   1868
Asn Asp Gly Asp Asn Gly Ser Glu Phe Cys Leu Arg Gly Ser Leu Pro
                445                 450                 455

aga gct aaa gtc cat gga aaa atc gtt gta tgt gat cgt gga gtt aat   1916
Arg Ala Lys Val His Gly Lys Ile Val Val Cys Asp Arg Gly Val Asn
            460                 465                 470

gga aga gca gag aaa ggt caa gtt gtt aaa gaa tca ggt ggt gtt gcc   1964
Gly Arg Ala Glu Lys Gly Gln Val Val Lys Glu Ser Gly Gly Val Ala
        475                 480                 485

atg atc cta gca aat aca gca gta aat atg gag gaa gat tct gtg gac   2012
Met Ile Leu Ala Asn Thr Ala Val Asn Met Glu Glu Asp Ser Val Asp
    490                 495                 500

gta cat gtc cta cct gca aca ttg att ggt ttt gac gaa tca att cag   2060
Val His Val Leu Pro Ala Thr Leu Ile Gly Phe Asp Glu Ser Ile Gln
505                 510                 515                 520

ttg caa agc tat atg aac tca acg cga aaa cca aca gct cga atc ata   2108
Leu Gln Ser Tyr Met Asn Ser Thr Arg Lys Pro Thr Ala Arg Ile Ile
                525                 530                 535

ttt gga gga aca gtt ata gga aaa tct agt gca cct gct gta gca caa   2156
Phe Gly Gly Thr Val Ile Gly Lys Ser Ser Ala Pro Ala Val Ala Gln
            540                 545                 550

ttt tct tca agg ggt cca agt ttt act gat cct tca att ctc aaa cct   2204
Phe Ser Ser Arg Gly Pro Ser Phe Thr Asp Pro Ser Ile Leu Lys Pro
        555                 560                 565

gat gtg att gct cca ggt cagtttttat tgaacccaca attatttatt          2252
Asp Val Ile Ala Pro Gly
    570

tagatcatag atagcaatgt gaccaacagg ttagggattc gagccgtgga atctatcatt 2312

gatgcttgaa tcagggtaga ctgcttacat cacacccttc accagaccat gcatgaaaac 2372

gggatgctct ttttatatgc atgtgaaaaa aactttaata aatagtgtaa tgttatgttt 2432

tgaacctata tcttcgtata actcagaatc ttgaatccgc ctctgctcca ggt gtc    2488
                                                          Val
                                                          575

aac ata att gct gct tgg ccg caa aat cta ggt cct agt ggc ctg gct   2536
Asn Ile Ile Ala Ala Trp Pro Gln Asn Leu Gly Pro Ser Gly Leu Ala
                580                 585                 590

gag gat tca aga aga gta aac ttc act gtc tta tca gga act tca atg   2584
Glu Asp Ser Arg Arg Val Asn Phe Thr Val Leu Ser Gly Thr Ser Met
            595                 600                 605

gct tgt cct cat gtt agt ggc att gct gca cta ctc cat tca att cat   2632
```

```
Ala Cys Pro His Val Ser Gly Ile Ala Ala Leu Leu His Ser Ile His
        610                 615                 620

cct aaa tgg tca cca gct gca atc aaa tcc gcg cta atg aca act gca   2680
Pro Lys Trp Ser Pro Ala Ala Ile Lys Ser Ala Leu Met Thr Thr Ala
    625                 630                 635

gac aca aca aac cac caa gga aaa cca atc atg gat ggt gac aca cga   2728
Asp Thr Thr Asn His Gln Gly Lys Pro Ile Met Asp Gly Asp Thr Arg
640                 645                 650                 655

gct gga ctt ttc gcc ata gga gct gga cat gta aat cct gga aga tcc   2776
Ala Gly Leu Phe Ala Ile Gly Ala Gly His Val Asn Pro Gly Arg Ser
                660                 665                 670

gat gat ccc gga ttg ata tat gac att aat gca aat gac tat atc act   2824
Asp Asp Pro Gly Leu Ile Tyr Asp Ile Asn Ala Asn Asp Tyr Ile Thr
            675                 680                 685

cac ctt tgc act att ggt tac aaa aac tct gaa atc ctc agc att act   2872
His Leu Cys Thr Ile Gly Tyr Lys Asn Ser Glu Ile Leu Ser Ile Thr
        690                 695                 700

cac aag aat gtt agc tgc cac gac gtt tta cag aaa aac agg ggt ttt   2920
His Lys Asn Val Ser Cys His Asp Val Leu Gln Lys Asn Arg Gly Phe
    705                 710                 715

agt ctc aat tac ccc tct att tcc gta atc ttt aag gca gga aaa acg   2968
Ser Leu Asn Tyr Pro Ser Ile Ser Val Ile Phe Lys Ala Gly Lys Thr
720                 725                 730                 735

aga aaa atg atc aca agg aga gtg aca aat gtg ggg agt cct aat tca   3016
Arg Lys Met Ile Thr Arg Arg Val Thr Asn Val Gly Ser Pro Asn Ser
                740                 745                 750

atc tac tca gtt gaa att gtg gca cca gaa gga gtt aaa gtg aga gtt   3064
Ile Tyr Ser Val Glu Ile Val Ala Pro Glu Gly Val Lys Val Arg Val
            755                 760                 765

aaa ccg cga cgt ctg gta ttt aaa cat gtt aat caa agt tta agt tac   3112
Lys Pro Arg Arg Leu Val Phe Lys His Val Asn Gln Ser Leu Ser Tyr
        770                 775                 780

aga gtt tgg ttt ata tca agg aag aga att ggg act caa agg aga agc   3160
Arg Val Trp Phe Ile Ser Arg Lys Arg Ile Gly Thr Gln Arg Arg Ser
    785                 790                 795

ttt gca gaa gga caa ttg atg tgg atc aac tcc aga gat aaa tac cag   3208
Phe Ala Glu Gly Gln Leu Met Trp Ile Asn Ser Arg Asp Lys Tyr Gln
800                 805                 810                 815

aaa gtt aga agt cct att tca gtt gca tgg gca tca aag aag tga       3253
Lys Val Arg Ser Pro Ile Ser Val Ala Trp Ala Ser Lys Lys
                820                 825                 830

aggctgtgcc tattttcacg tacacggaaa ataggcaggt tacgtgctat aacatatact 3313

actgatagtg taaaaattct ttatactatc agcgtagaca gtacgtaagt ngaatctatt 3373

gttgtagcac caaagtttca ttgttccgaa catttaatta ggattctatt actatattgt 3433

atcagcacca aaagtttcat cgtcttagtt ccaaaaattt gattaagctt ttaagttgca 3493
```

ttgtcttagt tccaaatatg ttactataac ttgctgataa aaacgtaaat aattatcaaa 3553

tagggtattg aacattcaaa gaatttagga taaccaaata aacaataaaa aaatgaaaac 3613

acaaaattgt tcctatttag taatttttaca aatgtcaatt gttttgagaa ctcatcgatt 3673

ttgcaataaa tttatagaag aacttgtcta ttttagtaaa atatagatca gaatttcctt 3733

gcttgttcaa gtttcattct tttcatttta ttttatttta aaaaaagacc caaagtttgc 3793

ctcataaaag aattttctct tatcatataa gagggagtta gtgctgactt tcctcttatc 3853

atatccgtcg ac 3865

<210> 8
<211> 829
<212> PRT
<213> Solanum tuberosum

<400> 8

Ile Leu Phe Asn Pro Phe Lys Tyr Pro His Gln Ile Ile Ser Thr Asn
1 5 10 15

Ile Pro Leu Phe Asn Phe Lys Tyr Asn Ser Met Glu Leu Asn Phe Gln
20 25 30

Phe Tyr Phe Leu Cys Phe Leu Leu Cys Phe Ile Pro Leu Leu Gln Ala
35 40 45

Gln Asn Leu Gln Thr Tyr Ile Val Gln Leu His Pro Gln His Ala Ser
50 55 60

Thr Arg Thr Pro Phe Ser Ser Lys Phe Gln Trp His Leu Ser Phe Leu
65 70 75 80

Glu Asn Phe Thr Asn Ile Pro Leu Phe Asn Phe Lys Tyr Ile Gln Trp
85 90 95

Asn Ser Ile Pro Ile Leu Phe Leu Cys Phe Tyr Ser Val Tyr Ser Pro
100 105 110

Ala Thr Ser Ile Ser Ser Gly Glu Asn Ser Ser Ser Arg Leu Leu Tyr
115 120 125

Ser Tyr His Ser Ala Phe Glu Gly Phe Ala Ala Leu Leu Ser Glu Asn
130 135 140

Glu Leu Lys Ala Leu Lys Lys Ser Asn Asn Val Leu Ser Ile Tyr Pro
145 150 155 160

Glu Arg Lys Leu Glu Val Gln Thr Thr Tyr Ser Tyr Lys Phe Leu Gly
165 170 175

Leu Ser Pro Thr Lys Glu Gly Thr Trp Leu Lys Ser Gly Phe Gly Arg
180 185 190

Gly Ala Ile Ile Gly Val Leu Asp Thr Gly Ile Trp Pro Glu Ser Pro
195 200 205

Ser Phe Val Asp His Gly Met Ser Pro Ile Pro Lys Lys Trp Lys Gly
210 215 220

Xaa Cys Gln Glu Gly Lys Asn Phe Asn Ser Ser Ser Cys Asn Arg Lys
225 230 235 240

Leu Ile Gly Ala Arg Phe Phe Gln Ile Gly His Met Met Ala Ser Lys
245 250 255

Thr Ser Lys Ser Ile Asp Phe Met Glu Asp Tyr Val Ser Pro Arg Asp
260 265 270

Ser Gln Gly His Gly Thr His Thr Ala Ser Thr Ala Gly Gly Ala Pro
275 280 285

Val Pro Met Ala Ser Val Leu Gly Asn Gly Ala Gly Glu Ala Arg Gly
290 295 300

Met Ala Pro Gly Ala His Ile Ala Ile Tyr Lys Val Cys Trp Ser Ser
305 310 315 320

Gly Cys Tyr Ser Ser Asp Ile Leu Ala Ala Met Asp Val Ala Ile Arg
325 330 335

Asp Gly Val Asp Ile Leu Ser Leu Ser Ile Gly Gly Phe Pro Val Pro
340 345 350

Leu Tyr Glu Asp Thr Ile Ala Ile Gly Ser Phe Arg Ala Met Glu Arg
355 360 365

Gly Ile Ser Val Ile Cys Ala Ala Gly Asn Asn Gly Pro Ile Leu Ser
370 375 380

Ser Val Ala Asn Glu Ala Pro Trp Ile Ala Thr Ile Gly Ala Ser Thr
385 390 395 400

Leu Asp Arg Lys Phe Pro Ala Ile Ile Gln Leu Gly Asn Gly Lys Tyr
405 410 415

Val Tyr Gly Glu Ser Leu Tyr Pro Gly Lys Gln Val His Asn Ser Gln
420 425 430

Lys Val Leu Glu Ile Val Tyr Leu Asn Asp Gly Asp Asn Gly Ser Glu
435 440 445

Phe Cys Leu Arg Gly Ser Leu Pro Arg Ala Lys Val His Gly Lys Ile
450 455 460

Val Val Cys Asp Arg Gly Val Asn Gly Arg Ala Glu Lys Gly Gln Val
465 470 475 480

Val Lys Glu Ser Gly Gly Val Ala Met Ile Leu Ala Asn Thr Ala Val
485 490 495

Asn Met Glu Glu Asp Ser Val Asp Val His Val Leu Pro Ala Thr Leu
500 505 510

Ile Gly Phe Asp Glu Ser Ile Gln Leu Gln Ser Tyr Met Asn Ser Thr
515 520 525

Arg Lys Pro Thr Ala Arg Ile Ile Phe Gly Gly Thr Val Ile Gly Lys
530 535 540

Ser Ser Ala Pro Ala Val Ala Gln Phe Ser Ser Arg Gly Pro Ser Phe
545 550 555 560

```
Thr Asp Pro Ser Ile Leu Lys Pro Asp Val Ile Ala Pro Gly Val Asn
                565                 570                 575

Ile Ile Ala Ala Trp Pro Gln Asn Leu Gly Pro Ser Gly Leu Ala Glu
            580                 585                 590

Asp Ser Arg Arg Val Asn Phe Thr Val Leu Ser Gly Thr Ser Met Ala
        595                 600                 605

Cys Pro His Val Ser Gly Ile Ala Ala Leu Leu His Ser Ile His Pro
    610                 615                 620

Lys Trp Ser Pro Ala Ala Ile Lys Ser Ala Leu Met Thr Thr Ala Asp
625                 630                 635                 640

Thr Thr Asn His Gln Gly Lys Pro Ile Met Asp Gly Asp Thr Arg Ala
                645                 650                 655

Gly Leu Phe Ala Ile Gly Ala Gly His Val Asn Pro Gly Arg Ser Asp
            660                 665                 670

Asp Pro Gly Leu Ile Tyr Asp Ile Asn Ala Asn Asp Tyr Ile Thr His
        675                 680                 685

Leu Cys Thr Ile Gly Tyr Lys Asn Ser Glu Ile Leu Ser Ile Thr His
    690                 695                 700

Lys Asn Val Ser Cys His Asp Val Leu Gln Lys Asn Arg Gly Phe Ser
705                 710                 715                 720

Leu Asn Tyr Pro Ser Ile Ser Val Ile Phe Lys Ala Gly Lys Thr Arg
                725                 730                 735

Lys Met Ile Thr Arg Arg Val Thr Asn Val Gly Ser Pro Asn Ser Ile
            740                 745                 750

Tyr Ser Val Glu Ile Val Ala Pro Glu Gly Val Lys Val Arg Val Lys
        755                 760                 765

Pro Arg Arg Leu Val Phe Lys His Val Asn Gln Ser Leu Ser Tyr Arg
    770                 775                 780

Val Trp Phe Ile Ser Arg Lys Arg Ile Gly Thr Gln Arg Arg Ser Phe
785                 790                 795                 800

Ala Glu Gly Gln Leu Met Trp Ile Asn Ser Arg Asp Lys Tyr Gln Lys
                805                 810                 815

Val Arg Ser Pro Ile Ser Val Ala Trp Ala Ser Lys Lys
            820                 825
```

<210> 9
<211> 2492
<212> DNA
<213> Solanum tuberosum

<220>
<221> CDS
<222> (3)..(2489)

<400> 9

```
ga att ctg ttc aac ccc ttt aaa tac ccc cat caa att ata tca aca    47
   Ile Leu Phe Asn Pro Phe Lys Tyr Pro His Gln Ile Ile Ser Thr
     1               5                  10                  15

aac att cca tta ttc aac ttc aaa tat aat tca atg gaa ctc aat ttc    95
Asn Ile Pro Leu Phe Asn Phe Lys Tyr Asn Ser Met Glu Leu Asn Phe
                 20                  25                  30

caa ttc tat ttt ctc tgt ttt cta ctc tgt ttt att ccc ctg cta caa   143
Gln Phe Tyr Phe Leu Cys Phe Leu Leu Cys Phe Ile Pro Leu Leu Gln
             35                  40                  45

gct caa aat ttg caa act tat ata gta caa tta cat cca caa cat gca   191
Ala Gln Asn Leu Gln Thr Tyr Ile Val Gln Leu His Pro Gln His Ala
         50                  55                  60

tca aca aga acc cct ttt agt tct aaa ttt cag tgg cac ctt tca ttt   239
Ser Thr Arg Thr Pro Phe Ser Ser Lys Phe Gln Trp His Leu Ser Phe
     65                  70                  75

ctt gaa aat ttc aca aac att cca tta ttc aac ttc aaa tat att caa   287
Leu Glu Asn Phe Thr Asn Ile Pro Leu Phe Asn Phe Lys Tyr Ile Gln
 80                  85                  90                  95

tgg aac tca att cca att cta ttt ctc tgt ttc tac tct gtt tat tcc   335
Trp Asn Ser Ile Pro Ile Leu Phe Leu Cys Phe Tyr Ser Val Tyr Ser
                100                 105                 110

cct gct aca agc att tcc tca ggt gaa aac tcg agt tct cgc ctt ttg   383
Pro Ala Thr Ser Ile Ser Ser Gly Glu Asn Ser Ser Ser Arg Leu Leu
            115                 120                 125

tac tct tac cat tct gca ttt gaa ggt ttt gca gca ctt cta tct gaa   431
Tyr Ser Tyr His Ser Ala Phe Glu Gly Phe Ala Ala Leu Leu Ser Glu
        130                 135                 140

aat gag cta aag gca ctg aag aaa tcg aat aat gtg tta tca ata tat   479
Asn Glu Leu Lys Ala Leu Lys Lys Ser Asn Asn Val Leu Ser Ile Tyr
    145                 150                 155

ccg gag agg aag ctt gag gtt caa aca act tat tct tac aag ttc tta   527
Pro Glu Arg Lys Leu Glu Val Gln Thr Thr Tyr Ser Tyr Lys Phe Leu
160                 165                 170                 175

gga ctt agt cct aca aag gaa ggt act tgg tta aag tct gga ttt ggt   575
Gly Leu Ser Pro Thr Lys Glu Gly Thr Trp Leu Lys Ser Gly Phe Gly
                180                 185                 190

cga ggc gcg atc att gga gtt ctt gat act gga att tgg cca gaa agt   623
Arg Gly Ala Ile Ile Gly Val Leu Asp Thr Gly Ile Trp Pro Glu Ser
            195                 200                 205

cca agt ttt gtt gat cat gga atg tct cct att cca aag aaa tgg aaa   671
Pro Ser Phe Val Asp His Gly Met Ser Pro Ile Pro Lys Lys Trp Lys
        210                 215                 220

ggt ntc tgc caa gaa gga aaa aac ttc aat tct tca agt tgc aat cgc   719
Gly Xaa Cys Gln Glu Gly Lys Asn Phe Asn Ser Ser Ser Cys Asn Arg
    225                 230                 235

aag ctt att ggt gca agg ttt ttc cag ata gga cac atg atg gca tca   767
Lys Leu Ile Gly Ala Arg Phe Phe Gln Ile Gly His Met Met Ala Ser
240                 245                 250                 255
```

```
aag aca tca aaa tca ata gat ttt atg gag gat tat gta tca cct cga   815
Lys Thr Ser Lys Ser Ile Asp Phe Met Glu Asp Tyr Val Ser Pro Arg
                260                 265                 270

gat tct caa ggc cat ggt aca cat aca gca tct act gca ggg gga gct   863
Asp Ser Gln Gly His Gly Thr His Thr Ala Ser Thr Ala Gly Gly Ala
            275                 280                 285

ccc gtt cca atg gcg agt gtg ctt gga aat gga gca gga gag gct cga   911
Pro Val Pro Met Ala Ser Val Leu Gly Asn Gly Ala Gly Glu Ala Arg
        290                 295                 300

ggg atg gcc cct ggt gct cat atc gcg ata tac aaa gtt tgt tgg tct   959
Gly Met Ala Pro Gly Ala His Ile Ala Ile Tyr Lys Val Cys Trp Ser
    305                 310                 315

agt ggt tgt tat agt tct gat ata ctt gca gca atg gat gta gct att   1007
Ser Gly Cys Tyr Ser Ser Asp Ile Leu Ala Ala Met Asp Val Ala Ile
320                 325                 330                 335

aga gat gga gta gac ata ttg tct ctt tca att ggt ggt ttc cct gtt   1055
Arg Asp Gly Val Asp Ile Leu Ser Leu Ser Ile Gly Gly Phe Pro Val
                340                 345                 350

cca ctt tat gag gat act att gct att ggc agt ttt cga gct atg gaa   1103
Pro Leu Tyr Glu Asp Thr Ile Ala Ile Gly Ser Phe Arg Ala Met Glu
            355                 360                 365

cgt gga att tca gtt ata tgt gct gca gga aat aat ggt cca att cta   1151
Arg Gly Ile Ser Val Ile Cys Ala Ala Gly Asn Asn Gly Pro Ile Leu
        370                 375                 380

agt tca gta gca aat gag gct cct tgg att gcc act att ggt gct agc   1199
Ser Ser Val Ala Asn Glu Ala Pro Trp Ile Ala Thr Ile Gly Ala Ser
    385                 390                 395

aca ctt gac agg aaa ttt cca gca ata att cag cta ggt aat ggc aag   1247
Thr Leu Asp Arg Lys Phe Pro Ala Ile Ile Gln Leu Gly Asn Gly Lys
400                 405                 410                 415

tat gtg tat gga gaa tcc ttg tac ccg ggc aaa caa gtt cat aat tct   1295
Tyr Val Tyr Gly Glu Ser Leu Tyr Pro Gly Lys Gln Val His Asn Ser
                420                 425                 430

cag aaa gtt ctt gag att gtt tat ctc aat gac ggt gat aat gga agt   1343
Gln Lys Val Leu Glu Ile Val Tyr Leu Asn Asp Gly Asp Asn Gly Ser
            435                 440                 445

gaa ttt tgc tta aga ggg tct ctg cca aga gct aaa gtc cat gga aaa   1391
Glu Phe Cys Leu Arg Gly Ser Leu Pro Arg Ala Lys Val His Gly Lys
        450                 455                 460

atc gtt gta tgt gat cgt gga gtt aat gga aga gca gag aaa ggt caa   1439
Ile Val Val Cys Asp Arg Gly Val Asn Gly Arg Ala Glu Lys Gly Gln
    465                 470                 475

gtt gtt aaa gaa tca ggt ggt gtt gcc atg atc cta gca aat aca gca   1487
Val Val Lys Glu Ser Gly Gly Val Ala Met Ile Leu Ala Asn Thr Ala
480                 485                 490                 495

gta aat atg gag gaa gat tct gtg gac gta cat gtc cta cct gca aca   1535
Val Asn Met Glu Glu Asp Ser Val Asp Val His Val Leu Pro Ala Thr
```

```
                500                 505                 510

ttg att ggt ttt gac gaa tca att cag ttg caa agc tat atg aac tca   1583
Leu Ile Gly Phe Asp Glu Ser Ile Gln Leu Gln Ser Tyr Met Asn Ser
            515                 520                 525

acg cga aaa cca aca gct cga atc ata ttt gga gga aca gtt ata gga   1631
Thr Arg Lys Pro Thr Ala Arg Ile Ile Phe Gly Gly Thr Val Ile Gly
        530                 535                 540

aaa tct agt gca cct gct gta gca caa ttt tct tca agg ggt cca agt   1679
Lys Ser Ser Ala Pro Ala Val Ala Gln Phe Ser Ser Arg Gly Pro Ser
    545                 550                 555

ttt act gat cct tca att ctc aaa cct gat gtg att gct cca ggt gtc   1727
Phe Thr Asp Pro Ser Ile Leu Lys Pro Asp Val Ile Ala Pro Gly Val
560                 565                 570                 575

aac ata att gct gct tgg ccg caa aat cta ggt cct agt ggc ctg gct   1775
Asn Ile Ile Ala Ala Trp Pro Gln Asn Leu Gly Pro Ser Gly Leu Ala
                580                 585                 590

gag gat tca aga aga gta aac ttc act gtc tta tca gga act tca atg   1823
Glu Asp Ser Arg Arg Val Asn Phe Thr Val Leu Ser Gly Thr Ser Met
            595                 600                 605

gct tgt cct cat gtt agt ggc att gct gca cta ctc cat tca att cat   1871
Ala Cys Pro His Val Ser Gly Ile Ala Ala Leu Leu His Ser Ile His
        610                 615                 620

cct aaa tgg tca cca gct gca atc aaa tcc gcg cta atg aca act gca   1919
Pro Lys Trp Ser Pro Ala Ala Ile Lys Ser Ala Leu Met Thr Thr Ala
    625                 630                 635

gac aca aca aac cac caa gga aaa cca atc atg gat ggt gac aca cga   1967
Asp Thr Thr Asn His Gln Gly Lys Pro Ile Met Asp Gly Asp Thr Arg
640                 645                 650                 655

gct gga ctt ttc gcc ata gga gct gga cat gta aat cct gga aga tcc   2015
Ala Gly Leu Phe Ala Ile Gly Ala Gly His Val Asn Pro Gly Arg Ser
                660                 665                 670

gat gat ccc gga ttg ata tat gac att aat gca aat gac tat atc act   2063
Asp Asp Pro Gly Leu Ile Tyr Asp Ile Asn Ala Asn Asp Tyr Ile Thr
            675                 680                 685

cac ctt tgc act att ggt tac aaa aac tct gaa atc ctc agc att act   2111
His Leu Cys Thr Ile Gly Tyr Lys Asn Ser Glu Ile Leu Ser Ile Thr
        690                 695                 700

cac aag aat gtt agc tgc cac gac gtt tta cag aaa aac agg ggt ttt   2159
His Lys Asn Val Ser Cys His Asp Val Leu Gln Lys Asn Arg Gly Phe
    705                 710                 715

agt ctc aat tac ccc tct att tcc gta atc ttt aag gca gga aaa acg   2207
Ser Leu Asn Tyr Pro Ser Ile Ser Val Ile Phe Lys Ala Gly Lys Thr
720                 725                 730                 735

aga aaa atg atc aca agg aga gtg aca aat gtg ggg agt cct aat tca   2255
Arg Lys Met Ile Thr Arg Arg Val Thr Asn Val Gly Ser Pro Asn Ser
                740                 745                 750

atc tac tca gtt gaa att gtg gca cca gaa gga gtt aaa gtg aga gtt   2303
```

```
Ile Tyr Ser Val Glu Ile Val Ala Pro Glu Gly Val Lys Val Arg Val
            755                 760                 765

aaa ccg cga cgt ctg gta ttt aaa cat gtt aat caa agt tta agt tac   2351
Lys Pro Arg Arg Leu Val Phe Lys His Val Asn Gln Ser Leu Ser Tyr
        770                 775                 780

aga gtt tgg ttt ata tca agg aag aga att ggg act caa agg aga agc   2399
Arg Val Trp Phe Ile Ser Arg Lys Arg Ile Gly Thr Gln Arg Arg Ser
    785                 790                 795

ttt gca gaa gga caa ttg atg tgg atc aac tcc aga gat aaa tac cag   2447
Phe Ala Glu Gly Gln Leu Met Trp Ile Asn Ser Arg Asp Lys Tyr Gln
800                 805                 810                 815

aaa gtt aga agt cct att tca gtt gca tgg gca tca aag aag tga       2492
Lys Val Arg Ser Pro Ile Ser Val Ala Trp Ala Ser Lys Lys
                820                 825
```

<210> 10
<211> 829
<212> PRT
<213> Solanum tuberosum

<400> 10

```
Ile Leu Phe Asn Pro Phe Lys Tyr Pro His Gln Ile Ile Ser Thr Asn
 1               5                  10                  15

Ile Pro Leu Phe Asn Phe Lys Tyr Asn Ser Met Glu Leu Asn Phe Gln
            20                  25                  30

Phe Tyr Phe Leu Cys Phe Leu Leu Cys Phe Ile Pro Leu Leu Gln Ala
        35                  40                  45

Gln Asn Leu Gln Thr Tyr Ile Val Gln Leu His Pro Gln His Ala Ser
    50                  55                  60

Thr Arg Thr Pro Phe Ser Ser Lys Phe Gln Trp His Leu Ser Phe Leu
65                  70                  75                  80

Glu Asn Phe Thr Asn Ile Pro Leu Phe Asn Phe Lys Tyr Ile Gln Trp
                85                  90                  95

Asn Ser Ile Pro Ile Leu Phe Leu Cys Phe Tyr Ser Val Tyr Ser Pro
            100                 105                 110

Ala Thr Ser Ile Ser Ser Gly Glu Asn Ser Ser Ser Arg Leu Leu Tyr
        115                 120                 125

Ser Tyr His Ser Ala Phe Glu Gly Phe Ala Ala Leu Leu Ser Glu Asn
    130                 135                 140

Glu Leu Lys Ala Leu Lys Lys Ser Asn Asn Val Leu Ser Ile Tyr Pro
145                 150                 155                 160

Glu Arg Lys Leu Glu Val Gln Thr Thr Tyr Ser Tyr Lys Phe Leu Gly
                165                 170                 175

Leu Ser Pro Thr Lys Glu Gly Thr Trp Leu Lys Ser Gly Phe Gly Arg
            180                 185                 190

Gly Ala Ile Ile Gly Val Leu Asp Thr Gly Ile Trp Pro Glu Ser Pro
```

195 200 205

Ser Phe Val Asp His Gly Met Ser Pro Ile Pro Lys Lys Trp Lys Gly
210 215 220

Xaa Cys Gln Glu Gly Lys Asn Phe Asn Ser Ser Ser Cys Asn Arg Lys
225 230 235 240

Leu Ile Gly Ala Arg Phe Phe Gln Ile Gly His Met Met Ala Ser Lys
245 250 255

Thr Ser Lys Ser Ile Asp Phe Met Glu Asp Tyr Val Ser Pro Arg Asp
260 265 270

Ser Gln Gly His Gly Thr His Thr Ala Ser Thr Ala Gly Gly Ala Pro
275 280 285

Val Pro Met Ala Ser Val Leu Gly Asn Gly Ala Gly Glu Ala Arg Gly
290 295 300

Met Ala Pro Gly Ala His Ile Ala Ile Tyr Lys Val Cys Trp Ser Ser
305 310 315 320

Gly Cys Tyr Ser Ser Asp Ile Leu Ala Ala Met Asp Val Ala Ile Arg
325 330 335

Asp Gly Val Asp Ile Leu Ser Leu Ser Ile Gly Gly Phe Pro Val Pro
340 345 350

Leu Tyr Glu Asp Thr Ile Ala Ile Gly Ser Phe Arg Ala Met Glu Arg
355 360 365

Gly Ile Ser Val Ile Cys Ala Ala Gly Asn Asn Gly Pro Ile Leu Ser
370 375 380

Ser Val Ala Asn Glu Ala Pro Trp Ile Ala Thr Ile Gly Ala Ser Thr
385 390 395 400

Leu Asp Arg Lys Phe Pro Ala Ile Ile Gln Leu Gly Asn Gly Lys Tyr
405 410 415

Val Tyr Gly Glu Ser Leu Tyr Pro Gly Lys Gln Val His Asn Ser Gln
420 425 430

Lys Val Leu Glu Ile Val Tyr Leu Asn Asp Gly Asp Asn Gly Ser Glu
435 440 445

Phe Cys Leu Arg Gly Ser Leu Pro Arg Ala Lys Val His Gly Lys Ile
450 455 460

Val Val Cys Asp Arg Gly Val Asn Gly Arg Ala Glu Lys Gly Gln Val
465 470 475 480

Val Lys Glu Ser Gly Gly Val Ala Met Ile Leu Ala Asn Thr Ala Val
485 490 495

Asn Met Glu Glu Asp Ser Val Asp Val His Val Leu Pro Ala Thr Leu
500 505 510

Ile Gly Phe Asp Glu Ser Ile Gln Leu Gln Ser Tyr Met Asn Ser Thr
515 520 525

Arg Lys Pro Thr Ala Arg Ile Ile Phe Gly Gly Thr Val Ile Gly Lys

530 535 540

Ser Ser Ala Pro Ala Val Ala Gln Phe Ser Ser Arg Gly Pro Ser Phe
545 550 555 560

Thr Asp Pro Ser Ile Leu Lys Pro Asp Val Ile Ala Pro Gly Val Asn
565 570 575

Ile Ile Ala Ala Trp Pro Gln Asn Leu Gly Pro Ser Gly Leu Ala Glu
580 585 590

Asp Ser Arg Arg Val Asn Phe Thr Val Leu Ser Gly Thr Ser Met Ala
595 600 605

Cys Pro His Val Ser Gly Ile Ala Ala Leu Leu His Ser Ile His Pro
610 615 620

Lys Trp Ser Pro Ala Ala Ile Lys Ser Ala Leu Met Thr Thr Ala Asp
625 630 635 640

Thr Thr Asn His Gln Gly Lys Pro Ile Met Asp Gly Asp Thr Arg Ala
645 650 655

Gly Leu Phe Ala Ile Gly Ala Gly His Val Asn Pro Gly Arg Ser Asp
660 665 670

Asp Pro Gly Leu Ile Tyr Asp Ile Asn Ala Asn Asp Tyr Ile Thr His
675 680 685

Leu Cys Thr Ile Gly Tyr Lys Asn Ser Glu Ile Leu Ser Ile Thr His
690 695 700

Lys Asn Val Ser Cys His Asp Val Leu Gln Lys Asn Arg Gly Phe Ser
705 710 715 720

Leu Asn Tyr Pro Ser Ile Ser Val Ile Phe Lys Ala Gly Lys Thr Arg
725 730 735

Lys Met Ile Thr Arg Arg Val Thr Asn Val Gly Ser Pro Asn Ser Ile
740 745 750

Tyr Ser Val Glu Ile Val Ala Pro Glu Gly Val Lys Val Arg Val Lys
755 760 765

Pro Arg Arg Leu Val Phe Lys His Val Asn Gln Ser Leu Ser Tyr Arg
770 775 780

Val Trp Phe Ile Ser Arg Lys Arg Ile Gly Thr Gln Arg Arg Ser Phe
785 790 795 800

Ala Glu Gly Gln Leu Met Trp Ile Asn Ser Arg Asp Lys Tyr Gln Lys
805 810 815

Val Arg Ser Pro Ile Ser Val Ala Trp Ala Ser Lys Lys
820 825

<210> 11
<211> 3140
<212> DNA
<213> Solanum tuberosum

<220>
<221> CDS
<222> (1)..(2298)

<400> 11

```
act cat tta ttc tcc ttt cta tgt ctt tta cta tgt ttt gtt tgc ata   48
Thr His Leu Phe Ser Phe Leu Cys Leu Leu Leu Cys Phe Val Cys Ile
  1               5                  10                  15

caa gct caa gat ttg caa act tac ata gtt cag tta cat cca cat gga   96
Gln Ala Gln Asp Leu Gln Thr Tyr Ile Val Gln Leu His Pro His Gly
             20                  25                  30

gca aca aga ccc cct ttt agc tct aaa cta caa tgg cac ctt tct ttc   144
Ala Thr Arg Pro Pro Phe Ser Ser Lys Leu Gln Trp His Leu Ser Phe
         35                  40                  45

ctt gca aaa gca gtt tcc tct gga gaa caa gac tcg tct tct cgt ctt   192
Leu Ala Lys Ala Val Ser Ser Gly Glu Gln Asp Ser Ser Ser Arg Leu
     50                  55                  60

ttg tac tct tac cat tct gcg atg gaa ggt ttt gca gct cga ctc act   240
Leu Tyr Ser Tyr His Ser Ala Met Glu Gly Phe Ala Ala Arg Leu Thr
 65                  70                  75                  80

gaa gat gag gtt gag ttg tta agg gaa tct aat gat gtg ttg tcg ata   288
Glu Asp Glu Val Glu Leu Leu Arg Glu Ser Asn Asp Val Leu Ser Ile
                 85                  90                  95

cgt gct gag agg agg ctt gaa att cag act act tat tct tac aag ttc   336
Arg Ala Glu Arg Arg Leu Glu Ile Gln Thr Thr Tyr Ser Tyr Lys Phe
            100                 105                 110

ttg gga tta agt cca acg aga gaa gga gct tgg ttg aag tct gga ttt   384
Leu Gly Leu Ser Pro Thr Arg Glu Gly Ala Trp Leu Lys Ser Gly Phe
        115                 120                 125

ggt cga ggg gcg atc att gga gtg ttg gat act gga gtt tgg cca gaa   432
Gly Arg Gly Ala Ile Ile Gly Val Leu Asp Thr Gly Val Trp Pro Glu
    130                 135                 140

agt cca agt ttt gat gat cat ggg atg cca cct gct cca cag aag tgg   480
Ser Pro Ser Phe Asp Asp His Gly Met Pro Pro Ala Pro Gln Lys Trp
145                 150                 155                 160

agg ggt gtc tgc caa gga gga cag gat ttt aat tct tct agt tgt aat   528
Arg Gly Val Cys Gln Gly Gly Gln Asp Phe Asn Ser Ser Ser Cys Asn
                165                 170                 175

cgc aag ctt att ggt gca agg ttt ttc aga aaa gga cat cgt gtg gct   576
Arg Lys Leu Ile Gly Ala Arg Phe Phe Arg Lys Gly His Arg Val Ala
            180                 185                 190

tca atg aca tca tca cca gat gca gtg gag gaa tat gtg tcg cca cgg   624
Ser Met Thr Ser Ser Pro Asp Ala Val Glu Glu Tyr Val Ser Pro Arg
        195                 200                 205

gat tcc cat ggc cat ggt aca cat aca gca tcc act gct gga gga gct   672
Asp Ser His Gly His Gly Thr His Thr Ala Ser Thr Ala Gly Gly Ala
    210                 215                 220

gca gtt cca ttg gct ggt gtg ctc gga aat gga gca ggg gag gct cga   720
Ala Val Pro Leu Ala Gly Val Leu Gly Asn Gly Ala Gly Glu Ala Arg
```

```
225                 230                 235                 240

ggg atg gcc ccg ggt gcc cac att gca ata tat aaa gta tgc tgg ttc   768
Gly Met Ala Pro Gly Ala His Ile Ala Ile Tyr Lys Val Cys Trp Phe
                245                 250                 255

agt ggt tgt tac agc tct gat ata ctt gca gca atg gat gtg gcc atc   816
Ser Gly Cys Tyr Ser Ser Asp Ile Leu Ala Ala Met Asp Val Ala Ile
            260                 265                 270

aga gat gga gta gac ata ttg tca ctc tca ctt ggt ggc ttc cct att   864
Arg Asp Gly Val Asp Ile Leu Ser Leu Ser Leu Gly Gly Phe Pro Ile
        275                 280                 285

cca ctt tat gat gat act att gcc att gga agt ttc cga gcc atg gag   912
Pro Leu Tyr Asp Asp Thr Ile Ala Ile Gly Ser Phe Arg Ala Met Glu
    290                 295                 300

cat gga att tca gtt ata tgt gct gca ggg aat aat gga cca atc caa   960
His Gly Ile Ser Val Ile Cys Ala Ala Gly Asn Asn Gly Pro Ile Gln
305                 310                 315                 320

agt tca gta gcc aac ggt gct cct tgg att gcc act att ggt gct agc  1008
Ser Ser Val Ala Asn Gly Ala Pro Trp Ile Ala Thr Ile Gly Ala Ser
                325                 330                 335

aca ctt gac agg aga ttt cca gcg tca gtt cag tta ggc aac gga aag  1056
Thr Leu Asp Arg Arg Phe Pro Ala Ser Val Gln Leu Gly Asn Gly Lys
            340                 345                 350

ttc ctg tac gga gaa tcc ttg tac cct ggg aag aaa gtt cct agc tct  1104
Phe Leu Tyr Gly Glu Ser Leu Tyr Pro Gly Lys Lys Val Pro Ser Ser
        355                 360                 365

cag aag aat ctt gag atc gtt tat gta aag gat aag gac aag gga agt  1152
Gln Lys Asn Leu Glu Ile Val Tyr Val Lys Asp Lys Asp Lys Gly Ser
    370                 375                 380

gaa ttt tgc ttg aga gga tcg cta tca aaa gca caa gtc cga ggg aaa  1200
Glu Phe Cys Leu Arg Gly Ser Leu Ser Lys Ala Gln Val Arg Gly Lys
385                 390                 395                 400

atg gtt gtg tgt gat agg gga gtc aat gga agg gca gaa aaa ggc cag  1248
Met Val Val Cys Asp Arg Gly Val Asn Gly Arg Ala Glu Lys Gly Gln
                405                 410                 415

gtt gtg aag gag gca ggt ggt gct gcc atg atc tta gca aat aca gca  1296
Val Val Lys Glu Ala Gly Gly Ala Ala Met Ile Leu Ala Asn Thr Ala
            420                 425                 430

ata aat atg gag gaa gat tcc att gat gtc cat gtc ctc cca gca acg  1344
Ile Asn Met Glu Glu Asp Ser Ile Asp Val His Val Leu Pro Ala Thr
        435                 440                 445

ttg att ggc ttc gat gaa tca att caa tta caa aac tac ctg aac tca  1392
Leu Ile Gly Phe Asp Glu Ser Ile Gln Leu Gln Asn Tyr Leu Asn Ser
    450                 455                 460

aca aaa aga cca aca gct cga ttc ata ttt gga gga acg gta ata gga  1440
Thr Lys Arg Pro Thr Ala Arg Phe Ile Phe Gly Gly Thr Val Ile Gly
465                 470                 475                 480

aag tct aga gca cct gca gta gct cag ttt tcg tca agg ggg cca agc  1488
```

```
Lys Ser Arg Ala Pro Ala Val Ala Gln Phe Ser Ser Arg Gly Pro Ser
                485                 490                 495

tat act gat cct tca att ctc aaa cct gat ttg att gct cca ggg gta  1536
Tyr Thr Asp Pro Ser Ile Leu Lys Pro Asp Leu Ile Ala Pro Gly Val
            500                 505                 510

aac ata att gcc gct tgg cca caa aac tta ggc ccc agt ggt ctt ccc  1584
Asn Ile Ile Ala Ala Trp Pro Gln Asn Leu Gly Pro Ser Gly Leu Pro
        515                 520                 525

gaa gat tca cga aga gta aat ttc act gtt atg tca ggg acc tca atg  1632
Glu Asp Ser Arg Arg Val Asn Phe Thr Val Met Ser Gly Thr Ser Met
    530                 535                 540

gca tgt cct cat gta agt gga att gcc gca ttg ctc cat tca gct cat  1680
Ala Cys Pro His Val Ser Gly Ile Ala Ala Leu Leu His Ser Ala His
545                 550                 555                 560

cct aaa tgg act cca gca gca ata aga tcc gca tta atg acc act gca  1728
Pro Lys Trp Thr Pro Ala Ala Ile Arg Ser Ala Leu Met Thr Thr Ala
                565                 570                 575

gat aca gct gat cat atg gga aaa cca atc atg gat gga gat gca cca  1776
Asp Thr Ala Asp His Met Gly Lys Pro Ile Met Asp Gly Asp Ala Pro
            580                 585                 590

gct aaa ctt ttt gca gct gga gct gga cac gtg aac cct gga aga gcc  1824
Ala Lys Leu Phe Ala Ala Gly Ala Gly His Val Asn Pro Gly Arg Ala
        595                 600                 605

atc gat cct gga ttg ata tat gac atc cag gtt gat gaa tat atc act  1872
Ile Asp Pro Gly Leu Ile Tyr Asp Ile Gln Val Asp Glu Tyr Ile Thr
    610                 615                 620

cat ctt tgc act atc gga tac aga aat tct gaa gtc ttc agc att act  1920
His Leu Cys Thr Ile Gly Tyr Arg Asn Ser Glu Val Phe Ser Ile Thr
625                 630                 635                 640

cat agg aat gtc agc tgc cat gac att tta cag aac aac agg ggt ttc  1968
His Arg Asn Val Ser Cys His Asp Ile Leu Gln Asn Asn Arg Gly Phe
                645                 650                 655

agc cta aat tac ccc tca att tca ata act ttc aga gca gga atg act  2016
Ser Leu Asn Tyr Pro Ser Ile Ser Ile Thr Phe Arg Ala Gly Met Thr
            660                 665                 670

aga aag ata atc aag agg aga gta aca aat gtg ggg aac cct aac tct  2064
Arg Lys Ile Ile Lys Arg Arg Val Thr Asn Val Gly Asn Pro Asn Ser
        675                 680                 685

att tac tca gtt gac att gag gca cct gag gga gtc aaa gtg aga gtg  2112
Ile Tyr Ser Val Asp Ile Glu Ala Pro Glu Gly Val Lys Val Arg Val
    690                 695                 700

aag cca cgt cgt ctg ata ttt aaa cat gtg aac caa agc tta agc tat  2160
Lys Pro Arg Arg Leu Ile Phe Lys His Val Asn Gln Ser Leu Ser Tyr
705                 710                 715                 720

aga gtt tgg ttt ata tca cga aag awa ata gag tct aaa agg atg agc  2208
Arg Val Trp Phe Ile Ser Arg Lys Xaa Ile Glu Ser Lys Arg Met Ser
                725                 730                 735
```

```
ttt gca gag ggg caa ttg aca tgg ttc aat gta gga aac aaa gcc acg   2256
Phe Ala Glu Gly Gln Leu Thr Trp Phe Asn Val Gly Asn Lys Ala Thr
            740                 745                 750

aaa gtt aaa agt cct att tcc gtc aca tgg gca tca atg aag           2298
Lys Val Lys Ser Pro Ile Ser Val Thr Trp Ala Ser Met Lys
        755                 760                 765

tgatcactat caccactatc acaagcacca tatatttcat tgtcttagtt caaaatttcc 2358

aattaggaat ttcacatcac attataaatt gatgttagag cagatacact ttatctttcc 2418

acaaagaaga aatgatcgat aatcattgaa atgatttgtg ttttactaag tagatgtgtc 2478

tccacaatgt taagaagtat taatatgtat aaatagatta gacaaagcac gagattgcgc 2538

ctgagtgagg nattttctca agtttacacc ttttgaacta aattacttcat aaaccagtat 2598

gacagacaaa aaattcaaga aattggcgag gcaaaagaaa acatacaata taatctcaac 2658

ttttaacaaa ttgcaagcca tttgaattag cataccgctc cataaatctc atgaacctgt 2718

cccagtctcg tggagtccgc ataatatact tagcttcaat tcctgcaggc tttccattaa 2778

caaacttagc attgacatca actgacgtta gaaccccttc ttcgtcaatc atgtagaatc 2838

cagtgatatc ccctacttca ccagatgaat caaatacgga gggttgatca aacctgaata 2898

tagccatacc atttgtccat cccttgactt tgttaatttc acatctggta ttgtttgctc 2958

atcagttcct tgtatgaact gaatttttgg ttgaaccatc attatacata gtctggacat 3018

tttctggttt ttgatattgg tactgaaacg cgaacgggat aggcacaatc gttggccaat 3078

tgaatgaaga acctgcactt tgatgaacta tccttgatgc tattcctaca gtacatgaca 3138

ca                                                                3140
```

<210> 12
<211> 766
<212> PRT
<213> Solanum tuberosum

<400> 12

```
Thr His Leu Phe Ser Phe Leu Cys Leu Leu Leu Cys Phe Val Cys Ile
  1               5                  10                  15

Gln Ala Gln Asp Leu Gln Thr Tyr Ile Val Gln Leu His Pro His Gly
             20                  25                  30

Ala Thr Arg Pro Pro Phe Ser Ser Lys Leu Gln Trp His Leu Ser Phe
         35                  40                  45

Leu Ala Lys Ala Val Ser Ser Gly Glu Gln Asp Ser Ser Ser Arg Leu
     50                  55                  60

Leu Tyr Ser Tyr His Ser Ala Met Glu Gly Phe Ala Ala Arg Leu Thr
 65                  70                  75                  80

Glu Asp Glu Val Glu Leu Leu Arg Glu Ser Asn Asp Val Leu Ser Ile
                 85                  90                  95
```

```
Arg Ala Glu Arg Arg Leu Glu Ile Gln Thr Thr Tyr Ser Tyr Lys Phe
            100                 105                 110

Leu Gly Leu Ser Pro Thr Arg Glu Gly Ala Trp Leu Lys Ser Gly Phe
        115                 120                 125

Gly Arg Gly Ala Ile Ile Gly Val Leu Asp Thr Gly Val Trp Pro Glu
    130                 135                 140

Ser Pro Ser Phe Asp Asp His Gly Met Pro Pro Ala Pro Gln Lys Trp
145                 150                 155                 160

Arg Gly Val Cys Gln Gly Gly Gln Asp Phe Asn Ser Ser Ser Cys Asn
                165                 170                 175

Arg Lys Leu Ile Gly Ala Arg Phe Phe Arg Lys Gly His Arg Val Ala
            180                 185                 190

Ser Met Thr Ser Ser Pro Asp Ala Val Glu Glu Tyr Val Ser Pro Arg
        195                 200                 205

Asp Ser His Gly His Gly Thr His Thr Ala Ser Thr Ala Gly Gly Ala
    210                 215                 220

Ala Val Pro Leu Ala Gly Val Leu Gly Asn Gly Ala Gly Glu Ala Arg
225                 230                 235                 240

Gly Met Ala Pro Gly Ala His Ile Ala Ile Tyr Lys Val Cys Trp Phe
                245                 250                 255

Ser Gly Cys Tyr Ser Ser Asp Ile Leu Ala Ala Met Asp Val Ala Ile
            260                 265                 270

Arg Asp Gly Val Asp Ile Leu Ser Leu Ser Leu Gly Gly Phe Pro Ile
        275                 280                 285

Pro Leu Tyr Asp Asp Thr Ile Ala Ile Gly Ser Phe Arg Ala Met Glu
    290                 295                 300

His Gly Ile Ser Val Ile Cys Ala Ala Gly Asn Asn Gly Pro Ile Gln
305                 310                 315                 320

Ser Ser Val Ala Asn Gly Ala Pro Trp Ile Ala Thr Ile Gly Ala Ser
                325                 330                 335

Thr Leu Asp Arg Arg Phe Pro Ala Ser Val Gln Leu Gly Asn Gly Lys
            340                 345                 350

Phe Leu Tyr Gly Glu Ser Leu Tyr Pro Gly Lys Lys Val Pro Ser Ser
        355                 360                 365

Gln Lys Asn Leu Glu Ile Val Tyr Val Lys Asp Lys Asp Lys Gly Ser
    370                 375                 380

Glu Phe Cys Leu Arg Gly Ser Leu Ser Lys Ala Gln Val Arg Gly Lys
385                 390                 395                 400

Met Val Val Cys Asp Arg Gly Val Asn Gly Arg Ala Glu Lys Gly Gln
                405                 410                 415

Val Val Lys Glu Ala Gly Gly Ala Ala Met Ile Leu Ala Asn Thr Ala
            420                 425                 430
```

```
Ile Asn Met Glu Glu Asp Ser Ile Asp Val His Val Leu Pro Ala Thr
        435                 440                 445

Leu Ile Gly Phe Asp Glu Ser Ile Gln Leu Gln Asn Tyr Leu Asn Ser
    450                 455                 460

Thr Lys Arg Pro Thr Ala Arg Phe Ile Phe Gly Gly Thr Val Ile Gly
465                 470                 475                 480

Lys Ser Arg Ala Pro Ala Val Ala Gln Phe Ser Ser Arg Gly Pro Ser
                485                 490                 495

Tyr Thr Asp Pro Ser Ile Leu Lys Pro Asp Leu Ile Ala Pro Gly Val
            500                 505                 510

Asn Ile Ile Ala Ala Trp Pro Gln Asn Leu Gly Pro Ser Gly Leu Pro
        515                 520                 525

Glu Asp Ser Arg Arg Val Asn Phe Thr Val Met Ser Gly Thr Ser Met
    530                 535                 540

Ala Cys Pro His Val Ser Gly Ile Ala Ala Leu Leu His Ser Ala His
545                 550                 555                 560

Pro Lys Trp Thr Pro Ala Ala Ile Arg Ser Ala Leu Met Thr Thr Ala
                565                 570                 575

Asp Thr Ala Asp His Met Gly Lys Pro Ile Met Asp Gly Asp Ala Pro
            580                 585                 590

Ala Lys Leu Phe Ala Ala Gly Ala Gly His Val Asn Pro Gly Arg Ala
        595                 600                 605

Ile Asp Pro Gly Leu Ile Tyr Asp Ile Gln Val Asp Glu Tyr Ile Thr
    610                 615                 620

His Leu Cys Thr Ile Gly Tyr Arg Asn Ser Glu Val Phe Ser Ile Thr
625                 630                 635                 640

His Arg Asn Val Ser Cys His Asp Ile Leu Gln Asn Asn Arg Gly Phe
                645                 650                 655

Ser Leu Asn Tyr Pro Ser Ile Ser Ile Thr Phe Arg Ala Gly Met Thr
            660                 665                 670

Arg Lys Ile Ile Lys Arg Arg Val Thr Asn Val Gly Asn Pro Asn Ser
        675                 680                 685

Ile Tyr Ser Val Asp Ile Glu Ala Pro Glu Gly Val Lys Val Arg Val
    690                 695                 700

Lys Pro Arg Arg Leu Ile Phe Lys His Val Asn Gln Ser Leu Ser Tyr
705                 710                 715                 720

Arg Val Trp Phe Ile Ser Arg Lys Xaa Ile Glu Ser Lys Arg Met Ser
                725                 730                 735

Phe Ala Glu Gly Gln Leu Thr Trp Phe Asn Val Gly Asn Lys Ala Thr
            740                 745                 750

Lys Val Lys Ser Pro Ile Ser Val Thr Trp Ala Ser Met Lys
        755                 760                 765
```

<210> 13
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 13
Gln Thr Tyr Ile Val
1 5

<210> 14
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 14
Ile Val Gln Leu His
1 5

<210> 15
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 15
Ser Ser Arg Leu Leu
1 5

<210> 16
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 16
Gln Thr Thr Tyr Ser
1 5

<210> 17

<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 17
Ser Ser Ser Cys Asn
1 5

<210> 18
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 18
Val Leu Gly Asn Gly
1 5

<210> 19
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 19
Gly Ala His Ile Ala
1 5

<210> 20
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 20
Phe Arg Ala Met Glu
1 5

<210> 21
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 21
Val Ile Cys Ala Ala
1 5

<210> 22
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 22
Ala Ala Gly Asn Asn
1 5

<210> 23
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 23
Ser Ser Val Ala Asn
1 5

<210> 24
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 24
Tyr Gly Glu Ser Leu
1 5

<210> 25
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial

sequence

<400> 25
Gly Ser Glu Phe Cys
1 5

<210> 26
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 26
Cys Leu Arg Gly Ser
1 5

<210> 27
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 27
Arg Gly Val Asn Gly
1 5

<210> 28
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 28
Pro Ala Thr Leu Ile Gly
1 5

<210> 29
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 29

Ile Phe Gly Gly Thr
1 5

<210> 30
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 30
Pro Gln Asn Leu Gly
1 5

<210> 31
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 31
Val Asn Phe Thr Val
1 5

<210> 32
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 32
His Val Ser Gly Ile
1 5

<210> 33
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 33
Gly Phe Ser Leu Asn
1 5

<210> 34
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 34
Arg Arg Val Thr Asn
1 5

<210> 35
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 35
Pro Asn Ser Ile Tyr
1 5

<210> 36
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 36
Leu Ser Tyr Arg Val
1 5

<210> 37
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 37
Ser Pro Ile Ser Val
1 5

<210> 38

<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 38
Val Ile Cys Ala Ala
1 5

<210> 39
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 39
Cys Ala Ala Gly Asn
1 5

<210> 40
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 40
Ala Ala Gly Asn Asn
1 5

<210> 41
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 41
Val Ile Cys Ala Ala Gly Asn Asn Gly
1 5

<210> 42
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 42
Ile Ile Gly Val Leu
1 5

<210> 43
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 43
Gly Val Leu Asp Thr
1 5

<210> 44
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 44
Thr His Thr Ala Ser Thr
1 5

<210> 45
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 45
Ser Arg Asp Ser
1

<210> 46
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial

sequence

<400> 46
Arg Asp Ser Gly
1

<210> 47
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 47
His Val Ser Gly Ile
1 5

<210> 48
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 48
Phe Thr Val Ser Gly Thr
1 5

<210> 49
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 49
Ser Tyr His Ser Ala
1 5

<210> 50
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 50

Gly Leu Ser Pro Thr
1 5

<210> 51
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 51
Trp Leu Lys Ser Gly
1 5

<210> 52
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 52
Phe Asn Ser Ser Ser
1 5

<210> 53
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 53
Ala Ser Thr Ala Gly
1 5

<210> 54
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 54
Ala Ala Met Asp Val
1 5

<210> 55
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 55
Trp Ile Ala Thr Ile
1 5

<210> 56
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 56
Gly Pro Ser Gly Leu
1 5

<210> 57
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 57
Ile Ala Ala Leu Leu His
1 5

<210> 58
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 58
Lys Pro Ile Met Asp
1 5

<210> 59

<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 59
Val Ser Cys His Asp
1 5

<210> 60
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 60
Tyr Pro Ser Ile Ser
1 5

<210> 61
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: artificial sequence

<400> 61
Ser Leu Ser Tyr Arg
1 5